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ABSTRACT
INTER-INDIVIDUAL VARIATION IN RESPONSE TO ESTROGEN AND
IMPLICATIONS FOR BREAST CANCER RISK
MAY 2020
AMYE L. BLACK, B.S., UNIVERSITY OF CONNECTICUT
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: D. Joseph Jerry
Breast cancer is the second leading cause of cancer related death among women
and the most prevalent cancer type in women worldwide. Many risk factors for breast
cancer are related to estrogen exposure, including early menarche, late menopause,
nulliparity, hormone replacement therapy, and high serum estrogen levels. These factors
all involve prolonged or high levels of estrogen exposure. However, estrogen exposure
during early pregnancy lowers risk by up to 50% and high dose estrogen treatment is an
effective antitumor treatment in postmenopausal women.

The mechanisms behind

estrogen’s paradoxical role in both contributing to and reducing breast cancer risk are
currently unknown. We hypothesized that a subset of women may be more sensitive to
estrogen exposure, and the following experiments were designed to test this hypothesis and
determine if sensitivity to estrogen is due to estrogen receptor levels or downstream
regulation of estrogen signaling using 3 human breast tissue or cell models.
Our first model used to characterize responses to estrogen treatment was the human
breast ex-vivo explant model. Donor human breast explants were treated with control or
estrogen for 4 days and then transcriptional and functional responses were compared
between individuals. Up to 80 or 100-fold variation in estrogen receptor alpha (ERα) and
estrogen receptor beta (ERβ) mRNA levels were observed in explants. Responses to
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estrogen also varied among individuals, although estrogen receptor target gene expression
(AREG, PGR, and TGFβ2), progesterone receptor protein (PR) expression, proliferation,
and irradiation induced apoptotic responses were not significantly correlated with estrogen
receptor levels. These results indicated that there are variable responses to estrogen
exposure among individuals but that these responses do not appear connected to estrogen
receptor expression levels. Our second model, conditionally immortalized primary human
mammary epithelial cells (ciHMEC), also demonstrated variable responses in luciferase
reporter assays with estrogen and xenoestrogen treatment, though the responses were more
consistent than those observed in the human breast explant model. This was likely due to
transfection of saturating levels of estrogen receptor.
Lastly, we examined estrogen-induced responses in 4 inducible ERα HMEC cell
lines. While all 4 lines were able to activate luciferase reporter assays and expressed ERα
protein, only 3 out of 4 demonstrated a proliferation response to estrogen. Expression of
estrogen receptor target genes (AREG and PGR) however, was not regulated by estrogen
treatment. Conditioned growth media assays demonstrated that this proliferative response
was not due to secretion of factors into the media but is instead driven by intracellular
factors. As others have implicated the pioneer factors FOXA1 and GATA3 in restoring
estrogen-induced responses, we examined mRNA expression of these factors in our cells
and found no correlation with estrogen-induced proliferation. These results imply that
while FOXA1 and GATA3 are not sufficient to induce biological responses to estrogen.
Collectively, our work demonstrated individual variation in estrogen receptor expression
and estrogen and xenoestrogen-induced responses. Sensitivity to estrogen treatment was
not driven by estrogen receptor expression levels. Further, our results suggest intracellular
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factors, such as estrogen receptor coregulators, are important for modulation of estrogeninduced biological responses.
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CHAPTER 1
INTRODUCTION
Estrogen Exposure and Breast Cancer Risk
Breast cancer is the most prevalent cancer type among women worldwide and the
second leading cause of cancer related death in women (Siegel et al., 2019). Known risk
factors for breast cancer include age, genetics, obesity, increased breast density, early onset
of menarche, late menopause, nulliparity, and late full-term pregnancy (Travis and Key,
2003; Samavat and Kurzer, 2015; Brooks et al., 2018). Many of these risk factors are
related to endogenous estrogen levels. Chronic lifetime exposure to estrogen, through early
menarche (RR = 1.3), late menopause (RR = 1.2-2.0), hormone replacement therapy with
estrogen and progesterone (RR = 1.2), or having the highest quartile of serum estrogen
levels (RR = 1.8-5.0) all increase breast cancer risk in women (Brinton et al., 1983, 1988;
Trichopoulos et al., 1972, 1983; Clemons and Goss, 2001; Rossouw et al., 2002; Eliassen
et al., 2006; Dall and Britt, 2017). These reproductive risk factor suggest that longer
lifetime exposure to estrogen increases breast cancer risk. Accordingly, treatment with
selective estrogen receptor modulators (SERMs) to inhibit estrogen activity in the breast
has been shown to lower breast cancer incidence (Cuzick et al., 2013). Estrogen is also
known to contribute to breast tumor initiation and growth (Russo and Russo, 2006; Tian et
al., 2018).
Strikingly, while a full-term pregnancy after the age of 35 increases breast cancer
risk, a full-term pregnancy before the age of 20 decreases breast cancer risk by up to 50%
(MacMahon et al., 1970; Trichopoulos et al., 1983; Rosner et al., 1994; Lambe et al., 1996).
The effectiveness of parity in reducing breast cancer risk after an early pregnancy is
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mimicked in mice with estrogen and progesterone treatment (Thordarson et al., 1995;
Sivaraman, 1998; Guzman et al., 1999; Rajkumar et al., 2007; Dunphy et al., 2008), further
illustrating that estrogen can reduce breast cancer risk. High dose estrogen treatment is an
effective antitumor therapy in postmenopausal women with breast cancer, possibly due to
increased sensitivity to estrogen after the decrease estrogen levels during menopause
(Lonning et al., 2001; Coelingh-Bennink et al., 2017). Treatment of breast tumors with
SERMs may also sensitize tumors to estrogen-induced apoptosis (Yao et al., 2000; Song
et al., 2001). This evidence suggests that high levels of estrogen exposure, depending on
context, have antagonistic effects on breast cancer risk.

Familial Breast Cancer Risk
Familial breast cancer risk, or genetic susceptibility to breast cancer, is another
major breast cancer risk factor. Genetic susceptibility to breast cancer varies widely among
individuals. Twin studies suggest that hereditary factors account for approximately 2730% of overall breast cancer risk (Peto and Mack, 2000; Southey et al., 2013; Mucci et al.,
2016). High penetrance BRCA1, BRCA2, and TP53 mutations account for 16-20% of
inherited risk, but are rare in the general population (Peto et al., 1999; Anglian Breast
Cancer Study Group, 2000; Thompson and Easton, 2004; Antoniou and Easton, 2006;
Lalloo and Evans, 2012). Moderate penetrance mutations (CHEK2, ATM, BRIP1, and
PALB2) make up approximately 3-5% of inherited breast cancer risk (Peto et al., 1999;
Anglian Breast Cancer Study Group, 2000; Thompson and Easton, 2004; Rahman et al.,
2007). These mutations are more common than BRCA1, BRCA2, or TP53 mutations but
still occur in less than 1% of the population (Adank et al., 2011; Renwick et al., 2006; Seal
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et al., 2006; Rahman et al., 2007). Genome wide association studies (GWAS) have also
identified low penetrance mutations (CASP8, FGFR2, TOX3, MAP3K1, and LSP1) and
single nucleotide polymorphisms (Easton et al., 2007; Ahmed et al., 2009; Kuchenbaecker
et al., 2014; Michailidou et al., 2017) which are estimated to account for 8-15% of inherited
breast cancer risk. However, the mechanisms of these sites identified through GWAS have
are still unclear. These known inherited risk factors account for approximately 30-40% of
inherited breast cancer, but the remaining 60-70% are due to currently unknown inheritable
factors.

Estrogen Sensitivity in Rodents
Previous work has identified rodent strains with increased sensitivity or resistance
to mammary tumor development in response to carcinogen or estrogen treatment. These
rodent strains do not contain any previously known breast cancer risk genes, such as
BRCA1 or BRCA2. In DMBA induced models of mammary tumors, the Wistar-Kyoto rat
strain is resistant to tumor development while the Wistar-Furth strain is uniquely
susceptible (Gould, 1986; Lan et al., 2001). For estrogen-induced mammary tumor models,
the ACI strain is uniquely susceptible to estrogen-induced mammary tumors while the
Copenhagen and Brown Norway strains are resistant (Shull et al., 1997; Spady et al., 1998;
Dennison et al., 2015; Shull et al., 2018). Treatment of susceptible ACI rats with tamoxifen
reduces the development of estrogen-induced mammary tumors (Li et al., 2002; Singh et
al., 2011), demonstrating the involvement of estrogen receptor signaling in mammary
tumor development in the ACI strain. These studies have also identified quantitative trait
loci (QTL), regions of the chromosomes linked to mammary tumor susceptibility and
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resistance (Lan et al., 2001; Haag et al., 2003; Gould et al., 2004; Schaffer et al., 2006).
Several of these QTLs have been mapped to human orthologs previously identified in
GWAS for breast cancer risk loci (Schaffer et al., 2013; Colletti et al., 2014). Additionally,
deletion of the mouse ortholog to a human breast cancer susceptibility locus, 8q24, reduces
mammary tumor incidence in rats (Homer-Bouthiette et al., 2018). Taken together, these
results illustrate the potential for estrogen to contribute to breast cancer development in
certain genetic backgrounds, suggesting unique sensitivity to estrogen exposure.
In mice, BALB/c and C57BL/6 strains are also known to differ in susceptibility to
estrogen-induced mammary tumor formation but also in other estrogen-induced responses
in the mammary gland, including proliferation and apoptosis (Montero Girard et al., 2007;
Aupperlee et al., 2009). As estrogen is known to promote breast cancer risk in humans, we
propose that some women may be uniquely susceptible to this exposure based on their
genetic backgrounds, like the rodent strains mentioned previously. Further, some women
may also be more sensitive to estrogen exposure, which may be linked to increased breast
cancer risk. Increased breast density is a known risk factor for breast cancer which is
positively correlated with higher serum estrogen levels (Brooks et al., 2018) and may
indicate estrogen sensitivity. Specific SNPs in the ESR1 gene are associated with increased
breast cancer risk, resistance to anti-estrogen treatment, and poor overall prognosis
(Schubert et al., 1999; Conway et al., 2005; Herynk et al., 2007; Abbasi et al., 2012).
Included in this list of SNPs with increased breast cancer risk are 908A/G (K303R) and
1608T/A (Y537N) ESR1 polymorphisms, which produce estrogen receptor protein that is
hypersensitive to estrogen treatment or constitutively active (Conway et al., 2007;
Jeselsohn et al., 2014). Based on this data, if a subset of women is uniquely sensitive to
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estrogen exposure because of their genetic background, it may be connected to increased
breast cancer risk.

Estrogen Receptors Alpha and Beta
Biological responses to estrogen exposure are mediated through the two estrogen
receptors: estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) (Heldring et al.,
2007; Nilsson et al., 2001). ERα and ERβ are ligand activated transcription factors in the
steroid nuclear receptor family encoded by ESR1 and ESR2 respectively (Heldring et al.,
2007). ESR1 is located on chromosome 6q24-27 and ESR2 is on chromosome 14q22-24.
Both ERα and ERβ contain similar protein domains: an activation function (AF-1) domain,
DNA binding domain, a ligand binding domain, and an AF-2 domain (Figure 1.1) (Nilsson
et al., 2001; Leitman et al., 2010). The AF-1 and AF-2 domains are both known to be
involved in gene regulation (Kumar and Thompson, 1999) and binding of estrogen receptor
coregulators (Webb et al., 1998; Tremblay et al., 1999; Benecke et al., 2000; Maggi, 2011).
The DNA binding domain of ERα and ERβ is required for the binding of these
receptors to DNA, at estrogen response elements (EREs), to initiate estrogen-responsive
gene transcription (Gruber et al., 2002; Heldring et al., 2007; Yasar et al., 2017). In mice
with a mutated ERα DNA binding domain, mammary gland development is impaired, and
uterine and mammary gland phenotypes resemble those observed in the full ERα knockout
mice (Lubahn et al., 1993; Bocchinfuso and Korach, 1997; Ahlbory-Dieker et al., 2009),
suggesting that DNA binding is essential to ERα function. The DNA binding domains of
ERα and ERβ are 97% homologous, indicating that they likely bind to many of the same
regions of the DNA to control transcription. However, ERβ has lower affinity for EREs
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than ERα and lower transactivation of ERE-reporters in luciferase assays with estrogen as
a ligand (Hall and McDonnell, 1999; Yi et al., 2002).
The ligand binding domain is crucial for estrogen receptor function. 17β-estradiol
(E2) is the most prevalent estrogen in women (Gruber et al., 2002; Mukherjee et al., 2005)
and acts as a ligand for both ERα and ERβ equally. Ligand binding to estrogen receptors
initiates a conformational change, which allows for receptor dimers to form (Kumar et al.,
2011; Vrtačnik et al., 2014). These receptors can form homodimers or heterodimers. The
ligand binding domain of ERα and ERβ are 55% homologous (Witkowska et al., 1997;
Gruber et al., 2004; Leitman et al., 2010), suggesting that it is possible for these receptors
to be activated by different ligands. Accordingly, several estrogen receptor specific
agonists exist (Figure 1.2). Propyl pyrazole triol (PPT) is an ERα specific agonist, with
410-fold selectivity for ERα over ERβ (Stauffer et al., 2000). Multiple ERβ have been
developed, including ethenyl-2-(3-fluoro-4-hydroxyphenyl)-benzoxazolol (ERB041) and
diarylpropionitrile (DPN); ERB041 has 200-fold selectivity for ERβ over ERα and DPN
has 170-fold selectivity for ERβ (Harris et al., 2003; Meyers et al., 2001).
One class of endocrine disrupting chemicals, xenoestrogens, can also act as ligands
for the estrogen receptors. Endocrine disrupting chemicals can disrupt normal hormone
signaling by mimicking or antagonizing the effects of endogenous hormones and also by
disrupting the synthesis and metabolism of endogenous hormones and their receptors
(Sonnenschein and Soto, 1998; Fernandez and Russo, 2010).

Xenoestrogens have

estrogenic activity, suggesting the potential to activate estrogen signaling in the breast
(Singleton and Khan, 2003). They are common in food, drinking water, and personal care
products such as lotions, cosmetics, and sunscreens (Mortensen et al., 2014; Soni et al.,
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2001). Xenoestrogens, therefore, have the potential to disrupt estrogen receptor signaling
by acting as ligands for ERα and/or ERβ and could affect the balance between the
protective and risk promoting effects of estrogen exposure on breast cancer risk.

Estrogen Receptor Signaling
Classical estrogen receptor signaling involves direct binding of ligand-bound
estrogen receptor dimers to EREs, which then recruit coactivators or corepressors to control
target gene transcription (Figure 1.3). Other pathways for estrogen signaling have been
identified, including tethered, non-genomic, and ligand-independent pathways (Figure
1.4) (Heldring et al., 2007). The tethered pathway involves ligand-bound estrogen receptor
dimer binding to other transcription factors bound to DNA, instead of EREs (Gaub et al.,
1990; Saville et al., 2000). Non-genomic estrogen receptor signaling involves either
membrane bound estrogen receptors or other membrane bound receptors which in turn
activate the estrogen receptors (Heldring et al., 2007; Levin, 2009). Membrane bound
estrogen receptors are not sufficient to rescue mammary gland development in ERα
knockout mice (Pedram et al., 2009), however, and thus does not likely play a significant
biological role. Ligand-independent pathways involve estrogen receptor phosphorylation
by kinases activated by growth factor signaling and are hypothesized to be involved in
hormone-independent growth of breast tumors (Kato et al., 1995; Coutts and Murphy,
1998; Shim et al., 2000). More recent work has highlighted the increased complexity of
classical estrogen receptor signaling, where estrogen receptors can control the expression
of genes without EREs or other transcription factor binding sites through long range
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chromatin looping, which brings distant genes into close proximity to where estrogen
receptors are bound (Figure 1.5) (Fullwood et al., 2009).
Data from estrogen receptor knockout mice suggest that ERα function is crucial to
mammary gland development, while ERβ is not. ERα knockout mice (αERKO) have
rudimentary ductal mammary gland development similar to newborn mice (Bocchinfuso
and Korach, 1997). Conversely, ERβ knockout mice (βERKO) mammary glands are
indistinguishable from wild type mice (Krege et al., 1998). Therefore, the function of ERβ
in the breast has long been questioned and is still partially unanswered. It is known that
ERβ, including its multiple isoforms, can form heterodimers with ERα (Moore et al., 1998).
The question, therefore, was whether ERβ could act as a modulator of ERα activity. Early
work demonstrated that ERβ was able to act as a dominant inhibitor of ERα activity (Hall
and McDonnell, 1999). Later studies confirmed the ability of ERβ to repress estrogen
mediated proliferation in breast cancer cell lines (Williams et al., 2008), ERα induced
activation of target genes pS2 and PGR, promoter binding, and recruitment of cofactors
(Matthews et al., 2006). ERβ is thought to block estrogen-induced proliferation through
activation of MAPK and PI3K signaling (Cotrim et al., 2013) or in combination with p53
(Bado et al., 2017, 2018). However, while this work was done with the main ERβ isoform
(ERβ-1), other work has demonstrated a truncated ERβ isoform (ERβ-2, or ERβcx) is also
capable of repressing ERα activity and coactivator recruitment while not influencing ERβ1 function (Ogawa et al., 1998). Accordingly, ERβ loss during breast cancer progression
is associated with poorer prognosis (Omoto et al., 2001; Sugiura et al., 2007), resistance to
tamoxifen treatment (Hopp, 2004), and increased risk of advanced tumor progression
(Roger et al., 2001; Shaaban et al., 2003; Skliris et al., 2003). Contradictory results are
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obtained in other studies, however, which show poor prognosis with ERβ expression
(Novelli et al., 2008; Shaaban et al., 2008) even in ERα positive breast tumors (Saji et al.,
2002). For these reasons the exact function of ERβ is still unclear, especially regarding
breast cancer development. It is accepted, though, that the role of ERα can potentially be
modulated by ERβ and the ratios of ERα to ERβ may be important for determining the
effects of estrogen treatment within a cell.

Pioneer Factors, Coregulators, and Estrogen Receptor Signaling
Pioneer factors and coregulators are essential determinants of estrogen receptor
signaling and mammary gland development. Pioneer factors are transcription factors
which can bind to specific sites in the chromatin and recruit other transcription factors or
histone modifying enzymes to enhance or restrict transcription (Zaret and Carroll, 2011).
Forkhead box A1 (FOXA1) and GATA binding protein 3 (GATA3) are considered
estrogen receptor pioneer factors, and FOXA1, GATA3, and ERα interaction is thought to
maintain luminal epithelial cell phenotype in the mammary gland. FOXA1 regulates
expression of ERα, terminal end bud formation, and ductal outgrowth during puberty
(Bernardo et al., 2010). GATA3 is also involved in terminal end bud formation as well as
luminal cell differentiation and loss of GATA3 results in expansion of luminal progenitors
(Kouros-Mehr et al., 2006; Asselin-Labat et al., 2007). GATA3 and ERα have a crossregulatory feedback loop and GATA3 is crucial for estrogen-induced growth in breast
cancer cells (Eeckhoute et al., 2007). Attempts to generate ER negative breast cell lines
expressing exogenous ESR1 have shown that FOXA1 and GATA3, along with ESR1, are
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necessary for recovery of estrogen-induced phenotypes, including proliferation (Kong et
al., 2011).
Estrogen receptor coregulators interact with FOXA1 and GATA3 pioneer factors
as well as ERα and ERβ to modify estrogen receptor signaling. Many of these coregulators
are important for different developmental stages of mammary gland development (Figure
1.6). Coactivators typically facilitate the recruitment of transcriptional machinery to the
receptors while corepressors repress this recruitment, both acting through binding with the
AF-1 and AF-2 domains of the estrogen receptors (Heery et al., 1997; Nilsson et al., 2001;
Heldring et al., 2007). A total of over 200 estrogen receptor coregulators are known, most
identified through interactions with ERα. Fewer coregulators have been examined for ERβ.
Known coactivators for the estrogen receptors include SRC1-3, BRCA1 and BRCA2,
CITED-1, Ccdn1, NCOA1-3, TIF2, PELP1, CBP, p300, CARM1, RIP140, p/CIP, and
PRMT1. Known co-repressors include NCOR, SMRT, NRIP1, MTA1, NFIB, and YBX1
(Kurebayashi et al., 2000; Maggi, 2011; Merrell et al., 2011; Jiang et al., 2013; Vrtačnik et
al., 2014; Campbell et al. 2018).
Though affinity for estrogen is equal for both receptors, there is differential
recruitment of coregulators by ERα and ERβ, and this can be affected by phosphorylation
of these receptors (Nguyen et al., 2012; Tharun et al., 2015). In MCF7 cells, recruitment
of SRC3 and RIP140 to the PGR gene is higher in cells expressing ERα, slightly lower in
ERα and ERβ expressing cells, and lowest in cells with ERβ only (Jiang et al., 2013).
Similar results were obtained for other ER target genes FOS, TFF1, and CASP7 (Chang et
al., 2008). Recruitment of coregulators by estrogen receptors also differs for target genes
that are up or down regulated. pS2, an ER target gene upregulated by E2 treatment in
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MCF7 cells, shows increased recruitment of SRC1 and p/CIP coactivators and decreased
recruitment of NCoR, NRIP1, and SMRT corepressors; the opposite results are observed
for ER target genes that are downregulated (PSCA, SLC35A1) (Merrell et al., 2011). These
changes are associated with histone deacetylation and RNA polymerase II docking.
Previous studies have demonstrated tissue specific expression of nuclear receptor
coregulators and are hormonally regulated (Misiti et al., 1998; Shang and Brown, 2002;
Molenda et al., 2003). These differences have also been suggested to influence the tissue
specific antagonist/agonist actions of tamoxifen (Smith et al., 1997; Shang and Brown,
2002). Knockdown of NCOA3 was shown in MCF7 cells to prevent estrogen-induced
proliferation, but knockdown of other similar coactivators NCOA1 and NCOA2 had no
such effect (Karmakar et al., 2009). Overexpression of CARM1 in MCF7 cells also results
in inhibition of estrogen-induced proliferation and target gene regulation (Al-Dhaheri et
al., 2011). Expression of NFIB and YBX1 can inhibit luciferase reporter activity and
change target gene expression in ERα positive MCF7 breast cancer cells as well as promote
estrogen independent growth (Campbell et al., 2018).

Because expression of these

coactivators and corepressors are known to have cell/tissue specific expression and can
regulate estrogen receptor signaling, including modulation of proliferation, we hypothesize
that individual expression of these coregulators could influence sensitivity to estrogen.

Estrogen Receptor Levels in Normal Breast Epithelium
ERα and ERβ are both expressed in the epithelial cells of the human breast (Figure
1.7). ERα is restricted to the luminal epithelial cells of the ducts, whereas ERβ is expressed
in basal epithelial, luminal epithelial, stromal, lymphocytes, and endothelial cells of the
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breast (Speirs 2002). Previous studies of ERβ expression in the normal human breast are
limited by the availability of reliable ERβ antibodies (Andersson et al., 2017; Nelson et al.,
2017). Much work, however, has been done to quantify the ERα protein levels in the
normal human breast. A summary of these studies is shown in Table 1.1. ERα protein is
detectable in approximately 32-68% of human samples and is known to increase with age
(Battersby et al., 1992; Söderqvist et al., 1993; Gabrielson et al., 2016). The general
consensus is that ERα positive cells make up no more than 5-10% of the normal human
breast luminal epithelial population, in contrast to mouse epithelium where 15-40% of
luminal epithelial cells may be ERα positive depending on strain (Montero Girard et al.,
2007; Raafat et al., 2012). The proportion of ERα positive luminal epithelial cell is also
known to increase in premalignant breast lesions and in the majority of breast cancers
(Shoker et al., 1999a; Quong et al., 2002). Interestingly, it is thought that, although ERα
positive cells respond to estrogen treatment by releasing growth factors that stimulate
proliferation, only the ERα negative cell population responds by proliferating in the normal
breast. This is referred to as the paracrine hypothesis for estrogen mediated proliferation
(Shoker et al., 1999b; Mallepell et al., 2006; Ciarloni et al., 2007). In breast cancer cells
this is perturbed, as multiple ERα breast cancer cell lines increase proliferation when
treated with estrogen.

Human Models for Estrogenic Responses in the Normal Breast
The original studies determining responses to estrogen exposure in the normal
human breast were based on population studies using human breast tissue at different stages
of the menstrual cycle or at different life stages. One large drawback to these studies is
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that the levels of endogenous estrogen vary among women and responses to estrogen
treatment may vary as well. To overcome this obstacle, 2D human breast epithelial cell
models have been developed. Breast cancer cell lines, such as MCF7 and T47D, express
high ERα levels and have been useful for studying the effects of estrogen receptor signaling
in a breast cancer setting. They are not, however, an appropriate model for estrogen
receptor signaling in the normal human breast due to many perturbations that occur during
carcinogenesis and the heterogenous expression of ERα in normal human breast
epithelium. Induced pluripotent stem cell lines have been used in the study of tissue
development and function, but these cell lines are difficult to differentiate into breast
epithelial cells (Cravero et al., 2015). Recently, improved protocols were developed to
differentiate induced pluripotent stem cells into breast epithelial cells, but the widespread
application of this technique is yet to be seen (Qu et al., 2017).
After optimization of culture conditions, it became possible to propagate normal
human breast epithelial cells in 2D culture which now serve as an alternative to breast
cancer cell lines. Early work with human mammary epithelial cells (HMECs) was hindered
by early senescence. Methods to bypass this senescence were developed, including
transformation with HPV E6 and E7, human telomerase (TERT), Myc, SV40 large Tantigen, zinc-finger protein ZNF217, and BMI-1.

However, abnormal cell cycle

progression in these immortalized cells is attributed to loss of p53, retinoblastoma protein,
and p16INK4a, which perturb the underlying biology of these cells (Wang et al., 1998;
Dyson et al., 1989; Münger et al., 1989; Scheffner et al., 1990; Huschtscha et al., 2001;
Nonet et al., 2001; Dimri et al., 2002; Martinez-Zapien et al., 2016; Fischer et al., 2017).
These immortalized lines also can exhibit signs of transformation, including anchorage
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independent growth, reduced apoptotic responses, and altered gene expression (Wang et
al., 1998; Thibodeaux et al., 2009). Despite these changes, stably immortalized HMECs
are still one of the better options for studying normal breast biology.
An

alternative

approach

to

stably

immortalization

called

conditional

reprogramming, or conditional immortalization, allows the expansion of HMECs through
coculture with irradiated mouse fibroblasts and addition of a rho-associated protein kinase
(ROCK) inhibitor (Liu et al., 2012; Palechor-Ceron et al., 2013). With this method,
removal of feeder cells and ROCK inhibitor results in removal of the conditionally
reprogrammed phenotype. These reprogrammed cells are suggested to represent a stem
cell like epithelial population (Suprynowicz et al., 2012, 2017), though it has been noted
that HMEC cells in other culture methods can also lose expression of differentiation
markers (Breindel et al., 2017). Comparison of these conditionally immortalized HMECs,
or ciHMECs, isolated from breast tumors shows similar expression profiles to the original
tissue sample (Mahajan et al., 2017). Some groups have successfully used this method to
expand ERα positive luminal epithelial cells, but this population decreases in culture over
passaging (Jin et al., 2017).
Although conditional immortalization and stable immortalization methods have
enhanced the expansion of HMECS, one key issue that remains is the loss of estrogen
receptor positive cells in 2D culture conditions. Multiple groups have reported the loss of
ERα expressing luminal epithelial cell populations during passaging (Fridriksdottir et al.,
2015; Jin et al., 2017; Lee et al., 2018), and it is known that luminal epithelial cells only
make up a small population (10-25%) of epithelial cells isolated from human breast tissue
(Garbe et al., 2009). This population may be greater in breast tissue of older women (Lee
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et al., 2015). As only 5-10% of luminal epithelial cells express ERα, it is not surprising
that most epithelial cells isolated from breast tissue lack ERα expression. There are
multiple hypotheses explaining why ERα positive luminal epithelial cells are difficult to
grow in culture. It is thought that the luminal epithelial cell population is lost in 2D culture
due to reduced adherence (Soule and McGrath, 1986; Keller et al., 2010), faster growth of
basal epithelial cells (Keller et al., 2010; Fridriksdottir et al., 2015), triggering stress
responses in luminal epithelial cells (Lee et al., 2018), changes to the microenvironment
(Miyano et al., 2017), or epigenetic reprogramming that results in the loss of the
differentiated phenotype (Keller et al., 2010; Breindel et al., 2017). Calcium levels may
also be important as one group noted the growth of free-floating cells in low calcium
containing media, though these cells are thought to be less differentiated as they can form
ductal structures when placed in collagen gels (Soule and McGrath, 1986). It has been
noted that luminal epithelial cells grow better in serum containing media, as opposed to
basal epithelial cells which grow in serum free media (Kao et al., 1995), though growth in
serum containing media can lead to permanent senescence (Stampfer and Bartley, 1985).
Luminal epithelilal cells may be more sensitive to microenvironment changes and grow
better in mixed cell type populations (Miyano et al., 2017). Even with optimal media
conditions, ERα positive luminal epithelial cells are lost in early passages and the number
of passages is ultimately limited by the original percentage (Lee et al., 2018).
More recent work has focused on the creation of 3D breast organoid cultures from
primary HMECs of normal and cancerous breast tissue (Sokol et al., 2016; Sachs et al.,
2018; Djomehri et al., 2019; Florian et al., 2019; Goldhammer et al., 2019). Breast
organoids contain both luminal and basal epithelial cells, retain the ERα expressing
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population, and are responsive to hormone treatment. Our lab has found, however, that
propagation of breasts organoids from normal human breast tissue is limited, as
proliferation ceases after a few passages. We have had more success with human breast
explant ex-vivo models, which can be maintained in culture for up to 4 weeks and retain
all breast cell types (Zhuang et al., 2003; Eigeliene et al., 2006, 2008, 2012, 2016; Tanos
et al., 2013; Dunphy et al., 2020). The ERα expressing population is maintained in this
model as well as response to hormone treatment. Studies with these tissues, however, are
limited by the amount of available breast tissue from donors. Ultimately, all these breast
tissue and cell models remove some of the confounding factors of individual hormone
levels when a single breast biopsy is taken, and each have unique advantages and
disadvantages.

Hypothesis and Objectives
We hypothesize that a subset of women is uniquely sensitive to estrogen exposure,
and thus may be at increased risk for breast cancer. This increased sensitivity may be due
to differing levels of estrogen receptors, parity, or differing estrogen receptor coregulator
expression. First, a human breast explant model is utilized to determine the level of
variation in estrogen receptor expression among women, characterize transcriptional and
functional responses to estrogen, and determine if these are correlated with estrogen
receptor expression. Next, conditionally immortalized primary human mammary epithelial
cells are explored as a model for capturing variation in estrogen sensitivity, as well as
determining if xenoestrogen sensitivity also varies among individuals. Lastly, inducible
ERα human mammary epithelial cell lines are developed and utilized to probe estrogen
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receptor induced activation of biological responses and differences in response between
normal and breast cancer cells. If our hypothesis is correct, it has the potential to provide
additional insight into the paradoxical roles of estrogen in breast cancer risk and suggests
that this subset of individuals may be more susceptible to breast cancer through increased
endogenous estrogen exposure. The models used in this work can be utilized in future
studies to further identify factors mediating estrogen sensitivity.
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Table 1.1: ERα expression in the human breast
Literature review of ERα positivity in human breast epithelium.
First Author Year

% ERα positive cells

Petersen

1987

7%

Ricketts

1991

0-20%, but up to 65%

Battersby

1992

38-47% had detectable protein

Soderqvist

1993

Khan

1994

Clarke
Khan

1997
1998

32-68% had detectable protein,
5% in luteal phase, 18% in
follicular phase
Unspecified,
57% of patients were positive
(defined as >50%)
10-15%
7.7%

Anderson

1998

12-13%

Lawson

1999

Shoker

1999

Shoker

1999

Russo

1999

Khan

2002

Eigeliene

2006

Eigeliene

2008

Eigeliene

2016

Gabrielson

2016

Chamberlin

2017

14% in Australian women,
9% in Japanese women
11% in < 46 years old,
27% in 46-55 years old,
34% in > 55 years old
6.8% in premenopausal,
42% in postmenopausal (large
variation)
7% in Lob 1, 4% in Lob 2, 1%
in Lob 3
5-20%, but up to 40%
67% of patients had ER, 10%
positive after culturing explants
(7 days)
21% in premenopausal,
17.3% in postmenopausal
20% (in explant culture)
Detected protein in 61% of
samples, mean 30.4% (range 456.8%), women 41-76 years old
Premenopausal women: 0-50%
Postmenopausal women: 1045%
18

Antibody
Used
ER-ICA kit,
Abbot
Laboratories
H222
ER-ICA kit,
Abbot
Laboratories
ER-ICA kit,
Abbot
Laboratories
ER-ICA kit,
Abbot
Laboratories
1D5, Dako UK
H222
Unclear
(possibly 1D5)

Dilution
Not Stated
Not Stated
Not Stated

Not Stated

Not Stated
1:75
Not Stated
Not Stated

1D5, Dako UK

Not Stated

1D5, Dako UK

Not Stated

1D5, Dako UK

1:75

ER1D5,
Amac Lab
6F11
1D5, Dako
Denmark
1D5, Dako
Denmark
1D5, Dako
Denmark

1:400
1:100
1:2000
1:2000
1:400

1D5, Dako
Sweden

1:60

F-10, Santa
Cruz (sc-8002)

1:200

Figure 1.1: ERα and ERβ domains and homology
Structural domains of Estrogen Receptor alpha (ERα) and Estrogen Receptor beta (ERβ).
The DNA binding domains (C) are 97% homologous, indicating these receptors bind to the
same regions of DNA. The ligand binding domain (E) is only 55% homologous, which
allow for differences in ligand specificity between these two receptors. Adapted from
Leitman et al. 2010, Curr Opin Pharmacol.

Figure 1.2: ERα and ERβ agonists
17β-estradiol is an estrogen receptor agonist with equal affinity for both ERα and ERβ.
Propyl-pyrazole-triol (PPT) is a selective ERα agonist, while diarylpropionitrile (DPN) and
ERB041 are both selective ERβ agonists. Xenoestrogens benzophenone-3 (BP3) and
propylparaben (PP) are potential estrogen receptor agonists. Selectivity is indicated.
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a

b

Figure 1.3: Estrogen receptors mediate the actions of estrogen
Canonical estrogen receptor signaling overview. (a) 17β-estradiol (E2) binds to ERα
and/or ERβ in the cell nucleus, which triggers receptor dimerization. Homodimers or
heterodimers then bind to estrogen response element (ERE) sequences in the DNA to
trigger transcription of estrogen receptor target genes, such as AREG and PGR. (b)
Estrogen receptor recruitment of transcriptional machinery to EREs depends on the
presence of coactivators (such as FOXA1 and GATA3) or corepressors (example not
shown).
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Figure 1.4: Pathways for estrogen receptor signaling
Overview of ligand-dependent and independent mechanisms of estrogen receptor
signaling. Direct, ligand-dependent signaling involves ligand-bound estrogen receptor
dimers binding to estrogen response elements in the DNA. Tethered estrogen receptor
signaling involves ligand-bound receptor dimers binding to other transcription factors on
the DNA, such as AP-1 or SP-1. Nongenomic estrogen receptor signaling is thought to
involve membrane bound estrogen receptors or other membrane bound receptor which
activates the estrogen receptors. Ligand-independent signaling involves other growth
factor activation, which activates kinases and leads to phosphorylation of the estrogen
receptors. Adapted from Heldring et al. 2007, Physiological Reviews.
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Figure 1.5: Looping model of chromatin interaction in estrogen receptor signaling
Proposed model of ERα signaling through chromatin interactions. Chromatin looping
brings genes together for ERα induced transcriptional regulation. Genes near the anchored
chromatin are more highly expressed, due to close proximity to transcriptional machinery.
Genes far from the anchor site are expressed at lower levels. Adapted from Fullwood et
al. 2009, Nature.

Figure 1.6: Coregulators involved in mammary gland development
Overview of several coregulators of estrogen receptor signaling known to be required for
each stage of mammary gland development, including pioneer factors FOXA1 and GATA3.
Adapted from Manavathi et al. 2014, Frontiers in Cell and Developmental Biology.
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Figure 1.7: Overview of human breast epithelium
The breast epithelium consists of ductal structures formed by layers of breast epithelial
cells. Myoepithelial (basal) cells make up the outer epithelial layer of the duct while the
luminal epithelial cells are the inner layer, with a lumen in the center. Surrounding the
ducts are stromal cells, including fibroblasts, as well as adipose tissue. Adapted from
Visvader et al. 2009, Genes and Development.
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CHAPTER 2
INTER-INDIVIDUAL VARIARION IN ESTROGEN-INDUCED RESPONSES IN
HUMAN BREAST EXPLANT CULTURES

Introduction/Rationale
Epidemiological studies have identified lifestyle, environmental, and reproductive
risk factors for breast cancer. Early menarche (RR = 1.3), late menopause (RR = 1.2-2.0),
or having the highest quartile of serum estrogen levels (RR = 1.8 – 5.0) are all reproductive
risk factors linked to lifetime estrogen exposure (Brinton et al., 1983, 1988; Clemons and
Goss, 2001; Dall and Britt, 2017). Exogenous estrogens and use of hormone replacement
therapy containing both estrogen and progesterone also increases breast cancer risk (RR =
1.2)(Rossouw et al., 2002). These results suggest that longer lifetime exposure to estrogen
increases breast cancer risk. Estrogen has been demonstrated to contribute to breast tumor
infiltration and promote the growth of breast cancer cells (Russo and Russo, 2006; Tian et
al., 2018). In addition, treatment with selective estrogen receptor modulators to inhibit
estrogen activity in the breast has been shown to reduce breast cancer incidence (Cuzick et
al., 2013).
However, estrogen may also reduce breast cancer risk. A full-term pregnancy after
age 35 increases breast cancer risk, but a full-term pregnancy before age 20 decreases risk
by up to 50% (Albrektsen et al., 2005; Lambe et al., 1996; MacMahon et al., 1970;
Trichopoulos et al., 1983). This protective effect of early parity has been replicated in
rodent models with estrogen and progesterone treatment (Dunphy et al., 2008; Guzman et
al., 1999; Moon, 1969; Russo and Russo, 1980; Sivaraman, 1998; Thordarson et al., 1995).
High dose estrogen treatment can be an effective antitumor therapy in postmenopausal
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women with breast cancer (Lonning et al., 2001). It is hypothesized that a decrease in
endogenous estrogen after menopause or treatment with selective estrogen receptor
modulators may sensitize tumors to estrogen (Yao et al., 2000). Accordingly, estrogen
treatment can induce apoptosis in long-term estrogen deprived breast cancer cells (Song et
al., 2001). Therefore, the effects of estrogen exposure appear to have paradoxical effects
on breast cancer risk.
The effects of estrogen are mediated by the two estrogen receptors: estrogen
receptor alpha (ERα) and estrogen receptor beta (ERβ). Estrogen binds as a ligand to the
two estrogen receptors, which form homodimers or heterodimers, and then bind to DNA
to initiate target gene transcription (Gruber et al., 2002; Heldring et al., 2007b; Yasar et al.,
2017). Target gene transcription is modulated by estrogen receptor dimer combination and
the recruitment of transcriptional coregulators (Chang et al., 2008). ERα expression is
limited to luminal epithelial cells in the breast, while ERβ is expressed in luminal epithelial
cells, basal epithelial cells, and stromal cells (Speirs et al., 2002). Expression of ERα in
normal breast epithelial cells is positively correlated with breast cancer risk and age
(Gulbahce et al., 2017; Shoker et al., 1999a, 1999b; Umekita et al., 2007). The expression
of ERα is known to vary widely among women (Battersby et al., 1992; Söderqvist et al.,
1993), which suggests women vary in exposure to estrogen as well as estrogen receptor
expression. Estrogen mediated responses are carried out by ERα and ERβ and having more
receptor may indicate increased estrogen signaling.
It is estimated that 1 in 8 women will be diagnosed with breast cancer during their
lifetime. This also implies, however, that 7 out of 8 women will not develop breast cancer.
Are some women more sensitive to estrogen exposure? It is known in rodent models that
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certain mouse and rat strains are more sensitive to estrogen-induced responses and/or
mammary tumors. Mice strains exhibit differences in estrogen-induced proliferation,
apoptosis, and mammary tumor formation (Montero Girard et al., 2007; Aupperlee et al.,
2009; Jerry et al., 2018). Copenhagen and Brown Norway rat strains are resistant to
estrogen-induced mammary tumors while the ACI strain is susceptible (Dennison et al.,
2015b; Shull et al., 2001, 2018).
We hypothesized that specific individuals may be more sensitive to estrogen
exposure, and that this increased sensitivity may be due to increased ERα and ERβ levels,
age, parity, or differing expression of estrogen receptor signaling coregulators. To examine
this, we utilized an ex-vivo human breast explant model to compare estrogen receptor
levels, transcriptional responses, and functional responses in individual women. Human
breast explants retain luminal and basal epithelial cells, stromal cells, and adipose cells and
the interactions between those cells. They have also been shown to be maintained in culture
for up to 2-4 weeks and are responsive to hormone treatment (Eigeliene et al., 2016; Tanos
et al., 2013; Eigeliene et al., 2012, 2008; Eigėlienė et al., 2006; Zhuang et al., 2003). The
human breast explant model also allows for the clearing of endogenous hormones, so that
responses to a single consistent dose of estrogen can be measured.
We observed significant changes in estrogen receptor expression with age in breast
tissue from over 100 donors. In explant donors, levels of ESR1 and ESR2 varied by more
than 80-fold.

Estrogen-induced target gene responses (AREG, PGR, and TGFβ2),

regulation of progesterone receptor protein levels, proliferation, and irradiation-induced
apoptosis were not significantly correlated with estrogen receptor levels. Parity influenced
sensitivity to estrogen treatment, as nulliparous donor explants had consistent up-
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regulation of estrogen mediated target genes while parous had more variable expression.
Collectively, these data suggest that estrogen receptor expression does not correlate with
sensitivity to estrogen exposure.

We propose that differing expression of estrogen

signaling coactivators and corepressors may contribute to individual estrogen sensitivity
and estrogen-induced responses.

Materials and Methods
Sample Collection
Human breast tissue samples used for microarray analysis were collected from
female donors, age 14-70 years, undergoing reduction mammoplasty surgery at Baystate
Medical Center in accordance with the Institutional Review Boards at Baystate Medical
Center and the University of Massachusetts, Amherst (Troester et al., 2009; Sun et al.,
2012; Rotunno et al., 2014). Donated tissue was snap frozen in liquid nitrogen and stored
at -80oC at the Pioneer Valley Life Sciences Institute (PVLSI). Donor demographics and
reproductive history were recorded after tissue collection.
Human breast tissue for explants was gathered through the Rays of Hope Center
for Breast Cancer Research at the PVLSI according to IRB approval #286173 and #132204.
Tissue was collected from female donors (n=31) ages 18-62 years undergoing reduction
mammoplasty surgery. Donor information including age and parity status were recorded
(Table 2.1).
Microarray Analysis
Microarrays were performed at the University of North Carolina at Chapel Hill as
described previously (Troester et al., 2009; Sun et al., 2012; Rotunno et al., 2014). Briefly,
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100mg of frozen tissues were homogenized for RNA isolation using RNeasy kits. RNA
quality and concentration were determined using an Agilent 2100 Bioanalyzer and a ND1000 Nanodrop spectrophotometer. Two-color 4x44K Agilent whole genome arrays were
performed.

Data are publicly available through the Gene Expression Omnibus

(GSE:16113 and GSE:33526). When multiple probe sets for a gene were present, we used
the probe with expression values for the most donor samples. Trends were analyzed using
linear regression analysis in Graphpad Prism (GraphPad Prism version 7, La Jolla, CA).
Explant Culture
See Figure 2.3 for overview of model.

Fresh breast tissue was cut into

approximately 1x1x4mm sections using a Stadie-Riggs microtome. For each donor, tissue
sections were frozen or fixed immediately for time zero (T=0) samples. The remaining
sections were placed on top of surgical foam (Ethicon) in 60mm plastic dishes and cultured
for a total of 7 days. The explants were kept in a humidified incubator with 5% CO2 at
37oC. Explants were cultured in basal media for 3 days to clear endogenous hormones and
then cultured in basal or E2 media for an additional 4 days. Basal culture media consisted
of phenol red free DMEM:F12 (Sigma-Aldrich), 10% charcoal stripped FBS (FB-04,
Omega Scientific), 10ng/mL human EGF (21-8356-U100, Tonobo Biosciences), and
antibiotic-antimycotic (15240-062, Gibco). E2 treatment media included basal media with
the addition of 10nM 17β-estradiol (E2758-250MG, Sigma-Aldrich). 4,4’,4”-(4-Propyl[1H]-pyrazole-1,3,4-triyl)trisphenol-treatment media (PPT; ERα specific agonist) or 7Ethenyl-2-(3-fluoro-4-hydroxyphenyl)-5-benzoxazolol (ERB041; ERβ specific agonist)
included basal media with the addition of 200nM PPT or 200nM ERB041; respectively
(Tocris, Minneapolis, MN). Half of the tissue from each donor was irradiated with 5Gy 6
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hours prior to tissue collection on day 7 of culture. Half of the explant sections intended
for histological endpoints were fixed in 10% NBF overnight and transferred to 70% ethanol
before processing and paraffin embedding. The other half of the explant samples were
snap frozen and stored at -80oC for later RNA isolation. Table 2.2 summarizes the
experimental analyses performed on each individual donor sample.
RT-qPCR
RNA isolation was performed using TRIzol according to manufacturer’s
recommendation (15596018, ThermoFisher Scientific). cDNA was synthesized using 2 g
of RNA with the Transcriptor First Strand cDNA synthesis kit (04-379-012-001, Roche).
cDNA was diluted 1:10 before use in RT-qPCR.

RT-qPCR was performed in a

thermocycler (Mastercyler Epgradient S model 5345, Eppendorf). See Table 2.3 for
primer sequences. Statistical analysis was performed using 2-way ANOVA in Graphpad
Prism (GraphPad Prism version 7, La Jolla, CA). Expression is relative to mean control or
to an inter-run calibrator (IRC) consisting of pooled cDNA from a subset of T=0 (not
cultured) samples.
Hematoxylin and Eosin Staining
Hematoxylin and eosin (H&E) staining were performed on paraffin-embedded 4micron sections. Briefly, sections were deparaffinized in xylenes and rehydrated in graded
ethanols. Sections were stained with Mayer’s modified hematoxylin (S216-32OZ, Poly
Scientific) and eosin phloxine alcohol working solution (S176-32OZ, Poly Scientific).
After dehydration in graded ethanols and clearing with xylenes, slides were cover-slipped.
Images were obtained under 200x magnification (BZ-X700 microscope, Keyence, Itasca,
IL).
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Immunohistochemistry
Immunohistochemistry (IHC) was performed on paraffin-embedded 4-micron
sections using a DakoCytomation autostainer (Dako, Carpinteria, CA) and the antibodies
listed in Table 2.4. Sections were deparaffinized in xylenes, rehydrated in graded ethanols,
and rinsed in phosphate buffered saline (PBS) before antigen retrieval. For ERβ detection,
antigen retrieval was performed in heated 0.01M citrate buffer for 10 minutes. Using the
Acuity polymer detection system, primary antibody incubation was performed at room
temperature for 30 minutes, followed by incubation with horse-radish peroxidase (HRP)
polymer and chromogen detection. For ER, PR and PCNA detection the Envision HRP
Detection system was used (Dako). Antigen retrieval was performed by heating in 0.01M
citrate buffer (pH 6) for 10 minutes for PR and 20 minutes for ER and PCNA. Primary
antibody incubation was performed for 30 minutes. Primary antibody information and
dilutions are listed in Table 2.4. Incubation with secondary antibody (K4001 or K4003,
Dako) was performed according to manufacturer’s instructions (Dako, Carpinteria, CA).
Immunoreactivity was visualized with chromogen diaminobenzidine (DAB) incubation for
10 minutes. Sections were counterstained with hematoxylin. Images were obtained under
200x magnification (model BZ-X700 microscope). Positive cells were quantified (ImageJ
software, https://imagej.nih.gov/ij/) as the percentage of positive luminal cell nuclei in a
total of 600-1200 cells).
Immunofluorescence
Freshly cut 4-micron paraffin-embedded sections were deparaffinized/rehydrated
(3X xylenes 5 min, 2X 100% ethanol for 5 min, 95% ethanol for 3 min, 70% ethanol for 3
min). Samples were rinsed with PBS. Antigen retrieval was performed by boiling slides in
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0.1mM EDTA for 30 minutes. Samples were cooled to RT and treated with SSC 0.2X with
gentle shaking at RT for 20 minutes. Samples were blocked in 5% BSA/PBS with 0.5%
Tween-20 for 1 hr. Primary antibody incubation was done with monoclonal S9.6 antibody
(1:100, ENH0001 Kerafast) or anti-H2AX (1:100, 9718S Cell Signaling ) overnight at
4oC. After primary incubation, samples were washed 3 times with PBS containing 0.5%
Tween-20 and then incubated with secondary antibody for 1 hr. Samples were washed 2-3
times with PBS containing 0.5% Tween-20 and then mounted with Vectashield mounting
medium containing DAPI (H-1200, Vector Laboratories). Slides were imaged at 60X with
Nikon A1 Spectral Confocal microscope. Analysis of S9.6 or H2AX foci per nucleus were
calculated using Nikon analysis software.
Terminal Deoxynucleotide Transferase dUTP Nick-End Labeling (TUNEL)
TUNEL was performed on 4-micron sections. Sections were deparaffinized in
xylenes and rehydrated in graded ethanols. The Apoptag Plus Peroxidase in Situ Apoptosis
Detection kit was used according to manufacturer’s instructions to label apoptotic cells
(S7101, MilliporeSigma). Sections were rehydrated in ethanols and cleared in xylenes
before adding cover slips. Images were taken at 200x (model BX40 microscope, Olympus,
Tokyo, Japan) using a MicroPublisher 3.3RTV camera (QImaging, Surrey, British
Columbia, Canada). Positive cells were quantified using ImageJ as the percentage of
positive luminal epithelial cells.
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Results
Variation in Estrogen Receptor Expression
Previous studies have demonstrated that ERα protein levels in normal human breast
tissue increase with age. To determine if this trend could be observed also at the transcript
level, fresh breast tissue was collected from 129 women undergoing reduction
mammoplasty. We used cDNA synthesized from these samples in a microarray to examine
ESR1 mRNA levels. To account for variation in epithelial content between samples, we
normalized ESR1 by KRT18 expression (Figure 2.1a). Linear regression analysis of this
data revealed ESR1 levels significantly increase with age (p < 0.05), corresponding with
observed protein expression data. Variation in ESR1 mRNA level was high, as indicated
by a low R2 value for the line of best fit (R2 = 0.115). We next wanted to determine if
ESR2 expression was also correlated with age. Examination of ESR2 mRNA levels
normalized to KRT18 (Figure 2.1b) in these same patients from our microarray data
revealed a significant increase in expression with age (p < 0.001). There was also a weak,
but positive correlation between ESR1 and ESR2 (Pearson Correlation Coefficient 0.378,
p < 0.001) in this data set.
While ERα is expressed only in luminal epithelial cells of the breast, ERβ
expression has been observed in luminal epithelial cells, myoepithelial cells, stromal cells,
endothelial cells, and lymphocytes. To examine ERβ expression in luminal epithelial cells,
we performed IHC using the PGG5/10 mouse anti-human ERβ1 monoclonal antibody in a
subset of 45 samples (Figure 2.2). We observed ERβ positive cells in the stroma as others
have found, as well as in basal and luminal epithelial cells of the ducts (Figure 2.2a).
Linear regression analysis of ERβ positive epithelial cells revealed a significant decrease
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in ERβ protein expression with age (Figure 2.2b, p < 0.05). Both ESR2 mRNA and ERβ
protein levels had a high level of variance with low R 2 values of 0.068 and 0.106, just as
observed with ESR1 mRNA levels (Figure 2.2 and Figure 2.1, respectively). This data
demonstrates age-related changes in expression of both estrogen receptors and that the
effect is highly variable among individuals.

Human Breast Explant Model
It has previously been shown that estrogen receptor expression fluctuates with the
menstrual cycle. ER expression is highest at the follicular phase of the estrus cycle. Our
prior microarray data on ESR1 and ESR2 expression was performed using tissue from both
premenopausal and postmenopausal women, with the majority being premenopausal. As
we do not know the stage of the estrus cycle for each donor, this could significantly impact
the levels of ESR1 and ESR2 we observed (Figure 2.1). In order to observe responses to
E2 treatment ex vivo, we utilized a human breast explant model (Figure 2.3). This model
allows us to study responses to estrogen in a human ex vivo system, where each donor can
be compared to their own basal control. Donor information, including age and parity status,
is shown in Table 2.1. The donor explant samples collected in our initial culture conditions
will be referred to as set 1. A list of analyses performed on these samples is included in
Table 2.2.
One benefit of the human breast explant model is that stromal, epithelial, and
adipose cells are all present in culture, so cell-cell interactions can occur between these cell
types. Culture conditions are important for maintaining this tissue architecture. In order
to confirm that our culture conditions were not leading to degradation of the breast tissue,
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we compared tissue architecture from tissue that was fixed within 2 hours of the reduction
mammoplasty (T=0) to explant tissue after 7 days in culture (Figure 2.4). In this first set
of explant samples, we did not observe tissue degradation or gross apoptotic nuclei in the
epithelial ducts. Normal breast architecture was maintained, with cuboidal luminal and
basal epithelial cells, surrounding stromal cells, and adipocytes. Nulliparous individuals
consisted of smaller lobular structures (Figure 2.4a-d) than parous explants, which had
more complex ductal lobular structures (Figure 2.4e-f) as previously reported (Russo et
al., 1992). This tissue architecture is retained by the explants after 7 days in culture.

Optimization for RT-qPCR in explants
Breast tissue composition is known to vary greatly between individuals, which
affects the amount of epithelium collected in each tissue fragment and overall RNA yield.
Women with dense breast tissue have greater amounts of stromal and epithelial cells
compared to women with less dense breast tissue, who have more adipose and less
epithelium. ERα is known to be restricted to the luminal epithelial cells of the breast
epithelium. Expression of ERα protein can be detected by immunohistochemistry (IHC),
but quantification is complicated. Representative ERα IHC images from one explant donor
illustrate the heterogenous distribution of ERα protein (Figure 2.5). One lobule from
donor 234 shows relatively high and contiguous ERα positive cells (Figure 2.5a), but
another lobule from the same donor contains almost no ERα positive cells (Figure 2.5b).
Because of the heterogenous distribution of ERα and the limited amount of donor tissue
we receive for explant cultures, IHC quantification of ERα protein is unreliable in explant
cultures.
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For this reason, we sought to optimize our RT-qPCR procedure for our human
breast explant model. To account for differing amounts of epithelium between donors and
between tissue sections, we used keratin 18 as a normalizer for epithelial content, which is
expressed in luminal epithelial cells of the breast epithelium. To test this method, we took
multiple pieces of flash-frozen breast tissue from several donors which had not been
cultured and used them in separate RNA isolations. We then used RT-qPCR to determine
KRT18, ESR1, and ESR1 normalized to KRT18 (Figure 2.6). While fragments from donors
177 and 185 were consistent, fragments from donor 178 demonstrated marked variability
in both KRT18 and ESR1 expression. KRT18 expression in fragment 178b is 6-fold greater
and fragment 178d is 2.7-fold greater than fragment 178a. This is also reflected in ESR1
expression, but when normalized to KRT18, ESR1 expression is consistent across all donor
fragments.
Using this method, we then were able to compare the amount of ESR1 between
multiple donors (Figure 2.7a). Donor 178 had the lowest ESR1 expression, while donor
177 had the highest expression. Donor 185 had 2-fold higher ESR1 expression than donor
178 (p < 0.05). Donor 177 has 3.8-fold higher ESR1 expression than donor 178 (p < 0.01)
and 1.8-fold higher expression than donor 185 (p < 0.05). We next sought to examine
whether ESR1 expression is lost in our explant cultures, as is the case in primary breast
epithelial cell 2D culture. Comparing fresh tissue samples (T=0) to tissue which had been
cultured for 5 days (T=5), we looked at ESR1 expression normalized to KRT18 for two
donors, referred to as donor A and donor B (Figure 2.7b). Donor B had approximately 2fold higher expression of ESR1, but both donor A and donor B ESR1 levels were similar
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between T=0 and T=5. There was no difference in ESR1 expression in explant tissue which
had been cultured in basal or 10nM E2 media.

Transcriptional Responses to Estrogen
In order to determine if estrogen receptor levels correspond with estrogen-induced
transcriptional responses, we examined ESR1 and ESR2 expression in our donor explant
samples. Although previous work in breast cancer cell lines has suggested that E2
treatment decreases estrogen receptor expression, we did not notice any difference in ESR1
or ESR2 levels between basal and E2 treated explants (Figure 2.8, p = 0.18). Four
individual donors showed an increase of 1.6-3.1-fold for ESR1 and 1.2-5.6-fold for ESR2.
For 8 out of 12 donors, ESR1 and ESR2 expression was decreased. Parity status did not
appear to influence ESR1 and ESR2 expression in this subset. In agreement with our
previous microarray data, we observed variation in estrogen receptor mRNA levels among
our explant donors. We observed an over 80-fold variation in ESR1 expression and over
100-fold variation in ESR2 expression.
It has previously been shown that the opening of chromatin during estrogeninduced transcription leads to the formation of R-loops, DNA: RNA hybrids, which if not
resolved are sites of potential DNA damage (Stork et al., 2016). As a measure of global
transcription, we examined R-loop formation after estrogen treatment in our explants using
the S9.6 antibody in immunofluorescence (Figure 2.9). In basal control treated explants,
we observed low levels of R-loop formation indicative of basal transcription levels (Figure
2.9a). After estrogen treatment, there was an increase in the overall number of detectable
R-loop foci per nucleus, suggesting an increased level of transcription (Figure 2.9b).
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Quantification of R-loop foci per nucleus revealed no significant decrease in basal treated
explants compared to T=0 samples, but there was a significant 4-fold increase after E2
treatment in the group of 5 donor samples (Figure 2.9c, p < 0.01). For each donor there
was a similar fold increase in R-loop formation with estrogen treatment, apart from donor
237 which had significantly lower R-loop foci/nucleus than the other 4 donors (Figure
2.9d, p < 0.01). These results indicate an estrogen-induced transcriptional response in all
5 donors, with similar levels of induction in four out of five donor samples.
After determining that there was a global increase in transcription after estrogen
treatment in a small subset of our explant samples, we sought to look at estrogen receptor
target genes as a more specific endpoint of estrogen responsiveness. RT-qPCR of estrogen
receptor target genes AREG, PGR, and TGFβ2 in a set of combined nulliparous and parous
explant donors at first revealed no significant changes with estrogen treatment. However,
after separating the nulliparous and parous explants, we observed significant increases in
AREG (p < 0.05) and TGFβ2 (p < 0.05) and an increase in PGR (p = 0.059) in nulliparous
explants using 2-way ANOVA to account for individual variation (Figure 2.10a-c). In
nulliparous explants, AREG expression increased from 0.39+/-0.23 to 1.14+/-0.34 (Figure
2.10a, p < 0.05). PGR increased from 0.30+/-0.15 to 1.53+/-0.37 (Figure 2.10b, p < 0.06).
TGFβ2 expression increased from 0.46+/-0.25 to 1.68+/-0.34 (Figure 2.10c, p < 0.05).
Response among parous women was more variable, with no overall significant increase in
AREG, PGR, or TGFβ2. Notably, in certain parous explants, expression of one or more
target genes increased while other individuals had decreased expression or little change
(Figure 2.10a-c).
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Pearson correlation analysis of ESR1 and ESR2 mRNA levels and fold-change in
target gene (AREG, PGR, TGFβ2) expression after E2 treatment revealed no significant
correlation (Figure 2.11 and Table 2.5). ESR1 levels were positively and significantly
correlated with ESR2 (Table 2.5, p < 0.05). This data suggests that estrogen receptor levels
do not correlate with individual sensitivity to estrogen-induced transcriptional responses.

Functional Responses to Estrogen
To determine if estrogen receptor levels correlate with functional responses to
estrogen, we examined protein expression of PR, proliferation, and apoptosis in a larger
set of explant donor samples. PR protein was detected in T=0, basal, and E2 treated
explants (Figure 2.12a). Quantification of PR positive luminal epithelial cells revealed a
mean of 11.52% +/-2.55 positive cells in 14 T=0 samples (Figure 2.12b). Basal treated
explants had a mean of 7.9% +/-1.38 positive cells, which was not significantly different
from the T=0. Estrogen treated explants had a mean of 3.44% +/-0.94 which was not
significantly different from basal treated explants but was significantly lower than in T=0
samples (p < 0.05).
Although in other models estrogen induces a proliferative response, we did not
detect significant differences in proliferation as measured by PCNA expression between
T=0 (24.64%+/-5.78), basal (17.21%+/-3.6) or E2-treated (26.74+/-3.47) explants (Figure
2.13a-b). There was a trending increase in proliferation in the E2-treated explants
compared to the basal, but it was not significant (p = 0.067). We observed no significant
changes in proliferation with age or parity status within this sample set using linear
regression analysis (Figure 2.13c). Interestingly, some donors appeared insensitive to E2-
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induced proliferation, despite having low or high initial proliferative levels. Other donors
showed a marked increase in proliferation after E2 treatment.
Our last endpoint of estrogen mediated functional responses was apoptotic response
detected by TUNEL assay (Figure 2.14a-b). In our basal and E2 treated explants, we
examined both spontaneous apoptosis and irradiation induced apoptosis. Both basal and
E2 treated explants showed a significant increase in the number of apoptotic cells 6 hours
after exposure to 5Gy of irradiation (Figure 2.14c, p < 0.05). Basal treated explants
increased from 1.36 +/-0.34 to 4.53% +/-1.2 while E2 treated explants similarly increased
from 1.14 +/-0.33 to 2.94% +/-0.55.

This response was not enhanced by estrogen

treatment, and there was no observable difference between nulliparous and parous explants.
To determine if there was an increase in DNA damage after irradiation due to estrogen
treatment, we performed immunofluorescence for γH2AX in basal and E2 treated explants
(Figure 2.15a-b). While apoptotic cells showed high levels of γH2AX staining, we only
quantified the γH2AX foci in viable nuclei. Basal treated explants had 0.56 γH2AX foci
per nucleus at baseline levels but with irradiation increased to 1.06 foci per nucleus (Figure
2.15c, p < 0.05). Due to variable γH2AX foci levels among the E2 treated explants, there
was no significant increase in γH2AX after E2 treatment. However, the E2 irradiated
explants had significantly higher γH2AX foci per nucleus (2.3 foci/nucleus) than the basal
unirradiated explants (p < 0.05).
Pearson correlation analysis of the functional responses to E2 treatment in this set
of explant samples did not find any significant correlation with ESR1 or ESR2 levels. There
was a significant positive correlation of spontaneous apoptosis and proliferation in the
explants (Table 2.6). These results imply that functional E2 responses in human breast
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explants are also not correlated with estrogen receptor mRNA levels, suggesting that ESR1
and ESR2 levels do not alone determine sensitivity to estrogen.

ERα and ERβ in human breast explants
As another model to study how both ERα and ERβ contribute to the regulation of
estrogen-induced responses among individuals, we expanded the scope of our human
breast culture model. In order to study ERα and ERβ induces responses separately, we
treated with PPT, an ERα specific agonist, or ERB041, an ERβ specific agonist, in addition
to estrogen and control media. We compared expression of ER target genes AREG, PGR,
and TGFβ2 in two initial donors treated with these agonists (Figure 2.16). Donor 1 had
higher baseline expression of all 3 genes compared to donor 2, though the relative levels
varied by gene. E2 treatment only significantly increased PGR expression in donor 1, but
PPT treatment significantly increased AREG and PGR expression (p < 0.05). Interestingly,
ERB041 significantly decreased all 3 genes in donor 1 (p < 0.05). E2 treatment in donor 2
increased expression of AREG and TGFβ2, while PPT and ERB041 significantly increased
all 3 genes (p < 0.05). These donors indicate that both ERα and ERβ are involved in the
regulation of these ER target genes and that these transcriptional responses differ between
individuals.

Discussion
Breast cancer is the most prevalent cancer type and second leading cause of cancer
related death in women (Siegel et al., 2019). Reproductive risk factors for breast cancer,
including early menarche, late menopause, high serum estrogen levels, and pregnancy after
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age 35 are all related to lifetime estrogen exposure. Paradoxically, estrogen is also capable
of decreasing breast cancer risk, including through early parity. Periods of increased
estrogen exposure or prolonged lifetime exposure, depending on context, have differing
consequences for breast cancer risk in women. We demonstrate that in addition to varying
in their exposure to estrogen, women also vary in their sensitivity to estrogen treatment. It
is worth noting that increased breast density is also a risk factor for breast cancer and is
positively correlated with higher serum estrogen levels, and therefore may correlate with
estrogen sensitivity (Brooks et al., 2018). Identification of women who are more sensitive
to estrogen exposure may reveal a subpopulation at increased risk for breast cancer.
Mutations in ESR1, such as 908A/G (K303R) and 1608T/A (Y537N), are known to
produce ERα proteins which are more sensitive to estrogen treatment or constitutively
active and are associated with increased breast cancer risk (Abbasi et al., 2012; Conway et
al., 2005, 2007; Herynk et al., 2007; Jeselsohn et al., 2014).
Our goal was to utilize the ex-vivo human breast explant model to examine
variation in estrogen receptor expression and sensitivity to estrogen detected by estrogeninduced transcriptional and functional responses. We sought to determine if estrogen
sensitivity is correlated with estrogen receptor levels using a single dose of 10nM E2 vs
control media in each individual donor. Transcriptional responses to estrogen included the
detection of R-loops and quantification of AREG, PGR, and TGFβ2 target genes.
Functional responses to estrogen were regulation of PR, proliferation, irradiation-induced
apoptosis, and DNA damage. We then performed correlation analyses to determine if these
responses were correlated with estrogen receptor levels.
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Previous work quantifying estrogen receptor levels in luminal epithelial cells of
normal human breast tissue have shown that ERα expression increases with age and is
detectable in 32-68% of samples (Battersby et al., 1992; Söderqvist et al., 1993; Gabrielson
et al., 2016). In our microarray data of fresh normal breast tissue from over 100 donors,
we also observed a significant increase in ESR1 mRNA with age (Figure 2.1a). ESR2
mRNA expression was also significantly increased with age (Figure 2.1b), although ERβ
expression decreased with age (Figure 2.2b). ERβ is expressed in luminal epithelial, basal
epithelial, and stromal cells (Figure 2.2a) and the amount of stromal cells increases with
age (Goyal et al., 2016). The increase in ESR2 mRNA with age is likely affected by the
increased stromal cell population, even after normalizing to KRT18 for luminal epithelial
cell levels. It is also possible that our ERβ antibody, PPG5/10, detected another nuclear
protein as many ERβ antibodies are not specific for ERβ (Andersson et al., 2017; Nelson
et al., 2017).
Recent publications have questioned the validity of multiple commonly used ERβ
antibodies. Earlier reports with the PPG5/10 ERβ antibody confirmed effectiveness
through western blots detecting a 60kDa protein, which correspond to the ERβ 1 isoform,
and through in vitro work with ERβ overexpression in U2OS cells (Shaaban et al., 2008;
Wu et al., 2012). These studies also confirmed ERβ expression in both epithelial cells and
stromal cells, as we observed in our work. More reports suggest that the PPG5/10 ERβ
antibody is not specific for ERβ. Using rapid immunoprecipitation mass spectrometry of
endogenous protein, a 2017 paper demonstrated that the PPG5/10 antibody does have
specificity for ERβ but also binds non-specifically to a 77kDa band in western blots
(Nelson et al., 2017). Another 2017 paper states that the PPG5/10 antibody does not bind
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ERβ but instead binds to other nuclear proteins (Andersson et al., 2017). Regardless of
ERβ antibody specificity, we observed a high degree of variability in both ESR2 and ERβ
levels among women. This was also true for ESR1 expression, suggesting individual
variation in estrogen receptor expression.
In our human breast explant samples, we sought to correlate estrogen receptor
levels with estrogen-induced responses. We aimed to quantify ERα expression by IHC;
ERβ detection by IHC is unreliable with current available antibodies. We found that ERα
detection was highly variable both within an individual sample and between donors
(Figure 2.5). One lobule within a patient sample exhibited high ERα expression while
other lobules expressed almost no ERα (Figure 2.5a and b, respectively). This agrees with
previous work showing that, in normal human breast tissue, expression of ERα may be
contiguous, within a single lobule, or scattered (Battersby et al., 1992; Goyal et al., 2016).
Due to these issues with the quantification of ERα protein and the limited amount of donor
tissues we received for explant cultures, we examined mRNA expression of ESR1 and
ESR2 using KRT18 normalization to optimize for the amount of epithelium in each sample
(Figure 2.6 and Figure 2.7). In 12 explant donor samples, we observed up to 80-fold
variation in ESR1 and up to 100-fold variation in ESR2 expression, which was not
significantly changed with 10nM E2 treatment (Figure 2.8).
Examination of individual explant donors revealed a trending decrease in ESR1 and
ESR2 expression in 8 donors and increase in 4 donors (Figure 2.8). This suggests that
negative feedback inhibition of estrogen receptor may be prevalent in certain donors in our
study. In human breast cancer cell lines, some studies have observed negative feedback of
estrogen receptor while others are unchanged. T47D breast cancer cells show an increase
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in ESR1 mRNA levels and no change in ERα protein with estrogen treatment (Berkenstam
et al., 1989; Read et al., 1989; Pink and Jordan, 1996). MCF7 cells, in culture conditions
with estrogen containing serum, decrease ESR1 mRNA and ERα protein (Eckert et al.,
1984; Saceda et al., 1988; Read et al., 1989; Pink and Jordan, 1996). However, MCF7
cells cultured in media with charcoal stripped serum, to remove estrogens, no longer
decrease estrogen receptor expression with estrogen treatment (Read et al., 1989). Our
results therefore fit in with these previous studies, as some individual donors demonstrate
E2-mediated repression of ESR1 while others show an increase. This regulation likely
depends on previous estrogen exposure and genetic background.
Estrogen receptor signaling pathways activate transcription of numerous estrogen
receptor target genes (Gruber et al., 2002; Carroll et al., 2005; Heldring et al., 2007b; Yasar
et al., 2017). In breast cancer cells and normal mammary epithelial cells, estrogen
treatment is known to cause the formation of transient DNA:RNA hybrids known as Rloops (Stork et al., 2016; Belotserkovskii et al., 2018; Vanoosthuyse, 2018; Majhi et al.,
2020).

The formation of these R-loops is dependent on estrogen receptor induced

transcription. R-loop formation has been observed at estrogen receptor target genes in
MCF7 cells (Stork et al., 2016). Our lab has shown the presence of R-loops in T47D cells
and in normal mouse mammary epithelial cells (Majhi et al., 2020). Human mammary
epithelial cells, such as MCF10A and 76N Tert, do not form R-loops with estrogen
treatment (Stork et al., 2016; Majhi et al., 2020). However, addition of estrogen receptor
into these cells results in measurable R-loop formation upon estrogen treatment (Majhi et
al., 2020). As R-loops are dependent on estrogen receptor expression and estrogen-induced
transcription, we used R-loop detection as a measurement of global transcription in our
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human breast explants. We observed a significant increase in R-loop formation with
estrogen treatment, which was consistent across donors (Figure 2.9). This demonstrates
that explants response to estrogen treatment in culture by activating transcription, as in
mouse mammary glands and breast cancer cell lines.
Next, we examined specific transcriptional responses in our explants by RT-qPCR
analysis of ER target genes AREG, PGR, and TGFβ2. AREG and PGR are common ER
target genes induced upon E2 treatment in mice and in human breast cancer cell lines
(Ciarloni et al., 2007; Peterson et al., 2015). TGFβ2 is also an ER target gene and is
downregulated in MCF7 cells with E2 treatment (Putnik et al., 2012). In nulliparous
explants, we observed significant increases in AREG and TGFβ2 and a trending increase
in PGR (Figure 2.10). Parous explants had overall more variable responses in these 3
target genes, with some increasing, decreasing, or remaining unchanged (Figure 2.10).
These results were somewhat surprising, as we had expected to observe increases in AREG
and PGR and a decrease in TGFβ2. This may be due to the limited number of ER positive
cells in our heterogeneous explant samples and that many of these target genes were
identified in breast cancer cell lines.
Human breast organoids are thought to contain 7-10% ER positive cells (Meng et
al., 2019), which is comparable to the 5-20% in normal human breast tissue. In human
breast organoids E2 treatment upregulates PGR expression, but not AREG (Meng et al.,
2019). In human breast explants, AREG protein expression was increased with 10nM E2
treatment, which agrees with our data at the mRNA level in nulliparous explants (Eigeliene
et al., 2012). Expression of estrogen responsive genes, therefore, may be diluted by the
limited number of ER positive cells in the overall cell population in human breast organoids
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and our human breast explants. ER positive breast cancer cell lines have more homogenous
expression of ERα, and accordingly have consistent target gene responses. Although we
hypothesized that donors with greater estrogen receptor expression would be more
sensitive to E2 treatment, there was no correlation between ESR1 and ESR2 expression and
E2-induced changes in AREG, PGR, and TGFβ2 (Figure 2.11 and Table 2.5). These
estrogen receptor target genes are more diversely regulated in normal human breast
explants than in ER positive breast cancer cell lines, suggesting individual estrogen
mediated transcriptional responses.
ESR1 and ESR2 were also not correlated with function responses to E2 treatment.
PR protein expression is detectable by IHC in more than 80% of human breast samples
(Battersby et al., 1992; Söderqvist et al., 1993), but we did not observe a significant change
in PR expression between our basal control and 10nM E2 treated explants (Figure 2.12).
E2 treated explants had significantly lower PR than T=0 fresh breast tissue. Previous work
in human breast explants also demonstrated no change in control vs E2 treated samples
(Eigeliene et al., 2008). Additionally, PR expression studies in human breast tissue
collected during the follicular and luteal phases of the menstrual cycle, where estrogen
levels fluctuate, demonstrated no change in PR (Battersby et al., 1992; Söderqvist et al.,
1993). Responses in our human breast explants differed compared to human explants in
nude mice, however, where E2-treatment induced increases in PR expression (Laidlaw et
al., 1995). Of the 5 explant donors included in detection of both PGR and PR, one donor
(185) exhibited very little change in either mRNA or protein expression, one donor (238)
had an increase in mRNA and no change in protein, and three donors (179, 231, 234) had
an increase in mRNA and a decrease in protein with estrogen treatment.
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These PGR results are unexpected, as previous reports using breast cancer cell lines
have suggested progesterone receptor mRNA and protein levels are closely correlated
(Read et al., 1989; Cho et al., 1994; Fazzari et al., 2001). However, it has also been
demonstrated that PR regulation is controlled by several factors including cyclic adenosine
monophosphate, serum factors, and growth factors (Cho et al., 1994). One other study in
T47D cells also proposed, depending on the subline of breast cancer cells and basal PR
protein levels, as their T47D line showed estrogen-induced increase in PGR but no change
in PR protein (Vegeto et al., 1990). In most breast tumors examined, mRNA levels
correlated with protein activity, but in a subset of tumors (8%) this was not the case.
Regardless, 3 of 5 of our explants illustrate an apparent dysregulation of PGR mRNA and
PR protein, which could be due to increased protein turnover. However, our small sample
size makes it difficult to make any definitive conclusions.
E2-induced proliferation, detected by PCNA, was also not correlated with either
ESR1 or ESR2 mRNA levels (Figure 2.13). In human breast cancer studies, Ki67 is often
used as a marker for proliferation. The range of Ki67 positive cells in the normal human
breast, however, is very low (0.3-2.6%) (Shoker et al., 1999b). Another specific marker
for S/M phase of the cell cycle, phospho-histone H3, is also very lowly expressed in normal
breast (<0.05%) and did not report E2-induced proliferative responses (Tanos et al., 2013).
In our human breast explants, we found that Ki67 expression was very low (<2% of cells),
and with the limiting number of epithelial cells in our samples decided to use PCNA
instead. PCNA is expressed in the S and G2 phases of the cell cycle (Juríková et al., 2016;
Qiu et al., 2019), and has been used previously by our lab in ovariectomized mice to detect
estrogen-induced proliferation (Becker et al., 2005). In mice, we observed 60% PCNA
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positive cells with E2 treatment compared to 5% in control. Our human explants also
showed much higher levels of PCNA than Ki67, with a range of 3-58% (Figure 2.13b).
We observed a trending increase in proliferation in E2 treated explants in most donors,
though some with high basal levels were not responsive. Though it has been shown that
proliferation in the human breast is reduced in parous individuals and with age, we did not
find any relationship between PCNA positive cells and age or parity (Figure 2.13c).
Our lab has shown that parous BALB/c mice are more sensitive to irradiation
induced apoptosis than nulliparous mice and that this effect is enhanced by estrogen and
progesterone treatment (Becker et al., 2005; Dunphy et al., 2008). In our human breast
explants, while we observed a significant increase in apoptosis with irradiation, we did not
observe a significant difference in irradiation-induced or spontaneous apoptosis between
basal control and estrogen treated explants (Figure 2.14). It is known that spontaneous
apoptosis does not vary during the menstrual cycle, which supports the results observed
here (Navarrete et al., 2005; Potten et al., 1988). However, estrogen treatment has been
shown to repress spontaneous apoptosis in human breast explants (Eigėlienė et al., 2006).
Deficiency in DNA damage response pathways is correlated with increased breast cancer
risk (Venkitaraman, 2001; Roy et al., 2011), so we also examined a marker of DNA damage
(γH2AX) in our explants to detect any accumulation of damage from irradiation or estrogen
treatment. We observed a significant increase in DNA damage after irradiation in both
control and estrogen treated samples, but there was no increase with estrogen treatment
(Figure 2.15). This suggests that, in our explants, there was no notable accumulation of
DNA damage after 4-day estrogen treatment.
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We treated a preliminary set of explants with ER specific agonists, PPT and
ERB041, to characterize the role of ERα and ERβ in the variable estrogen-induced target
gene activation. In our two parous explant donors, we observed variable responses in
AREG, PGR, and TGFβ2 (Figure 2.16). PPT, an ERα specific agonist, induced AREG and
PGR expression in both explants (p < 0.05). In donor 2, PPT treatment increased TGFβ2
expression (p < 0.05), but in donor 1 TGFβ2 was unchanged. Donor 1, who had higher
basal expression of all 3 target genes, showed a significant decrease in all 3 genes with
ERB041, an ERβ specific agonist, treatment (p < 0.05). This agrees with reports that ERβ
opposes the actions of ERα (80-82). Interestingly, in donor 2, who had lower basal
expression of these genes, the reverse was observed; ERB041 significantly increased
expression of all 3 genes (p < 0.05). Both donor 1 and donor 2 exhibited modest target
gene induction with estrogen treatment, which could be attributed to the ratios of ERα and
ERβ in the breast epithelium of each individual (Chang et al., 2008; Covaleda et al., 2008).
Our work with the human breast explant model illustrates the inter-individual
variation in estrogen receptor expression as well as estrogen-induced transcriptional and
functional responses. In agreement with previous literature, we observed significant
increases in ESR1 and ESR2 with age which had only been shown at the protein level.
While global transcription, reported by R-loop detection, increases similarly among
individuals, specific estrogen receptor target gene responses vary and are influenced by
parity. Similarly, functional responses to E2, including regulation of PR and induction of
proliferation, varied by individual. Neither transcriptional nor functional responses were
correlated with ESR1 and ESR2 expression, indicating that the level of estrogen receptors
expressed do not dictate estrogen sensitivity. We propose that differences in estrogen
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receptor signaling, mediated by coactivators and corepressors, may modulate estrogen
sensitivity and have important implications for breast cancer risk.
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Table 2.1: Donor information for first set of human breast explants
Donor information for all nulliparous, parous, and unknown parity donors used in the
human breast explant model (set 1). Collected by Dr. Karen Dunphy.

Nulliparous

Parous

Unknown

Donor
Number

Age

Donor
Number

Age

Age at
First Birth

Donor
Number

Age

237

18

186

26

20

239

35

237

18

189

27

25

176

37

240

18

225

35

27

231

26

234

35

23

184

27

181

39

19

249

28

178

43

39

187

29

243

45

21

180

47

185

49

17

179

61

241

50

18

51

Table 2.2: List of analyses performed on first set of explant donor tissues
Summary donor information and experiments performed on RNA or tissue sections of
explant donor tissues from set 1. Experiments included R-loop detection, qPCR analysis
of ER and ER target genes, progesterone receptor (PR) IHC, PCNA IHC for proliferation,
TUNEL assay for detecting irradiation induced apoptosis, and irradiation induced DNA
damage by γH2AX detection.
Donor
Age
Number

Parity

RqPCR
PR PCNA
γH2AX
loop
TUNEL:
analysis: IHC: IHC:
IF:
IF:
Yes
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
No
No
No
No
No
Yes
No
No
Yes
Yes
Yes
Yes
No
Yes
No
Yes
Yes
Yes
Yes
No
No
Yes
Yes
No
No
No
No
Yes
Yes
Yes
No
No
Yes
No
No
Yes
No
No
Yes
Yes
Yes
Yes
No
No
No
Yes
No
No
No
No
Yes
No
Yes
Yes
No
No
No
No
Yes
Yes
No
No
No
No
No
Yes
No
Yes
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
No
Yes
No
No
No
Yes
Yes
Yes
No
Yes
No
No
Yes
No
Yes
No
Yes
Yes
Yes
Yes
No
Yes
No
No
Yes
Yes
Yes
No
No
Yes
No
Yes
No
No
Yes
No
Yes
Yes
No

ss237
ss238
ss240
ss231
ss184
ss249
ss187
ss180
ss179
ss250
ss186
ss189
ss225
ss234
ss181
ss178
ss243
ss185
ss241
ss244
ss177

18
18
18
26
27
28
29
47
61
62
26
27
35
35
39
43
45
49
50
56
58

Nulliparous
Nulliparous
Nulliparous
Nulliparous
Nulliparous
Nulliparous
Nulliparous
Nulliparous
Nulliparous
Nulliparous
Parous
Parous
Parous
Parous
Parous
Parous
Parous
Parous
Parous
Parous
Parous

ss239

35

Unknown

No

ss176

37

Unknown

No

ss379
ss438

21
51

Parous
Parous

No
No

Yes (ER
only)
Yes (ER
only)
Yes
Yes
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No

No

No

No

No

No

No

No

No
No

No
No

No
No

No
No

Table 2.3: RT-qPCR primer sequences
Primer sequences used in RT-qPCR of human explant samples. Used on Eppendorf
thermocycler.

Gene
Keratin 18 (KRT18)
Estrogen receptor 1 (ESR1)
Estrogen receptor 2 (ESR2)
Amphiregulin (AREG)
Progesterone receptor (PGR)
Transforming growth factor
β2 (TGFβ2)

Sequence: 5’ to 3’
Fwd – CAC AGT CTG CTG AGG TTG GA
Rev – GAG CTG CTC CAT CTG TAG GG
Fwd – TTA CTG ACC AAC CTG GCA GA
Rev – ATC ATG GAG GGT CAA ATC CA
Fwd – GTT TGG GTG ATT GCC AAG A
Rev – TCC ATC CCC TTG TTA CTG G
Fwd – CGG AGA ATG CAA ATA TAT AGA GCA C
Rev – CAC CGA AAT ATT CTT GCT GAC A
Fwd – TTT AAG AGG GCA ATG GAA GG
Rev – CGG ATT TTA TCA ACG ATG CAG
Fwd – ATA GAC ATG CCG CCC TTC TT
Rev – CTC CAT TGC TGA GAC GTC AA

Table 2.4: Antibody information for IHC
Antibodies used in IHC on human explant samples.

Target
Estrogen
receptor alpha
(ERα)
Estrogen
receptor beta
(ERβ)
Progesterone
receptor (PR)
Proliferating cell
nuclear antigen
(PCNA)

Name of Antibody,
Catalog Number

Manufacturer

Dilution
Used

Species

1D5, MA5-13191

Thermo Fisher
Scientific

1:200

Mouse,
monoclonal

PPG5/10, M7292

Dako

1:200

Mouse,
monoclonal

Progesterone receptor
A/B, D8Q2J

Cell Signaling

1:500

Rabbit,
monoclonal

PC10,
ab29

Abcam

1:10,000

Mouse,
monoclonal
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Table 2.5: E2-induced gene response does not correlate with estrogen receptor
expression
Results of Pearson correlation analysis comparing ESR1 or ESR2 mRNA expression with
fold change in AREG, PGR, and TGFβ2 expression induced by estrogen treatment
compared to basal controls. ESR1 and ESR2 were not positively or negatively correlated
with E2-induced change in AREG, PGR, and TGFβ2 expression (p > 0.05) as indicated by
correlation coefficients close to zero. ESR1 is positively correlated with ESR2 expression
(p < 0.05), indicated by a correlation coefficient close to 1.

Correlation Coefficient

ESR1

ESR2

AREG

-0.138, p = 0.705

0.016, p = 0.965

PGR

-0.126, p = 0.729

-0.036, p = 0.921

TGFβ2

-0.096, p = 0.792

0.005, p = 0.989

ESR2

0.702, p = 0.024

---

Table 2.6: ER mRNA levels do not correlate with functional responses to E2
Results of Pearson correlation analysis comparing ESR1 or ESR2 mRNA expression with
E2-induced increase in PGR protein expression, proliferation, spontaneous apoptosis, or
irradiation induced apoptosis. ESR1 and ESR2 were not positively or negatively correlated
with E2-induced functional endpoints (p > 0.05) as indicated by correlation coefficients
close to zero. Spontaneous apoptosis was significantly positively correlated with
proliferation.

Spontaneous Irradiation
apoptosis
induced
(no IR)
apoptosis

Correlation
Coefficient

ESR1

ESR2

PGR

PCNA

PGR

0.090,
p = 0.910

-0.368,
p = 0.632

---

-0.202,
p = 0.798

-0.744,
p = 0.256

-0.226,
p = 0.774

PCNA

0.116,
p = 0.784

0.222,
p = 0.597

-0.202,
p = 0.798

---

0.817,
p = 0.013

0.027,
p = 0.954

0.332,
p = 0.348

0.404,
p = 0.248

-0.744,
p = 0.256

0.817,
p = 0.013

---

0.349,
p = 0.357

0.126,
p = 0.678

0.297,
p = 0.438

-0.226,
p = 0.774

0.027,
p = 0.954

0.349,
p = 0.357

---

Spontaneous
apoptosis
(no IR)
Irradiation
induced
apoptosis
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a

b

Figure 2.1: ESR1 and ESR2 expression diversity among women.
Agilent microarray data of human breast tissue collected from donors undergoing reduction
mammoplasty surgery. Expression of (a) ESR1 is shown in 111 donor samples and (b)
ESR2 from 102 donor samples, both normalized to KRT18 expression. Linear regression
analysis showed a significant increase in both ESR1 (p < 0.001) and ESR2 (p < 0.01) levels
with age. Dotted lines indicate 95% confidence intervals and solid lines indicate the best
fit line. R2 values for best fit lines are indicated, and low values indicate high variability
between donors. Microarray data provided courtesy of Dr. Melissa Troester.

a

b

Figure 2.2: ERβ protein expression decreases with age.
IHC using ERβ antibody (PPG5/10) was performed on paraffin-embedded sections from
45 donor samples. Representative image (a) with arrows indicating representative positive
cells: yellow arrows indicate positive luminal epithelial cells, red indicate positive basal
epithelial cells, and black indicate positive stromal cells. Scale bar is 50uM. (b)
Quantification of ERβ positive ductal epithelial cells. Linear regression analysis shows a
significant decrease in ERβ with age (p < 0.05). Dotted lines indicate 95% confidence
intervals and solid lines indicate the best fit line. R 2 values for best fit lines are indicated.
Data provided courtesy of Dr. Karen Dunphy and Dr. Sallie Schneider.
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Figure 2.3: Overview of human breast explant model
Tissue obtained from donors undergoing reduction mammoplasty were sectioned into
strips. Some strips were flash frozen or fixed in 10% neutral buffered formalin (NBF) for
time 0 (T=0) samples. All other strips were placed on surgical foam in tissue culture dishes
and cultured in basal control media for 3 days to clear endogenous hormones. After
clearing, the explants were treated with either basal control or 10nM E2 media for an
additional 4 days. Six hours prior to collection, half of the samples were irradiated. At
collection, tissue strips were either flash frozen for later RNA isolation or fixed in 10%
NBF for later IHC.
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Figure 2.4: Explant tissue architecture at T=0 and T=7
Representative H&E images from four explant donors comparing tissue architecture at T=0
(a, c, e, g) and T=7 (b, d, f, h) for nulliparous (a-d) and parous (e-h). Donors are from set
1. No apoptotic nuclei were observed. Scale bar is 50uM.
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a

b

Figure 2.5: Heterogenous expression of ERα protein
Representative IHC images from donor 234 showing one lobule with high (a) and one
lobule with low (b) expression of ERα. Scale bar is 50uM.

Figure 2.6: Optimization of RT-qPCR with KRT18
3-4 separate 100ug pieces of flash-frozen tissue from three donors (177, 178, and 185) were
treated as separate samples and used for RT-qPCR analysis of ESR1, KRT18 and ESR1
expression normalized to KRT18. Data provided courtesy of Dr. Karen Dunphy.
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Donor A

Donor B

Figure 2.7: Comparison of ESR1 expression between donors and during culture
Gene expression analysis of (a) ESR1 normalized to KRT18 between three parous donors,
demonstrating variation between individuals. Data provided courtesy of Dr. Karen
Dunphy. (b) Normalized ESR1 expression of two explant donors using tissue collected at
T=0 and tissue from T=5 treated with either basal or 10nM E2 media. ESR1 expression
for each donor appears stable during culture.
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Figure 2.8: ESR1 and ESR2 expression in nulliparous and parous explants
RT-qPCR analysis of basal and 10nM E2 treated explant samples for ESR1 and ESR2 using
KRT18 normalization. Expression shown relative to control mean. Circles represent
nulliparous explants, squares parous explants, and triangles explants with unknown parity
status. Parity and age are shown next to donor ID. Individual fold change in gene
expression is indicated. No significant difference in ESR1 or ESR2 expression was
observed between basal and E2 treated explants (p > 0.05).
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Figure 2.9: E2 induces R-loop formation in human breast explants
Representative images of S9.6 (R-loop) immunofluorescence in (a) basal and (b) E2 treated
explants from donor 184. (c) Quantification of R-loop foci per nucleus in basal and luminal
epithelial cells demonstrates increased R-loop formation with E2 relative to T=0 or basal
treatment (n=5 for each treatment group). (d) R-loop foci per nucleus in basal and E2
treated explants from five donors. Error bars indicate SEM. Significance was determined
using ANOVA (p < 0.01 **). Data collected in collaboration with Aman Sharma.
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Figure 2.10: AREG, PGR, and TGFβ2 expression in nulliparous and parous explants
RT-qPCR analysis of basal and 10nM E2 treated explant samples for AREG, PGR, and
TGFβ2 normalized to KRT18. Expression is shown relative to basal mean. Circles
represent nulliparous explants and squares represent parous explants. Donor age and parity
status is shown in parentheses next to donor ID. Four-day E2 treatment significantly
increased (a) AREG (p < 0.05), increased (b) PGR (p = 0.059), and significantly increased
(c) TGFβ2 (p < 0.05) in nulliparous explants, but not in parous explants. Significance was
calculated using 2-way ANOVA analysis. Data provided courtesy of Dr. Karen Dunphy.
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Figure 2.11: E2-induced target gene responses do not correlate with ER mRNA
expression
Heatmaps representing (top) the fold change in PGR, AREG, and TGFβ2 expression in
basal vs E2 treated explants and (bottom) the expression of ESR1 and ESR2 for each donor
explant relative to the overall mean. All values are normalized to KRT18. Hierarchical
clustering was used to group donors by target gene response. Correlation analysis was
performed using Pearson correlation coefficients in Graphpad Prism. Heatmaps were
created in R studio using heatmap2 package. Donor number, parity status, and age are
indicated.
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Figure 2.12: PR regulation by E2 in human breast explants
Representative (a) progesterone receptor IHC and (b) quantification. E2 treatment
significantly decreased PR expression compared to T=0 samples (p < 0.05), but there was
no difference between T=0 and basal or basal and E2 treated explants. Circles represent
nulliparous explants and squares parous explants. Parity and age are shown next to donor
ID.
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Figure 2.13: E2-induced proliferation in human breast explants
Representative (a) proliferating cell nuclear antigen (PCNA) IHC and (b) quantification.
E2 treatment did not significantly increase proliferation in nulliparous or parous explants
(p > 0.05). Linear regression analysis (c) shows no significant changes in E2-mediated
proliferation due to age. Each individual donor is indicated by a color (see key): square
indicates E2-treated; circle indicates basal-treated. Black arrowhead identifies individuals
that are insensitive to E2-mediated proliferation. White arrow identifies individuals that
are highly sensitive to E2-mediated proliferation (compare to same color circle below
square).
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Figure 2.14: Irradiation induced apoptosis in human breast explants
Representative terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)
images from (a) basal and (b) E2 treated explants irradiated with 5Gy 6 hours prior to
collection to induce apoptosis. Quantification (c) revealed a significant increase in
apoptotic nuclei in irradiated explants compared to unirradiated (p < 0.05), but E2 treatment
did not enhance the apoptotic response (p > 0.05). Circles represent nulliparous explants
and squares parous explants. Parity and age are shown next to donor ID. Data provided
courtesy of Dr. Karen Dunphy and Zida Li.
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Figure 2.15: γH2AX foci formation in human breast explants
Representative images of γH2AX foci from (a) basal IR and (b) E2 IR explants, with inset
indicated. Scale bars are 50uM. Large arrows indicate apoptotic cells and small arrows
show an example of γH2AX foci. Quantification (c) of γH2AX foci per nucleus in five
donor explant samples showed an increase in γH2AX foci in basal treated explants (p <
0.05) but not in E2 treated explants (p > 0.05). Data collected in collaboration with Aman
Sharma.
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Figure 2.16: Effect of estrogen receptor specific agonists PPT and ERB041 on
AREG, PGR, and TGFβ2 target gene response
Two explant donors (379 and 438) from set 1 were treated with basal, E2, ERα specific
agonist PPT, or ERβ specific agonist ERB041 and examined for expression of estrogen
receptor target genes.
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CHAPTER 3
COMPARISON OF ESTROGENIC RESPONSES IN PRIMARY HMECS

Introduction/Rationale
Many epidemiological studies have identified risk factors for breast cancer, such as
early menarche (RR = 1.3), late menopause (RR 1.2-2.0), or having high serum estrogen
levels (RR = 1.8-5.0), which are linked to increased levels of estrogen and/or increased
duration of exposure (Brinton et al., 1983, 1988; Clemons and Goss, 2001; Dall and Britt,
2017). Conversely, estrogen exposure can also reduce breast cancer risk through early fullterm pregnancy by up to 50% (MacMahon et al., 1970; Trichopoulos et al., 1983; Lambe
et al., 1996; Albrektsen et al., 2005) and can be an effective antitumor therapy in
postmenopausal women with breast cancer (Lonning et al., 2001).

These results

demonstrate that estrogen exposure, depending on context, can have conflicting effects on
breast cancer risk. Exposure to xenoestrogens, a class of endocrine disrupting chemicals,
may affect this delicate balance between the protective effects of estrogen and its
contribution to breast cancer risk. Endocrine disrupting chemicals are able to disrupt
normal hormone signaling by mimicking or antagonizing the effects of endogenous
hormones and also by disrupting the synthesis and metabolism of endogenous hormones
and their receptors (Fernandez and Russo, 2010; Sonnenschein and Soto, 1998b).
Xenoestrogens are present in food, drinking water, ambient air, and many are found in
personal care products such as cosmetics and sunscreens (Soni et al., 2001; Mortensen et
al., 2014). Xenoestrogens have estrogenic activity, meaning they act as ligands for
estrogen receptors and thus can potentially regulate estrogen-responsive target genes in a
manner similar to estrogen (Singleton and Khan, 2003).
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Recent work has identified the potential for environmental chemical exposures to
contribute to breast cancer risk.

Two xenoestrogens, benzophenone-3 (BP3) and

propylparaben (PP) have been detected in > 95% of the U.S. population (Ye et al., 2006;
Calafat et al., 2008, 2010). Not much is yet known about potential breast cancer risk from
BP3 or PP exposure. BP3 is a UV-filter used in personal care products, including
sunscreens, while PP is an antimicrobial agent used in food packaging and personal care
products. Studies with MCF7 and T47D breast cancer cell lines, which express ERα, have
shown that 1uM concentrations of BP3 act as a weak agonist for ERα in reporter assays
(Schlumpf et al., 2001; Kerdivel et al., 2013; Schlotz et al., 2017). BP3 exposure during
pregnancy and lactation in mouse models results in altered mammary gland ductal
structures, and these alterations remain for weeks after the exposure has ended (LaPlante
et al., 2018). While some studies have shown that BP3 does not increase proliferation of
breast cancer cell lines (Schlotz et al., 2017; Majhi et al., 2020), others have indicated that
long term high dose exposure may increase cancer cell motility (Alamer and Darbre, 2018).
PP is also an ERα agonist in reporter assays but was also able to increase estrogen
responsive target gene expression and increase proliferation in MCF7 cells at 1uM levels
(Byford et al., 2002) and increased cell motility in short and long term exposures (Khanna
et al., 2014). Our lab has confirmed that BP3 and PP act as agonists for ERα and that only
PP is able to increase cell proliferation (Majhi et al., 2020). BP3 and PP can also induce
the formation of DNA:RNA hybrids (R-loops) in breast cancer cells, normal HMEC lines,
mouse mammary epithelial cells in vivo, and human breast epithelial cells in explant
culture which have the potential to create DNA double strand breaks if not resolved.
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Rodent studies have identified strains which have increased susceptibility to
estrogen-induced mammary tumor development (Shull et al., 1997; Spady et al., 1998;
Dennison et al., 2015; Shull et al., 2018) and have increased sensitivity to estrogen-induced
responses (Montero Girard et al., 2007; Aupperlee et al., 2009). These strains do not have
mutations in any well-known breast cancer risk genes such as BRCA1, BCRA2, or TP53
(Anglian Breast Cancer Study Group, 2000; Antoniou and Easton, 2006; Lalloo and Evans,
2012; Peto et al., 1999; Thompson and Easton, 2004). We have demonstrated in human
ex-vivo breast culture that there is significant inter-individual variation in response to
estrogen that is not correlated with estrogen receptor expression levels (Dunphy et al.,
2020). This data supports the hypothesis that a subset of women may be more sensitive to
estrogen exposure, and potentially more sensitive to xenoestrogen exposure as well.
Genetic variation between individuals is known to affect responses to therapeutic
drugs (Roden et al., 2011). Individual variation has also been demonstrated to influence
cell metabolism and responses to cytokines in human mammary epithelial cell (HMEC)
models (Schneider et al., 2017).

Additionally, genetic variation affects irradiation

sensitivity and apoptosis responses in human cells and mice (Smirnov et al., 2009, 2012;
Snijders et al., 2012; Yard et al., 2016). Gene by environment (gene-environment)
interactions are also known to influence breast cancer risk. SNPs in regions associated
with breast cancer risk increased risk further when combined with alcohol consumption,
height, hormone replacement therapy, and high body mass (Gonzales et al., 2018; Rudolph
et al., 2018).

The increased risk from gene-environment interactions follows a

multiplicative model of increased risk (Travis et al., 2010; Nickels et al., 2013; Barrdahl et
al., 2014; Rudolph et al., 2015; Maas et al., 2016). In related research, SNPS in specific
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genes involved in the metabolism of carcinogens predispose individuals who smoke or
drink alcohol to colon cancer development (Garcia-Closas et al., 2005; Wu et al., 2012a),
which emphasizes how gene-environment interactions can influence the potential risk of
environmental compounds.
It is important, therefore, to create a normal human breast model in which exposure
to xenoestrogens or other compounds can be characterized. Induced pluripotent stem cell
(iPS) lines are useful for differentiating into multiple cell types, but limited success with
iPS lines has been observed in mammary epithelial cell development (Cravero et al., 2015;
Qu et al., 2017). 3D breast organoid models are reliable for breast cancer cell expansion
and characterization, but we have found limited success with normal HMEC cells.
However, others have had success expanding basal and luminal mammary epithelial cells
in organoid culture which retain luminal epithelial cells with expression of ERα (Sokol et
al., 2016). Human explant culture models preserve all cell types in the mammary gland,
maintain estrogen receptor levels, and are hormonally responsive but have a limited
lifespan (2-4 weeks) which limits their use for characterization of xenoestrogen-induced
responses (Dunphy et al., 2020; Eigeliene et al., 2008, 2012, 2016; Eigėlienė et al., 2006;
Tanos et al., 2013).
HMEC models for studying normal breast biology have been limited by the early
senescence of HMECs in 2D culture. Transformation with adenovirus E6/E7, human
telomerase (TERT), Myc, SV40 large T-antigen, zinc-finger protein ZNF217, and BMI-1
can be used to bypass this senescence, but ultimately these methods perturb the biology of
the cells. Loss of retinoblastoma protein, p53, and p16INK14a in these methods results in
abnormal bypass of cell cycle checkpoints (Wang et al., 1998; Dyson et al., 1989; Münger
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et al., 1989; Scheffner et al., 1990; Huschtscha et al., 2001; Nonet et al., 2001; Dimri et al.,
2002; Martinez-Zapien et al., 2016; Fischer et al., 2017). Myc immortalized lines exhibit
morphological changes, anchorage independent growth, reduced apoptotic responses, and
altered gene expression (Wang et al., 1998; Thibodeaux et al., 2009).
In our work, we sought to use an alternative approach, which we refer to as
conditional immortalization.

The conditional immortalization process for mammary

epithelial cells involves coculture of mammary epithelial cells with irradiated mouse
fibroblasts and addition of a rho-associated protein kinase (ROCK) inhibitor (Liu et al.,
2012; Palechor-Ceron et al., 2013).

Other research has characterized conditionally

immortalized HMECs (ciHMECs) and found similar expression profiles to original tissue
samples (Mahajan et al., 2017). Some studies found that conditionally reprogrammed cells
are representative of an adult stem-like epithelial population and express specific stem cell
markers (Suprynowicz et al., 2012, 2017). Using this method, one group was able to
expand a population of ERα positive cells with luminal epithelial markers, but they noted
that this population decreased dramatically with passaging (Jin et al., 2017). Expansion of
ERα positive epithelial cells may be restricted by transforming growth factor beta (TGFβ)
signaling, as treatment with inhibitors for this pathway was shown to enhance the growth
of ERα positive HMECs (Fridriksdottir et al., 2015).
The overall goal for this aim was to characterize inter-individual variation in
estrogenic responses in primary cell lines, representative of individual patients, and to use
this information to investigate possible mechanisms contributing to estrogen and
xenoestrogen sensitivity. To do this, we utilized a ciHMEC panel. We performed dual
luciferase assays after transiently transfecting ciHMEC lines with estrogen receptor and a
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reporter construct to measure individual responses. While we did observe up to 3-fold
variation in response to E2, BP3, and PP, we only observed subtle differences in responses
between HMECs. Due to difficulties with the conditionally immortalized HMEC lines,
further work was not continued.

Materials and Methods
Cell culture
All Rays of Hope Registry cell lines were obtained from Dr. Sallie Schneider at
PVLSI. Primary cells were passaged in F-media (250 mL DMEM (- pyruvate), 250 mL
Ham’s F12, 5% FBS, 250 ng/mL hydrocortisone (Sigma), 10 ng/mL Epidermal Growth
Factor murine submaxillary (Sigma), 8.6 ng/mL Cholera Toxin Vibrio (Sigma), 1 µg/mL
human Insulin solution (Sigma), and 1X Antibiotic-Antimycotic (100X) (Lonza Basal,
Switzerland).
MCF10A, ME16C2, 76N Tert, HMECC, and H16N2 stably immortalized breast
cell lines (references) were also grown in F-media. NIH 3T3 mouse fibroblasts (gift of
Bruce Jacobson) were cultured in DMEM with 10% FBS and 15 ug/mL gentamycin. All
cells were incubated at 37°C with 5% CO2 and passaged every 2-4 days.
Conditional immortalization
NIH 3T3 cells were treated with 30-gray (Gy) of gamma radiation. Cells were then
plated in F media and allowed to adhere for 1-2 hours. HMEC cells were plated on the
feeder layer with 10uM ROCK inhibitor (Y27632, StemCell Technologies).
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RT-qPCR
RNA was isolated from cells using TRIzol according to manufacturer’s
instructions.

RT-qPCR

was performed using the Mx3005P real-time PCR system

(Agilent, Santa Clara, CA). Reactions were performed using the 1-Step Brilliant SYBRIII
Green QRT-PCR Master Mix Kit (Agilent) and 200 nM forward primer, 200 nM reverse
primer, and 10 ng RNA. Expression was set relative to universal mRNA control consisting
of 5 donors with normal tissue (BioChain, San Francisco CA). See Table 3.2 for primers
used.
Mammosphere Extreme Limiting Dilution Assay
A preliminary mammosphere forming assay was conducted to identify cell lines
that have primary mammosphere forming capability. Cells were cultured in ultra-low
attachment 96-well plates (Corning, NY) in 100 µL of F-media at differing concentrations:
250, 500, 1000, and 2000 cells/well. Cell lines that developed primary mammospheres
after 7 days were selected for extreme limiting dilution assay. For extreme limiting dilution
assays, each cell line was cultured in 100 µL of F-media in 96-well ultra-low attachment
plates for 7 days. Each line was cultured at 4 concentrations ranging from 25 to 2000
cells/well with 8 replicates per concentration. Concentrations varied between lines based
on initial preliminary mammosphere forming assay. After 7 days, positive wells containing
mammospheres were counted in each concentration for each cell line. Mammosphere
forming cell frequency (±95% confidence interval upper and lower limit) was calculated
using online software (bioinf.wehi.edu.au/software/elda16).
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ERE-Luciferase Assays
HMECs were plated in 24 well tissue culture plates at densities ranging from 7 x
104 to 1 x 105 cells/well in F-media with 10 uM Y27632. After an overnight incubation,
growth media was replaced with 0.3 mL/well Opti-MEM reduced serum media (11058021, Gibco). Plasmid DNA and Lipofectamine 2000 reagent (11668019, ThermoFisher)
were diluted in Opti-MEM media before adding 200 µL/well. Cells were transfected with
0.125 µg of either ESR1, ESR2, or both ESR1 and ESR2 expression plasmids, 1.5 µg of 3X
ERE-TATA-Luciferase reporter plasmid, and 0.02 µg of pRL-CMV Renilla plasmid using
lipofectamine 2000 (Invitrogen). As a receptor-negative control, 6 wells were transfected
with 1.5 µg 3x ERE-TATA-Luc reporter plasmid and 0.02 µg pRL-CMV plasmid; half
were treated with control media and the other half with 17β-estradiol (E2) media. For
Fugene 6 transfections, 0.01ug/well of pRL-CMV-Renilla, 0.6ug/well of 3X ERE-TATALuciferase and 0.02ug/well ESR1 were as above.

1.8uL/well of Fugene 6 (E2691,

Promega) was used for transfection.
After 6 hours of transfection, transfection media was replaced with 0.5 mL of
treatment media. Cells were incubated with treatment media for 24 hours. The Promega
Dual Luciferase Reporter Assay was used to perform luciferase assays (E1910, Promega).
Cells were lysed in 1x Passive Lysis Buffer and lysates stored at -20°C until reading.
Luciferase and Renilla activity in lysates were determined by using the Polar Star Optima
plate reader (BMG Labtech). Luciferase values for each well were normalized to the
amount of Renilla activity.
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Cell Treatments
Control treatment media consisted of MEM media (51200-038, Gibco), 5%
charcoal-dextran stripped serum (FB-04, Omega Scientific), and 2mM L-glutamine
(SH30034.01, Hyclone). 10 mM 17β-estradiol (E2758, Sigma-Aldrich) stock prepared in
ethanol was diluted to prepare E2 treatment media.

10 mM 2-hydroxy-4-

methoxybenzophenone (H36206, Sigma) and propyl 4-hydroxybenzoate (P53357, Sigma)
stocks were prepared in DMSO (D8418, Sigma) and diluted to make BP3 and PP treatment
media.
Immunofluorescence
Cells were plated on glass coverslips in 12 well plates at a density of 2x105
cells/well in normal growth media. After overnight incubation, the media was removed,
cells were washed with 1x phosphate buffered saline (PBS), and then fixed in 4%
paraformaldehyde for 15 minutes at room temperature. Cells were permeabilized with
0.5% TritonX-100 for 10 minutes at 4°C and washed 3 times with 1x PBS: Glycine
(130mM NaCl, 7mM Na2HPO4, 3.5mM NaH2PO4, 100mM Glycine) for 15 minutes each
at room temperature. Blocking was performed in immunofluorescence buffer (130mM
NaCl, 7mM Na2HPO4, 3.5mM NaH2PO4, 7mM NaN3, 0.1% BSA, 0.2% TritonX-100,
0.005% tween-20) with 10% donkey and goat serum for 1-2 hours. A second blocking
was performed using immunofluorescence buffer with 10% donkey and goat serum and
20ug/mL goat anti-mouse F(ab’)2 (ab6668, Abcam) for 30-40 minutes. Primary antibody
incubation was performed with 1:500 human mitochondrial antibody (ab92824, Abcam)
and 1:200 vimentin antibody (ab92547, Abcam) overnight at 4°C. Cells were washed with
1x PBS: Glycine 3 times for 15 minutes each, incubated with secondary antibody for 1
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hour (1:500 Cell Signaling 4408S and Abcam ab150076), washed, and mounted using
Vectashield mounting media with DAPI (H-1500, Vector Laboratories). Images were
obtained under 200x magnification (model BZ-X700 microscope).

Results
Characterization of HMECs
Using a previously published method for conditional immortalization of human
breast epithelial cells, we expanded a subset of donor primary breast cells for
characterization of estrogenic responses (Figure 3.1). Donor age, BMI, type of surgery,
ethnicity, and parity status were recorded for each donor (Table 3.1). Briefly, primary
human mammary epithelial cells (HMECs) were isolated from digestion of donor tissue
samples and plated in 2D tissue culture. To conditionally immortalize these primary cell
lines, we put them into co-culture with irradiated NIH 3T3 mouse fibroblasts and added a
rock inhibitor (Y27632). This allowed for expansion of these primary lines for further
analysis and are now referred to as conditionally immortalized HMECs (ciHMECs).
Our collaborator Stephanie Morin from the Schneider lab performed PCR
characterization of these HMECs for basal epithelial markers keratin 14 (KRT14) and
keratin 5 (KRT5), luminal epithelial marker keratin 18 (KRT18), and basal/mesenchymal
cell marker vimentin (VIM). Upon analysis, this characterization revealed 3 subgroups:
one group with low expression of all markers, one large group with low expression of
KRT18 and VIM but moderate to high levels of KRT14 and KRT5, and one with low
expression of all keratins but high expression of VIM (Table 3.3 and Figure 3.2). Based
on expression of these markers, we concluded that the cells isolated from this method were
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largely basal epithelial cells, with variable expression of KRT14 and KRT5.

This

characterization was also performed on 4 stably immortalized HMEC lines obtained from
other labs (MCF10A, 76N Tert, ME16C2, HME-CC), which all had low expression of
KRT18 and VIM while 3 of 4 also had low KRT14 and KRT5.
Further characterization of these ciHMEC lines demonstrated that some (5 of 6)
lines retained the ability to form primary mammospheres in a limiting dilution
mammosphere assay, indicating some cells in these populations may resemble basal
stem/progenitor cells (Figure 3.3a-c). Five stably immortalized HMEC lines (MCF10A,
76N Tert, ME16C2, HME-CC, H16N2) were also tested, and 3 of 5 lines had some primary
mammospheres (Figure 3.3a-b). Interestingly, the estimated number of mammosphere
forming cells (MFC) in the ciHMECs (10.6 MFC/1000 cells) was significantly higher than
in the stably immortalized HMEC lines (2.4 MFC/1000 cells, Figure 3.3c, p < 0.05). This
suggests that ciHMEC culturing conditions may support the growth of basal epithelial cells
with stem/progenitor characteristics.

Measuring Estrogenic Responses in HMECs
Because ERα positive luminal epithelial cells are lost when HMECs are plated in
2D tissue culture conditions, we sought to use transient transfection experiments with
estrogen receptors and an ERE reporter to measure variation in estrogen-induced responses
in our ciHMEC cell lines. To do this we first optimized our transient transfection protocol
for HMECs, which we found were more sensitive to transfection media conditions than
cancer cell lines. HMECs cultured in clearing media (10% charcoal stripped FBS,
10ug/mL insulin, 2mM L-Glutamine, MEM media) prior to transfections, to reduce
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estrogenic background, were found to have higher numbers of dead floating cells and no
successful uptake of plasmid DNA (data not shown), so this step was omitted for all future
transfection experiments.

Two alternative transfection protocols using either

Lipofectamine 2000 or Fugene 6 reagents were tested for optimal efficiency in HMEC cells
(Figure 3.4). Transfection efficiency was markedly improved with Lipofectamine 2000
reagent compared to Fugene 6. No luciferase readings were detected with Fugene 6 and
significantly lower Renilla transfection control levels were observed (Figure 3.4a and b,
respectively). When Lipofectamine transfected luciferase values were normalized to
Renilla, we were able to observe a significant increase in transactivation with 10nM E2,
30uM BP3, and 10uM PP treatment in ciHMEC line 910 (Figure 3.4c). The results of this
experiment suggested that Lipofectamine transfection reagent was more suitable for
transfection of ciHMEC cells, and thus was used for all subsequent experiments.
Further optimization was performed to determine the optimal amount of ESR1
plasmid DNA required to measure estrogenic responses in HMECs. In 76N Tert cells,
transient transfections were performed using ESR1 plasmid DNA levels ranging from
0.03ug/well to 1.5ug/well while keeping ERE-luciferase reporter and renilla plasmid
amounts consistent (Figure 3.5). At all levels of ESR1 used, a significant increase in
transactivation was seen in 10nM E2 treated cells compared to control (Figure 3.5a). The
highest amount of relative light units of luciferase was observed at 0.125ug/well ESR1 and
decreased at higher plasmid levels. Renilla relative light units were also greatest at
0.125ug/well ESR1 and decreased with higher plasmid concentration, but renilla levels
were consistent from 0.03ug/well to 0.125ug/well ESR1 (Figure 3.5b). When normalized
to renilla transfection control, values for all control treated wells reflected similar amounts
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of transactivation and the same was true for all 10nM E2 treated wells (Figure 3.5c). For
future experiments, we decided to use 0.125ug/well ESR1; this amount of ESR1 appeared
to be saturating.

BP3 and PP are Estrogen Receptor Agonists in HMECs
In order to determine if xenoestrogens benzophenone-3 (BP3) and propylparaben
(PP) are agonists for ESR1 and/or ESR2 in human breast epithelial cells, we first used 3
stably immortalized HMECs to generate dose responses to each compound. This was
measured using ERE-luciferase assays, where the amount of transactivation was compared
with ESR1 only, ESR2 only, and both ESR1 and ESR2. In all 3 lines, BP3 and PP were
capable of transactivation with all combinations of receptors, and the level of
transactivation increased with increasing doses (Figure 3.6). Activity observed with both
xenoestrogens was similar for ESR1 only and both ESR1 and ESR2 transfections,
suggesting that with these agonists, the activity of ESR1 is not enhanced or suppressed by
ESR2.
BP3 transactivation with ESR1 and both receptors in the 76N Tert line reached
approximately 60% of the activity observed with 10nM E2 treatment and ESR1 only
transfection (Figure 3.6a, gray dotted lines indicate 10nM E2 and ESR1 activity). In the
other two lines, BP3 transactivation with ESR1 and both receptors reached the full activity
seen with 10nM E2 (Figure 3.6b-c). With ESR2 only, 10nM E2 treatment induced lower
overall levels of transactivation; this was also observed with BP3 and PP treatment. BP3
treatment and ESR2 transfection reached approximately 40% of transactivation levels
induced with ESR2 and 10nM E2 treatment (green dotted lines) in the 76N Tert and HME-
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CC lines (Figure 3.6a and c). This level was close to 100% in the ME16C2 line (Figure
3.6b). Our results show that BP3 can act as an agonist for both ESR1 and ESR2 but
generates greater activity with ESR1.
PP induced transactivation with ESR1 alone and both receptors in the 76N Tert and
HME-CC lines which reached approximately 80% of the level induced by 10nM E2
treatment (Figure 3.6d and f). The ME16C2 line was more sensitive to PP treatment, as
the amount of transactivation reached the same levels as 10nM E2 treatment (Figure 3.6e).
With ESR2 only, all 3 lines reached 100% transactivation levels compared to 10nM E2 and
ESR2 transfection (Figure 3.6d-f). Overall, this data suggests that BP3 and PP can act as
agonists for both ESR1 and ESR2, but that most of the transactivation induced is due to
ESR1.

Limited Variation in Responses to E2, BP3, and PP in ciHMECs
After determining that BP3 and PP were acting primarily through ESR1 in our
immortalized HMECs, we performed a luciferase reporter screen in our ciHMEC donor
lines to identify individuals who are more sensitive to estrogen or xenoestrogen exposure.
Because little activity was seen with ESR2, we decided to transfect only ESR1 into these
cell lines at saturating levels. We also chose single saturating doses of BP3 and PP; 30 uM
BP3 reflects the 95th percentile of exposure in pregnant women, while 10uM PP is 3-fold
higher than the 95th percentile exposure level (Philippat et al., 2013). We performed
luciferase assays in a total of 11 lines, including 4 immortalized (HME-CC, 76N Tert,
MCF10A, ME16C2) and 7 ciHMEC donor lines (Figure 3.7). All HMEC and ciHMEC
lines responded to E2, BP3, and PP relative to control treated wells. This suggests BP3
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and PP are estrogenic in ciHMEC lines. We observed a 2.5-fold variation in response to
E2 treatment, 2.3-fold variation to BP3, and 3.6-fold variation to PP treatment (Figure
3.7). Similar levels of activation were seen with most HMEC lines in response to BP3 and
PP treatment (p > 0.05), but the 876 and 698 primary HMEC lines were more sensitive to
BP3 than PP (P < 0.05). The 76N Tert, MCF10A, and 569 primary HMEC exhibited
significantly more activity when treated with E2 compared to either xenoestrogen (P <
0.05), but the remaining 10 HMEC lines had similar activity levels with E2, BP3, and/or
PP (P > 0.05). The 811 line displayed a consistently lower response to E2, BP3, and PP
compared to the other 12 HMEC lines.
Based on the results obtained from our human breast explant model, we had
expected to see more inter-individual variation in responses in our ciHMEC donor cell
lines. We hypothesized that the limited levels of variation could be due to using saturating
levels of ESR1 or high doses of xenoestrogen treatment. It is possible that if we had
performed dose response curves to estrogen and each xenoestrogen in every cell line, we
would observe differing EC50 values for each patient, reflective of differing sensitivity.
Another possibility is that the coregulators involved in estrogen receptor signaling are
present at very low levels in these cell lines, as it has been shown that specific coactivators
can enhance luciferase responses in breast cancer cell lines (Wolf et al., 2007; Kong et al.,
2011). To investigate this possibility, we checked mRNA expression of FOXA1 and
GATA3 in our ciHMEC lines (Figure 3.8a-b). Expression of both coactivators was 10 to
12-fold lower than in MCF7 breast cancer cells, which may contribute to the limited
responses in our luciferase assays. However, more work would be needed to make this
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conclusion.

Feeder Cell Contamination in ciHMEC cultures
While our conditional immortalization method allowed us to expand multiple donor
primary breast epithelial cell lines for phenotypic characterization, we encountered
difficulties working with the mouse NIH 3T3 fibroblast cell line. Previous publications
have described the use of irradiation or mitomycin c to halt proliferation in NIH 3T3 cells
for use as feeder cell layers. We also used differential trypsinization to limit the number
of feeder cells carried over during passaging. However, with these methods, we still
observed NIH 3T3 feeder carry over in certain ciHMEC lines (Figure 3.9).
Immunofluorescence staining with a vimentin antibody, which marks fibroblasts and
mesenchymal cells, and a human specific mitochondrial antibody in 4 higher passage
ciHMEC lines revealed 3 of 4 lines carried some amount of NIH 3T3 contamination
(Figure 3.9d-f). Primary HMECs, which had never been co-cultured with NIH 3T3 cells,
were used as a negative control for detection of the contaminating mouse cells (Figure
3.9a). Of the 3 contaminated lines, 753 had only a few observable NIH 3T3 cells, 698
contained approximately 50% human and 50% mouse cells, and 569 contained only a
handful of human cells remaining (Figure 3.9d, e, and f, respectively). Compared to
normal NIH 3T3 cells, the contaminating cells sometimes appeared to have altered
morphology (Figure 3.9b vs f).
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Discussion
Previous in vitro work using HMECs to study the normal biological responses of
mammary epithelial cells was limited by the early senescence of HMECs in 2D culture and
limited expansion capabilities. Transformation with TERT, adenovirus E6/E7, Myc, SV40
large T-antigen, ZNF217, and BMI-1 are methods which have been used to expand subsets
of HMECs, but these methods ultimately disturb normal biological functions through loss
of p53, retinoblastoma protein, p16INK4a, or oncogenic transformation (Wang et al., 1998;
Dyson et al., 1989; Münger et al., 1989; Scheffner et al., 1990; Huschtscha et al., 2001;
Nonet et al., 2001; Dimri et al., 2002; Martinez-Zapien et al., 2016; Fischer et al., 2017).
Our main concern with using these methods to characterize inter-individual variation in
responses to estrogen or xenoestrogens was that these biological changes may influence
the HMECs’ responses to stimuli.

Therefore, we sought to utilize the conditional

reprogramming method (Liu et al., 2012; Palechor-Ceron et al., 2013), or conditional
immortalization, for expansion of our HMEC lines. This method is thought to gradually
reprogram the epithelial cell population but does induce TERT expression, though the
conditional reprogramming phenotype is believed to be reversible upon removal of the
ROCK inhibitor and feeder cells (Suprynowicz et al., 2012; Palechor-Ceron et al., 2013).
Using this method, we expanded a subset of HMEC lines from our panel of women donors
from the Rays of Hope Registry. Our goal was to use this subset to characterize the
variation in responses to estrogen and xenoestrogen treatment to determine if some women
are uniquely sensitive to these exposures and then determine the mechanism(s) responsible.
A recent paper by Kumar et al. used conditional immortalization to expand low
passage cultures of HMECs for permanent immortalization with TERT to generate
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immortalized HMEC lines from a panel of normal breast tissue (Kumar et al., 2018).
Though this approach has the potential issue of subpopulation selection, they were able to
preserve a small luminal cell population with ERα expression, luminal cell markers
(FOXA1 and GATA3), and mammosphere forming capability. Our method of HMEC
isolation and culture promoted the growth of epithelial cells with primarily basal epithelial
markers (Table 3.3 and Figure 3.2), but we did observe variability in the expression of
KRT5, KRT14, KRT18, and VIM markers between donor HMECs. These results were
confirmed with flow cytometry for an epithelial cell marker EpCAM and Keratin 14 (data
not shown). The low KRT18 expression in these HMEC lines suggests that any luminal
epithelial cell populations were lost during culturing, which agrees with other published
results (Fridriksdottir et al., 2015; Lee et al., 2018). This is likely due to reduced adherence
of luminal epithelial cells (Soule and McGrath, 1986; Keller et al., 2010), slower growth
rates compared to basal epithelial cell populations (Keller et al., 2010; Fridriksdottir et al.,
2015), increased stress responses in luminal cells (Lee et al., 2018), microenvironment
changes (Miyano et al., 2017), or loss of differentiated phenotypes (Keller et al., 2010;
Breindel et al., 2017).
Consistent with previous reports that conditionally reprogrammed epithelial cells
acquire an adult stem-like phenotype (Suprynowicz et al., 2012, 2017; Breindel et al.,
2017), we found that our ciHMECs had primary mammosphere forming cells in ultra-low
attachment conditions (Figure 3.3) and the number of these cells was increased compared
to spontaneous and TERT immortalized HMECs. Of the 6 ciHMEC lines tested, 5 were
able to form primary mammospheres, compared to only 3 of 5 stably immortalized
HMECs. Interestingly, though previous reports have shown MCF10A are capable of
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forming mammospheres (Arendt et al., 2014), we did not observe mammosphere
formation. It is possible that the number of mammosphere forming cells in the MCF10A
line were below our detectable limit, as others have noted their ability to form
mammospheres is low (Qu et al., 2015).
Although our prior work has shown significant inter-individual variation in
response to estrogen treatment (Dunphy et al., 2020) and others have shown effects on drug
response, cell metabolism, cytokine response, and irradiation sensitivity (Roden et al.,
2011; Snijders et al., 2012; Yard et al., 2016; Schneider et al., 2017), we only detected low
variation between the 7 ciHMEC and 4 stably immortalized HMEC lines in response to
estrogen or xenoestrogen treatment in our luciferase reporter assays (Figure 3.7). There
was up to 2.5-fold variation in response to E2 treatment, 2.3-fold variation to BP3, and 3.6fold variation to PP treatment. It is possible that if we had performed dose response
characterization on each HMEC line, we may be able to detect differences in EC50 values
that could be more reflective of inter-individual variation. Another alternative is that we
could not observe greater differences between lines due to using saturating levels of ESR1
(Figure 3.5) or low levels of estrogen receptor coactivators, including FOXA1 and GATA3
(Figure 3.8). Lastly, it is possible that we simply did not analyze a large enough number
of HMECs to find the subpopulation with increased sensitivity to these compounds.
Our results are consistent with other previous work that BP3 and PP are estrogenic
(Schlumpf et al., 2001; Byford et al., 2002; Kerdivel et al., 2013; Schlotz et al., 2017; Majhi
et al., 2020) and act as ligands for ERα and ERβ (Figure 3.6). While BP3 metabolites may
have greater affinity for ERβ (Molina-Molina et al., 2008), we observed greater affinity for
ERα for both BP3 and PP. Though they have potential to act as ligands for both estrogen
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receptors, it is unclear if this would translate into a biologically relevant response. BP3 is
not known to induce breast cancer cell proliferation (Schlotz et al., 2017; Majhi et al., 2020)
but can increase cell motility in long term exposure (Alamer and Darbre, 2018) and alter
ductal formation in mammary gland development (LaPlante et al., 2018). PP can induce
proliferation in breast cancer cells and increases cell motility (Byford et al., 2002; Khanna
et al., 2014; Majhi et al., 2020). Both xenoestrogens form estrogen receptor dependent
DNA:RNA hybrids in response to estrogen treatment, but only BP3 treatment caused DNA
damage in estrogen treated breast cancer cells (Majhi et al., 2020). Regardless of whether
BP3 and PP are able to induce all or some of the biological responses induced by estrogen
treatment, their ability to act as estrogen receptor ligands in all HMEC lines tested
highlights their potential risk during susceptible windows of development or to those that
may be uniquely sensitive to estrogen and xenoestrogen exposure.
Our major concern when starting this work with ciHMEC lines was the possibility
for contamination of mouse fibroblast feeder cells in the ciHMEC cultures. Though it is
well documented that irradiation of mouse 3T3 feeder cells or treatment with mitomycinC is sufficient to arrest cell growth (Chugh et al., 2016, 2017), our work has highlighted
the potential for a small population of 3T3 cells to undergo phenotypic changes and become
resistant to irradiation induced senescence (Figure 3.9). While some ciHMEC lines tested
were unaffected, others contained 50% or greater contamination.

Differential

trypsinization normally removes the 3T3 population from the ciHMEC culture, but this
irradiation resistance subpopulation is also more resistant to trypsinization. Optimization
of this method for future use could include fluorescent labeling of 3T3 cultures to identify
contamination more easily, or infection with recombinant plasmid containing a
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hygromycin phosphotransferase-thymidine kinase fusion gene to allow negative selection
with ganciclovir.
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Table 3.1: Donor information for primary human mammary epithelial cells
Donor age, BMI, type of surgery, ethnicity, and parity status for all HMECs collected at
PVLSI by Dr. Sallie Schneider and the limited donor information known about five
previously established immortalized HMEC lines.
ID Number or
Cell Line

Age

BMI

563

19

26.8

569

29

26.0

698
753
811

48
42
50

48.9
24.7
34.6

833

42

36.5

847
876
MCF10A

59
44
36

16.5
24.8
Unknown

76N Tert

Unknown

Unknown

ME16C2
HME-CC
H16N2

53
Unknown
36

Unknown
Unknown
Unknown

Surgery
Reduction
Mammoplasty
Reduction
Mammoplasty
Mastectomy
Mastectomy
Mastectomy
Prophylactic
Mastectomy
Mastectomy
Mastectomy
Mastectomy
Reduction
Mammoplasty
Mastectomy
Unknown
Mastectomy

Ethnicity

Parity

Caucasian Nulliparous
Caucasian Nulliparous
Caucasian Nulliparous
Caucasian
Parous
Caucasian
Parous
Caucasian

Parous

Latina
Caucasian
Unknown

Parous
Parous
Parous

Unknown

Unknown

Unknown
Unknown
Unknown

Unknown
Unknown
Unknown

Table 3.2: RT-qPCR primers
RT-qPCR primer pairs used on Mx3005P real-time PCR system.
Gene
Forward Primer (5’ to 3’)
TTC TCC TCT GGA TCG CAG TC
Keratin 14
TGC AGA CTC AGT GGA GAA GG
Keratin 5
CAC AGT CTG AGG TTG GA
Keratin 18
ACG AAG AGG AAA TCC AGG AG
Vimentin
GAG AGA GAG ACG GAG GGA GA
Gata3
GGA ACA GCT ACT ACG CAG AC
Foxa1
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Reverse Primer (5’ to 3’)
ATG ACC TTG GTG CGG ATT T
TCC AGA GGA AAC ACT GCT TG
GAG CTG CTC CAT CTG TAG GG
CAG AGA GTC AGC AAA CTT GGA
GTC ACC TGG GTA GCG AAG AG
ATG TTG CCG CTC GTA GTC AT

Table 3.3: Keratin expression profiles of HMEC lines
RT-qPCR results for keratin 14 (KRT14), keratin 5 (KRT5), keratin 18 (KRT18), and
vimentin (VIM). Expression is shown relative to human universal RNA from breast tissue,
normalized to beta-actin (ACTB), and log2 transformed. Passage number is shown for
ciHMEC lines. Data provided by Stephanie Morin.
Cell Line
563 P20
569 P8
698 P14
753 P12
811 P4
833 P4
847 P1
876 P6
MCF10A
76N Tert
ME16C2
HME-CC

KRT14
3.78
4.07
6.32
1.06
4.81
2.52
-0.71
2.04
0.14
-0.10
0.77
2.93

KRT5
4.50
4.37
5.04
2.18
4.28
2.65
-1.51
3.40
-2.18
-2.84
-1.15
2.99
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KRT18
-3.32
-5.06
-2.94
-3.18
-3.06
-3.06
-1.29
-3.32
-0.27
-1.51
-2.84
-1.65

VIM
-3.64
-4.32
-1.60
0.32
-1.43
-1.94
-1.15
-1.32
-6.64
-2.64
-0.22
-5.46

Figure 3.1: Overview of Conditionally Immortalized HMEC model
Primary human mammary epithelial cells (HMECs) were isolated from digestion of human
donor breast tissue samples at PVLSI and put into 2D tissue culture conditions. For
conditional immortalization, primary HMECs were cocultured with irradiated NIH 3T3
mouse feeder cells in the presence of a rock inhibitor (Y27632). This allowed expansion
of conditionally immortalized HMECs (ciHMEC).
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Figure 3.2: ciHMEC PCR Characterization
Heatmap of the keratin expression profiles for HMEC lines shown in table 3.3 and
additional HMEC lines (total of 61 lines analyzed, 51 unique HMECs and 4 immortalized
HMEC lines). Heatmap was created from log2 transformed data using R studio with a
scale of 5. Hierarchical clustering was performed. Yellow indicates high expression, black
indicates average expression, and blue indicates low expression relative to universal human
breast RNA.

93

a

b

c

Figure 3.3: ciHMEC Lines Can Form Primary Mammospheres
Primary mammosphere forming assays were used to determine the number of
mammosphere forming cells (MFC) in stably and conditionally immortalized HMEC lines.
A preliminary mammosphere forming assay (a-b) was used to select HMEC lines for
further analysis. Cells were cultured in ultra-low attachment 96-well plates for 7 days. (a)
Representative images of mammosphere formation in three HMEC lines (563, HME-CC,
and 876). (b) Examples of no mammosphere formation in three HMEC lines (76N TERT,
MCF10A, 847). (c) Extreme limiting dilution assays (ELDA) were performed to determine
the number of MFC in each HMEC line. Only lines that had mammosphere in preliminary
mammosphere forming assay were tested. Error bars represent 95% confidence interval.
Scale bars indicate 100uM. Data provided courtesy of Dr. Gat Rauner.
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Figure 3.4: Comparison of Lipofectamine 2000 and Fugene 6 reagents
ERE-luciferase results for ciHMEC 910 comparing the efficiency of lipofectamine 2000
and fugene 6 transfection reagents. Relative light units for (a) luciferase and (b) renilla
transfection control showed higher readings for lipofectamine. No luciferase readings were
detected for fugene transfected cells. (c) Ratio of luciferase to renilla, relative to
lipofectamine control treated cells.
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Figure 3.5: Increasing amounts of ESR1 DNA in ERE-luciferase assays
ERE-luciferase assay performed with 76N Tert cells with increasing amounts of ESR1
plasmid DNA. Relative light units shown for (a) luciferase and (b) renilla transfection
control. (c) Ratio of luciferase to renilla shows saturating levels of activity at 0.125ug of
ESR1, which was used for further experiments. With higher amounts of DNA, decreases
in both luciferase and renilla were observed.
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Figure 3.6: Benzophenone-3 and propylparaben dose response curves in HMECs
ERE-luciferase assay dose response curves for (a-c) benzophenone-3 (BP3) and (d-f)
propylparaben (PP) in three stably immortalized HMEC lines: 76N Tert, ME16C2, and
HME-CC. Activity is shown relative to transactivation with 10nM E2 and ESR1 (gray
lines). Blue lines indicate ESR1 transfection, red for ESR2, and purple for both receptors.
Green dotted lines indicate transactivation with 10nM E2 and ESR2.

97

Figure 3.7: Limited variation in response to E2, BP3, and PP in HMECs
Four stably immortalized (HME-CC, 76N Tert, MCF10A, ME16C2) and eight
conditionally immortalized HMEC lines were transfected with ESR1 for luciferase assays
with control or single doses of E2, BP3, or PP. 10nM E2, 30uM BP3, and 10uM PP
induced significant transactivation compared to control in all cell lines (p < 0.05). Parity
status and age are shown for ciHMECs. Activity is shown relative to experimental control
for each individual line. Luciferase readings were normalized to renilla transfection
control.
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a

b

Figure 3.8: FOXA1 and GATA3 expression in ciHMECs
RT-qPCR analysis of FOXA1 and GATA3 expression in seven ciHMEC lines, with MCF7
cells as a comparison. Gene expression is not normalized.
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Figure 3.9: NIH 3T3 contamination in ciHMEC lines
Immunofluorescence staining for vimentin (red), a marker of fibroblasts and epithelial
cells, and a species specific human mitochondrial marker (green), which only labels human
cells. Differential trypsinization was performed before plating cells for staining.
Representative images of (a) a primary HMEC line, which has never been cocultured with
NIH 3T3 cells, shown in (b). Two ciHMEC lines tested had low or very low carryover of
mouse feeder cells (c-d), one line had significant levels of contamination (e), and one line
had almost no human cells remaining (f). Passage numbers indicated. Scale bars are
100uM.
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CHAPTER 4
ESTROGEN-INDUCED RESPONSES IN INDUCIBLE ERΑ HMECS

Introduction/Rationale
Early studies examining the effects of estrogen in the human breast utilized breast
biopsies from donors during different stages of the menstrual cycle. However, these studies
were rarely able to follow individual donors across menstrual stages and comparisons had
to be made using pooled population data. As the levels of endogenous estrogen (Dall and
Britt, 2017) and responses to estrogen (Dunphy et al., 2020) vary among women, a better
model for studying estrogen signaling in the human breast was needed. Breast cancer cell
lines, such as T47D and MCF7 cells, have been used extensively to study the effects of
estrogen receptor signaling, but they are not reflective of the normal breast epithelium.
These cancer cells acquire mutations during carcinogenesis and express higher levels of
ERα than normal breast epithelium, which has heterogenous ERα expression (Battersby et
al., 1992; Söderqvist et al., 1993; Gabrielson et al., 2016). Another key difference is that
breast cancer cell lines use autocrine signaling pathways to induce proliferation after
estrogen treatment (Tan et al., 2009). In normal breast epithelium, paracrine signaling is
hypothesized to be responsible for estrogen-induced proliferation as proliferating cells do
not express ERα (Clarke et al., 1997; Russo et al., 1999; Shoker et al., 1999b). ERα positive
proliferating cells are only observed in hyperplasia and carcinoma samples (Shoker et al.,
1999b). Secretion of growth factors including AREG, FGF, and EGF are required for
mediating ERα induced proliferation through paracrine signaling (Ciarloni et al., 2007;
Fillmore et al., 2010; Harrison et al., 2013). For these reasons, breast cancer cell lines are
not an ideal model for studying estrogen-induced responses in the normal breast.
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Primary human mammary epithelial cell (HMEC) models are a cell model which is
reflective of the normal breast, but these were originally limited by senescence and loss of
ERα in 2D culture. Multiple methods to bypass HMEC senescence were developed
including transformation with HPV E6 and E7, human telomerase (TERT), Myc, SV40
large T-antigen, zinc-finger protein ZNF217, and BMI-1. It is known, however, that loss
of p53, retinoblastoma protein, and p16INK4a occurs as a result of these transformations
(Wang et al., 1998; Dyson et al., 1989; Münger et al., 1989; Scheffner et al., 1990;
Huschtscha et al., 2001; Nonet et al., 2001; Dimri et al., 2002; Martinez-Zapien et al., 2016;
Fischer et al., 2017). Anchorage independent growth, reduced apoptotic responses, and
altered gene expression resulting from these methods also suggest transformation can occur
(Wang et al., 1998; Thibodeaux et al., 2009). However, these HMEC models are still one
of the better options for studying normal breast biology.
As an alternative to stable immortalization, another model called conditional
reprogramming was developed involving expansion of primary HMECs by treatment with
a rho-associated protein kinase (ROCK) inhibitor and co-culture with irradiated mouse
fibroblasts (Liu et al., 2012; Palechor-Ceron et al., 2013). Studies have suggested that
conditionally immortalized HMECS (ciHMECs) created with this method represent a stem
like epithelial population (Suprynowicz et al., 2012, 2017). Other culture methods for
HMECs have also noted to result in loss of differentiation markers (Breindel et al., 2017).
One group has reported successful use of the ciHMEC method to expand ERα positive
luminal epithelial cells, but this population decreases during passaging (Jin et al., 2017).
Our experience with this method has proven that feeder cell contamination is a large
potential issue. We also have found that stably immortalized cells appear to behave

102

similarly to ciHMECs in reporter assays of estrogen-induced transactivation. Others have
used a combination of conditional reprogramming and Tert immortalization to obtain ERα
positive HMECs (Kumar et al., 2018).
More recent models of the human breast have been developed which retain ERα
positive luminal epithelial cells, but these have their own limitations. Recent studies have
identified protocols for development of 3D breast organoids from primary HMECs and
cancerous breast tissue (Sokol et al., 2016; Sachs et al., 2018; Djomehri et al., 2019; Florian
et al., 2019; Goldhammer et al., 2019). Breast organoids contain luminal and basal
epithelial cell populations, can organize into ductal structures, retain the ERα positive cell
population, and are responsive to hormone treatment. We have found, however, that
propagation of breast organoids from normal breast tissue is limited as they can only be
expanded for a short number of passages. Another model, human breast explants, can also
only be maintained for a limited amount of time (up to 4 weeks) but provide similar benefits
to breast organoids. Breast explants from normal tissue retain all breast cell types, tissue
morphology, ERα expressing luminal epithelial cells, and response to hormone treatment
(Zhuang et al., 2003; Eigeliene et al., 2006, 2008, 2012, 2016; Tanos et al., 2013; Dunphy
et al., 2020). Ultimately, the use of breast explant models is limited by the amount of tissue
obtained by donors and therefore only a finite number of experiments can be performed.
Due to current limitations of breast organoid and explant models, HMECs are still
one of the better models for studying human breast biology. However, even after bypassing
the senescence block to expand HMEC populations, the ERα expressing population of
epithelial cells is lost over time (Fridriksdottir et al., 2015; Jin et al., 2017; Lee et al., 2018).
Expression of ERα is limited to luminal epithelial cells in the normal breast. Luminal
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epithelial cells make up 10-25% of cells isolated from human breast tissue (Garbe et al.,
2009) but may be more prevalent in breast tissue of older women (Lee et al., 2015). Many
have hypothesized that the ERα positive luminal cell population is lost in 2D culture due
to reduced adherence (Soule and McGrath, 1986; Keller et al., 2010), faster growth of basal
epithelial cells (Keller et al., 2010; Fridriksdottir et al., 2015), triggering stress responses
in luminal epithelial cells (Lee et al., 2018), changes to the microenvironment (Miyano et
al., 2017), or epigenetic reprogramming that results in the loss of the differentiated
phenotype (Keller et al., 2010; Breindel et al., 2017). With optimal conditions, ERα
positive luminal epithelial cells are still lost in early passages and the number of passages
is ultimately limited by the original percentage present (Lee et al., 2018). This means that
HMEC models primarily represent basal epithelial cell populations, and in order to study
the effects of estrogen in these cells we have to introduce exogenous ERα expression.
In order to study ERα induced responses in HMECs, many have tried to introduce
expression of this receptor with mixed results.

Previous studies have shown that

overexpression of ESR1 in the ER negative breast cancer line MDA-MB-231 is not able to
induce normal estrogen-induced proliferation (Garcia et al., 1992; Lazennec and
Katzenellenbogen, 1999) and instead causes activation of anti-proliferative pathways
through aberrant cell cycle regulation (Moggs et al., 2005). Additionally, while exogenous
expression of ESR1 in MDA-MB-231 cells can induce target gene TFF1 expression, PGR
upregulation is not restored (Lazennec and Katzenellenbogen, 1999; Moggs et al., 2005).
In MCF10A cells, exogenous expression of ESR1 has been shown to lead to a modest
increase in proliferation with E2 treatment when EGF is removed from media (Pilat et al.,
1996; Abukhdeir et al., 2006; Pugazhendhi and Darbre, 2010). Additionally, expression
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of estrogen receptor targets genes TFF1 and PGR was increased by E2 treatment in
MCF10A cells (Abukhdeir et al., 2006). These studies illustrate that in breast cancer and
normal HMEC cell lines, restored expression of ERα alone is not sufficient to restore
estrogen responsiveness.
Exogenous expression of ERα may not be able to induce normal biological
responses to estrogen for a number of reasons. For example, in ERα negative basal breast
cancer cells, epigenetic silencing of estrogen receptor target genes, including PGR (Leu et
al., 2004) is present, which may explain why exogenous expression does not impart normal
E2 responses. Abnormal responses induced in breast epithelial cells during overexpression
of ERα may also be due to prolonged high expression of this receptor. MCF7 breast cancer
cells demonstrate estrogen independent growth and expression of ER target genes with
overexpression of exogenous ERα (Tolhurst et al., 2011). Overexpression of ERα in
MDA-MB-231 breast cancer cells only results in E2-induced proliferation and target gene
response when used in combination with overexpression of other regulatory factors,
including forkhead box A1 (FOXA1) and GATA binding protein 3 (GATA3) (Kong et al.,
2011). Expression of ESR1, FOXA1, and GATA3 in E2 treated MDA-MB-231 cells results
in a gene expression profile more like E2 treated MCF7 cells, though these expression
profiles are not identical. In HMECs, estrogen- induced proliferation can be induced when
exogenous ESR1 is combined with exogenous expression of Polycomb-group gene BMI1
(Duss et al., 2007). Additionally, transduction with ESR1 and BMI1 in HMECs induces
expression of target genes GREB1 and PRLR but does not affect PGR or TFF1 expression.
These results demonstrate that even expression of these factors in combination does not
fully induce estrogen regulated gene response. A recent study in mouse mammary
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epithelium demonstrated that forced expression of ERα is lost over time, suggesting either
silencing of ERα or selection against ERα positive epithelial cells (Cornelissen et al.,
2019). Contrary to the results of Kong et al. in MDA-MB-231 breast cancer cells,
Cornelissen et al. found that exogenous expression of ERα combined with FOXA1 and
GATA3 was not sufficient to induce estrogen receptor target gene expression (Areg and
Ccnd1) or estrogen-induced proliferation in mouse mammary epithelial cells.
The goal of this study was to develop inducible ERα HMEC lines and utilize this
model to study factors which may enhance or restrict estrogen signaling and sensitivity to
estrogen. We used 4 stably immortalized HMEC lines: 76N Tert (Band and Sager, 1989;
Shamanin and Androphy, 2004), MCF10A (Soule et al., 1990), HME-CC (Troester et al.,
2004), and ME16C2 (Troester et al., 2004). The 76N Tert, HME-CC, and ME16C2 HMEC
lines were immortalized by expression of telomerase (TERT). The MCF10A line is
spontaneously immortalized, likely through the loss of p16INK4A, p14ARF, and
p15INK4B tumor suppressors (Iavarone and Massague, 1997). All 4 HMEC lines are
considered basal epithelial cell lines with expression of KRT5 and KRT14 (Prat et al.,
2013), although some groups have shown the 76N Tert and MCF10A lines also have some
expression of luminal epithelial markers KRT8 and KRT18 (Zhao et al., 2010; Qu et al.,
2015).
In order to investigate estrogen-induced responses in our 4 HMEC lines and
examine the role of estrogen receptor coregulators, we developed a doxycycline inducible
ESR1 expression construct using an inducible lentiviral backbone. We hypothesized that
ERα induced responses among individuals may be influenced by individual expression of
estrogen receptor coregulators.

Induced expression of ESR1 with 100ng/mL of
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doxycycline was sufficient to increase E2-induced transactivation in luciferase reporter
assays. Although 2 of our 4 inducible ERα HMEC showed even higher transactivation
levels with increased doses of doxycycline, we limited our dose to 100ng/mL to avoid
adverse metabolic effects of doxycycline (Ahler et al., 2013). This dose of doxycycline
was sufficient to induce ERα protein levels comparable to MCF7 cells in all 4 lines. With
induced expression of ERα, 3 of our 4 HMEC lines demonstrated modest proliferation with
estrogen treatment. Expression of estrogen receptor target genes AREG and PGR was
unregulated by estrogen treatment, however. Conditioned media from 2 iERα HMEC lines
suggests that the estrogen-induced growth in these HMEC lines is due to cell intrinsic
factors, supporting the idea that estrogen receptor coregulators may play an important role.
However, expression of FOXA1 and GATA3 did not correspond with E2-induced
proliferation in our 4 HMEC lines. This work suggests FOXA1 and GATA3 are not
sufficient to restore estrogen responses in HMECs and that there may be other coregulators
or other cell intrinsic factors influencing estrogen sensitivity.

Materials and Methods
pIND-ESR1 Construct Design
An N-terminal FLAG tagged inducible ESR1 expression construct was generated
using the pINDUCER14 vector (Meerbrey et al., 2011). First, FLAG sequence was
amplified from pFLAG-CMV-2 (Andersson et al., 1989) using forward primer 5’ATACCGGTACCATGGACTACAAAGACGATGACGAC-3’ and reverse primer 5’TCGACCGGTACGCGTGCGATCGCTGAATTCGCGGCAAG-3’. This sequence was
cleaned using the Monarch PCR and DNA Cleanup Kit (NEB #T1030) and ligated into
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pINDUCER14 after digestion of both plasmids with AgeI, dephosphorylation with shrimp
alkaline phosphatase (NEB #M0371S), and extraction from gel electrophoresis (DNAland
Scientific #GP1001). Sequencing was performed to confirm insertion.
ESR1 coding sequence was amplified from pIRES-hrGFPII-ESR1 containing the
ESR1 coding sequence (Open Biosystems #MHS6278-211691051) in the pIRES-hrGFPII
vector (Stratagene #240157).

ESR1 was amplified with forward primer 5’-

GCAGAAATGACCATGACCCTCCACACCAAAGC-3’
TAAACGCGTTCAGACCGTGGCAGGGAAACCCT-3’.

and

reverse

primer

5’-

ESR1 was ligated into

pINDUCER14-FLAG by digestion with EcoRI and MluI and cleaned as described above.
Two linker sequences were inserted between FLAG and ESR1 to keep the sequence in
frame

(Linker

A:

5’-AATTGCGCGATCGCGG-3’

and

Linker

B:

5’-

AATTCCGCGATCGCGC-3’) . Sequencing of the final construct (pINDUCER14-FLAGESR1, or pIND-ESR1) confirmed insert orientation, all inserts were in frame, and that the
ESR1 sequence was identical to the Homo Sapiens ESR1 gene (primers: forward 5’CGGTGGGAGGCCTATATAAG-3’, reverse 5’- ACTTATATACGGTTCTCCCC-3’).
pIND-ESR1 expresses a constitutive GFP reporter and tetracycline inducible ERα with Nterminal FLAG tag. Cloning was performed by Puneet Singh in the AMB program.
Cell Culture
76N Tert, MCF10A, ME16C2, and HME-CC cells were grown in F-media: DMEM
-pyruvate (Gibco #11965-092), Ham’s F12 (Gibco #11765-054), 5% FBS, 250ng/mL
hydrocortisone (Sigma #H4001), 10ng/mL human epidermal growth factor (Tonobo
Biosciences #21-8356-U100), 8.6ng/mL cholera toxin (Millipore Sigma #227035), 10
ug/mL human insulin (Sigma #I9278-5ML), and 1X antibiotic/antimycotic (Caisson Labs
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ABL02-100ML). 239T cells were cultured in DMEM:F12 (Sigma #D8900) with 10%
FBS, 15ug/mL gentamycin (Gibco #15750-060), and 1X antibiotic/antimycotic. T47D
cells were grown in DMEM:F12 supplemented with 10% FBS, 15ug/mL gentamycin,
2mM L-Glutamine, and 1X antibiotic/antimycotic and cleared in 10% CSS, 2mM LGlutamine, 10ug/mL human insulin, and MEM media for 48-72 hours prior to experiments.
All cells were incubated at 37˚C with 5% CO2 and passaged every 2-3 days.
Generation of inducible ERα HMEC lines
293T cells were lifted with 0.05% trypsin and plated in 60 mm tissue culture dishes
at 2.5x106 cells/dish and left overnight. Transfection was performed next day using 3.5ug
pIND-ESR1, 3ug psPAX2 (Addgene #12260, gag, pol, and rev packaging vector), and 2ug
pMD2.G (Addgene #12259, vsv-g packaging vector) in antibiotic free media with
Lipofectamine 2000 (Invitrogen). After 24 hours, media was refreshed and replaced with
293T growth media. At 48 and 54 hours post initial transfection, viral media was collected
and filtered using a 0.45-micron filter (Corning #431220) and added to HMEC lines in a
1:1 ratio with F-media twice, 6 hours apart. After 24 hours, viral media was replaced with
F-media. FACS was performed using pooled HMECs in 1% FBS/PBS by selecting for
GFP positive cells using FACSAria II (Becton-Dickinson). Uninfected parental HMECs
were used as a negative control to set background fluorescence.
Cell Treatments
Control treatment media consisted of MEM media (51200-038, Gibco), 5%
charcoal-dextran stripped serum (FB-04, Omega Scientific), and 2mM L-glutamine
(SH30034.01, Hyclone). 10 mM 17β-estradiol (E2758, Sigma-Aldrich) stock prepared in
ethanol was diluted to prepare E2 treatment media, and 10mM ICI (Tocris #1047) in
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ethanol was used to prepare ICI treatment media. Doxycycline was added to treatment
media at 100ng/mL except in dose response experiments. Alamar blue proliferation assay
control treatment media was the same as above with the addition of 10ug/mL human
insulin.
ERE-Luciferase Assays
HMECs were plated in 24 well tissue culture plates at 1 x 105 cells/well in F-media.
After an overnight incubation, growth media was replaced with 0.3 mL/well Opti-MEM
reduced serum media (11058-021, Gibco). Plasmid DNA and Lipofectamine 2000 reagent
(11668019, ThermoFisher) were diluted in Opti-MEM media before adding 200 µL/well.
Uninfected cells were transfected with 0.125 µg of pIND-ESR1, 1.5 µg of 3X ERE-TATALuciferase reporter, and 0.02 µg pRL-CMV Renilla plasmid using Lipofectamine 2000
(Invitrogen). iERα HMECs were infected with 3X ERE-TATA-Luc and Renilla. After 6
hours of transfection, transfection media was replaced with 0.5 mL of control media. The
next morning, treatment media containing 0-200ng/mL doxycycline was added. Promega
Dual Luciferase Reporter Assay was used to perform luciferase assays (E1910, Promega).
Cells were lysed in 1x Passive Lysis Buffer after 24-hour treatment and lysates stored at 20°C until reading. Luciferase and Renilla activity in lysates were determined by using
the Polar Star Optima plate reader (BMG Labtech). Luciferase values for each well were
normalized to the amount of Renilla activity.
Western Blot for ERα
Cells were lysed in ice cold RIPA lysis buffer [50 mM Tris–HCl pH 8.0, 150 mM
NaCl, 1 mM EDTA, 1% Triton X-100, 1% Sodium deoxycholate, 0.1% SDS, 1% protease
inhibitors (Sigma-Aldrich #P8340), 1% phosphatase inhibitor #2 (Sigma-Aldrich #P5726),
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and 1% phosphatase inhibitor #3 (Sigma-Aldrich #P0044)]. Lysates were centrifuged at
13,000 rpm for 15 minutes at 4˚C to remove cellular debris. BCA protein assay was
performed to quantify protein concentration (Thermo Scientific #23225). Equal amounts
of protein (25ug or 28ug, as indicated) were separated using SDS-PAGE on 10%
acrylamide gels under denaturing conditions and blotted onto PVDF membrane (Millipore
#IPVH00010). Blocking was performed using 5% nonfat dry milk in TBST (10mM TrisHCl pH 7.5, 150mM NaCl, 0.05% tween-20) for 1 hour. Blots were incubated with 1:100
anti-ERα (Abcam [Sp1] #ab16660, Lot #GR3202692-2) overnight at 4˚C.

During

optimization, other antibodies for ERα were also tested: MC-20 (1:500 Santa Cruz #sc542, Lot #H0415), F-10 (1:200 Santa Cruz #sc8002, Lot #D0708), and C1355 (1:1000
Millipore Sigma #06-935, Lot #3169865). See Table 4.1 for antibody information.
The next day, blots were washed 3 times with TBST and then incubated for 1 hour
with HRP-conjugated secondary antibody (1:5000, GE Healthcare #NA934V). Bands
were detected using enhanced chemiluminescence solution and imaged on G-box
(Syngene). The blots were washed with TBST and incubated with anti-β actin (1:5000,
Sigma #A1978, or Cell Signaling #4967 [for F-10 blot]) overnight at 4˚C. Washing,
secondary antibody incubation (1:5000, GE Healthcare #NA931C), and detection were
performed as described above. Expected molecular weights were 67 kDa for ERα and 42
kDa for β actin.
Alamar Blue Proliferation Assay
Cells were plated in 5% CSS, 2mM L-Glutamine, 10ug/mL insulin, and MEM
media at 4000, 7000, or 10000 cells per well on five 96-well plates (one for each day), with
7 replicates per treatment and one empty row for a blank. The next day, treatment media
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was added (control, 10nM ICI, 10nM E2) diluted in 5% CSS, 2mM L-Glutamine, 10ug/mL
insulin, and MEM media. Each day, Alamar blue reagent was added (final concentration
10%) and plates were read 4, 8, and 24 hours after addition. BioTek Synergy 2 plate reader
(BioTek) readings were performed at 570nm and 600nm. Media was refreshed on day 3.
Plates were read for 5 days unless cells appeared confluent. Percent Alamar blue reduction
was calculated using the Alamar blue protocol (DAL1100, Invitrogen).
Conditioned Growth Media
HMECs were plated at 1.6x106 cells/T75 in 5% CSS, 2mM L-Glutamine, 10ug/mL
insulin, and MEM media. T47D cells were plated at 1.2x10 6 cells/T75 after clearing in
10% CSS, 2mM L-Glutamine, 10ug/mL insulin, and MEM media for 48-72 hours. The
next day, treatment media was added (control, 10nM ICI, 10nM E2) diluted in 5% CSS,
2mM L-Glutamine, 10ug/mL insulin, and MEM media. 48 hours after treatment, media
was collected and replaced with fresh media. Conditioned media was filtered with a 0.2micron syringe filter, diluted 1:1 in fresh media, and used to treat cells in proliferation
assays. After an additional 48 hours, this process was repeated, and conditioning cells were
discarded.
RT-qPCR
RNA isolation was performed using TRIzol according to manufacturer’s
recommendation (15596018, ThermoFisher Scientific). cDNA was synthesized using 1 ug
of RNA with the Protoscript II First Strand cDNA synthesis kit (E6560L, New England
Biolabs). RT-qPCR was performed in a thermocycler (CFX96 Real-Time thermocycler,
BioRad). See Table 4.2 for primer sequences. Expression is relative to an inter-run
calibrator (IRC) consisting of pooled cDNA from a subset of human breast tissue samples.
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Results
pIND-ESR1 Construct is Functional in HMECs
To create HMEC lines with inducible ERα expression, a doxycycline inducible
ESR1 expression vector was created using the pINDUCER14 vector (Meerbrey et al.,
2011) and the Homo sapiens ESR1 coding sequence with an N-terminal FLAG tag, referred
to as pIND-ESR1 (Figure 4.1). This construct contains an internal ribosome entry site
(IRES), which drives constitutive GFP expression (Figure 4.2). A human EF1-α promoter,
from EEF1A1, drives expression of a reverse tetracycline-transactivator (rtTA), which will
bind to doxycycline (Dox) when present and activate the tetracycline response element
(TRE2) to induce expression of FLAG-tagged ESR1. To determine if this construct was
functional, we first performed transient transfection into the 76N Tert HMEC line and
performed a luciferase reporter assay (Figure 4.3a-c). After 24-hour treatment with E2,
there was a significant 3-fold increase in transactivation in the cells transfected with pINDESR1 (p < 0.05), which was not observed in cells without the receptor (ERE reporter only
controls). While there was a significant 1.8-fold increase in activity with E2 treatment in
the cells without induced ESR1 expression (no Dox), there was a larger significant increase
when 100ng/mL of doxycycline was added to induce ESR1 expression (p < 0.05). This
suggested that the construct is indeed functional, but that there may be low levels of leaky
expression in transient transfection experiments.

Generation of iERα HMEC lines
We next sought to generate 4 HMEC lines with inducible ESR1 expression (iERα)
using the pIND-ESR1 vector. After lentiviral infection, each HMEC line was pooled and
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FACS sorting was used to isolate populations which successfully incorporated pIND-ESR1
and therefore expressed GFP constitutively (Figure 4.4, Figure 4.6, Figure 4.8, Figure
4.10). Each HMEC line was also checked post FACS to determine the percentage of GFP
expressing cells, and these lines were called 76N Tert-ESR1, MCF10A-ESR1, ME16C2ESR1, and HME-CC-ESR1 (Figure 4.5, Figure 4.7, Figure 4.9, Figure 4.11). The 76N
Tert-ESR1 were 90% GFP positive, MCF10A-ESR1 were 70% positive, ME16C2-ESR1
were 99% positive, and HME-CC-ESR1 were 90% positive. These 4 HMEC lines are our
iERα HMECs.

Luciferase Reporter Assays in iERα HMECs
After generating the four iERα HMEC lines, we performed luciferase assays to test
the function of the inducible ESR1 with increasing concentrations of doxycycline (Figure
4.12 through Figure 4.14). For all 4 iERα HMECs the amount of transactivation with
10nM E2 treatment was similar for each dose of doxycycline, except 0ng/mL.

A

significant dose dependent increase was observed at higher doses of doxycycline for the
MCF10A-ESR1 and HME-CC-ESR1 lines (Figure 4.13 and Figure 4.14, p < 0.05), but
this was not present in the other 2 lines. In the MCF10A-ESR1 and ME16C2-ESR1 lines,
there was significant activation upon treatment with E2 with 0ng/mL Dox, suggesting there
may be leaky expression of ESR1 in these cell lines (Figure 4.13 and Figure 4.15, p <
0.05). This was not present in the 76N Tert-ESR1 and HME-CC-ESR1 lines (Figure 4.12
and Figure 4.14, p > 0.05). In the MCF10A-ESR1 line, the level of transactivation with
leaky receptor expression and E2 treatment was not significantly different from 100ng/mL
or 150ng/mL with E2 treatment after Renilla normalization (p > 0.05), but the raw
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luciferase readings were significantly lower (Figure 4.13a and c, p < 0.05). Renilla
readings were significantly lowered in the 0ng/mL doxycycline and E2 treated cells, which
caused discrepancy between the normalized and raw data (Figure 4.13b, p < 0.05).
Similarly, the ME16C2-ESR1 line had significantly lower renilla values for cells treated
with any dose of doxycycline and 10nM E2 (Figure 4.15b, p < 0.05). There was significant
background activity in the ME16C2-ESR1 cells treated with control media and any dose of
doxycycline. This background activity is not due to normalization, as the raw luciferase
values were significantly higher than the no dox treated control cells (Figure 4.15a).
In order to compare activity between these 4 HMEC lines, we set transactivation
relative to the 76N Tert-ESR1 cells. When activity for all HMECs was set relative to the
76N Tert-ESR1 line, transactivation was similar in the 76N Tert-ESR1 and HME-CC-ESR1
lines, slightly lower in the MCF10A-ESR1 line, and higher in the ME16C2-ESR1 line
(Figure 4.16 and Figure 4.17). However, because the MCF10A-ESR1 and ME16C2-ESR1
had decreases in renilla readings with doxycycline and E2 treatment, we decided to
compare fold change for each cell line in raw luciferase values, renilla values, and
normalized luciferase values. In the 76N Tert-ESR1 line, the normalized fold change with
doxycycline and E2 treatment compared to control was 5 to 8-fold (Figure 4.18a) and was
similar in the raw luciferase values (Figure 4.18b), which was expected because the renilla
values remained unchanged. The MCF10A-ESR1 line had a normalized fold change of 3
to 5.6-fold (Figure 4.19a), which was like the fold change in raw luciferase values for the
doxycycline treated cells (Figure 4.19b). The increase in transactivation observed in the
uninduced cells treated with E2 was skewed by the drop in renilla values, as the fold change
in raw luciferase values was 1.8 compared to 2.7 in the normalized values. This suggests
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that there is a small increase in activity in the MCF10A-ESR1 cells with doxycycline
treatment to induce ESR1, though the leaky expression is still present. The HME-CC-ESR1
cells had a 3 to 5-fold increase in activity with Dox and E2 treatment and, similarly to the
76N Tert-ESR1 cells, this did not differ when comparing the normalized fold change
(Figure 4.20a) and raw luciferase values (Figure 4.20b).
Lastly, in the ME16C2-ESR1 cells the normalized fold change in cells treated with
doxycycline and E2 was 37 to 60-fold (Figure 4.21a) compared to 23 to 40-fold in the raw
luciferase values (Figure 4.21b), indicative of the effects of lowered renilla values.
Interestingly, the uninduced ME16C2-ESR1 cells had the highest fold change in both
normalized and unnormalized readings (11-fold for both). This is likely because in the
doxycycline treated cells, the control treatment had significant background activity which
was not observed in the uninduced cells (Figure 4.15). This background activity was
reduced with 10nM ICI treatment, which suggests that there was a small amount of
estrogenic activity in the control treated cells. This data suggests that the ME16C2-ESR1
cells are highly sensitive to E2 treatment in luciferase reporter assays, 76N Tert-ESR1 and
HME-CC-ESR1 are approximately equal in response, and the MCF10A-ESR1 cells may
be less sensitive.
ERα Protein Expression in iERα HMECs
To check if ERα protein was expressed in the iERα HMEC lines, western blot
analysis was performed. Antibody optimization was performed using a total of 4 anti-ERα
antibodies: mouse monoclonal F-10, rabbit monoclonal MC-20, rabbit monoclonal Sp1,
and rabbit polyclonal C1355. MCF7 cell lysates were used as a positive control and
parental 76N Tert lysates for a negative control in blots to examine ERα expression in 76N
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Tert-ESR1 lysates with 100ng/mL Dox or 200ng/mL Dox. The expected molecular weight
for ERα was 67 kDa. MC-20 and C1355 antibodies detected bands in all samples,
including the negative control (Figure 4.22b and d). The MC-20 antibody detected two
bands between 50 kDa and 75 kDa, while the C1355 antibody detected 3 bands in the 76N
Tert lysates and 2 bands in the MCF7 lysate ranging from 37 kDa to 75 kDa. The F-10
antibody also detected 2 bands in the MCF7 lysate and 76N Tert-ESR1 lysates, one around
75 kDa and one between 37 kDa and 50 kDa (Figure 4.22a). Interestingly, the larger
protein band was not detected in the 76N Tert parental lysate. The Sp1 antibody appeared
to be the most specific for ERα, as only one band was detected, and this band was absent
in the 76N Tert parental lysate (Figure 4.22c). Incubating these blots with anti-β-actin
antibody confirmed protein was loaded evenly (Figure 4.23). For all future ERα westerns,
the Sp1 antibody was used. It is likely that the other ERα antibodies were demonstrating
nonspecific binding.
Next, each of our 4 iERα HMEC lines was examined for ERα protein expression.
In all 4 lines, ERα protein was detected upon doxycycline treatment and was not detected
in the absence of doxycycline (Figure 4.24). Therefore, if any of the lines have leaky ESR1
expression (as indicated in luciferase assays), it does not lead to detectable protein levels.
Quantification of the ERα detected in these 4 lines, after normalization to β-actin, revealed
that 10nM E2 treatment does not appear to downregulate ERα expression in these cell lines
(Figure 4.25, Figure 4.26, Figure 4.27, and Figure 4.28). 76N Tert-ESR1, MCF10AESR1, and HME-CC-ESR1 appear to have ERα levels approximately equal to that in MCF7
cells with 100ng/mL doxycycline treatment. The ME16C2-ESR1 line may have more ERα
than the MCF7 cells (Figure 4.24 and Figure 4.28), but this would need to be confirmed
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with more replicates of MCF7 cell lysates. These results indicated that all 4 iERα HMECs
express ERα proteins at levels which could carry out estrogen-induced responses.

Estrogen-Induced Proliferation and ERα Target Gene Responses
After confirmation that the 4 iERα HMECs produce ERα protein, we next sought
to determine if this induced ERα could produce a biological response. In breast cancer cell
lines and normal mammary gland epithelial cells, it is well documented that treatment with
estrogen induces cell proliferation. Therefore, Alamar Blue proliferation assays were
performed with each cell line. With induced ERα expression and 10nM E2 treatment for
4 days, the 76N Tert-ESR1, MCF10A-ESR1, and HME-CC-ESR1 HMEC lines showed
modest but significant increases in proliferation compared to control or 10nM ICI treated
cells by day 4 (Figure 4.29a-d and Figure 4.30a). The proliferation induced resulted in
an approximately 20-25% increase in Alamar Blue reduction. The ME16C2-ESR1 cells,
however, did not demonstrate any E2-induced proliferation (Figure 4.30b).
Next, E2 induction of ERα target genes AREG and PGR were examined after 24hour treatment with E2 and 72-hour treatment with doxycycline. PGR was not detected in
any of the iERα HMECs (data not shown). AREG was detected in all 4 lines, but its
expression did not appear to be regulated by E2 treatment (Figure 4.31). Compared to
untreated T47D breast cancer cells and normal breast tissue, AREG expression in the 76N
Tert-ESR1, HME-CC-ESR1, and ME16C2-ESR1 lines was constitutively high. MCF10AESR1 expression of AREG was like that found in normal breast tissue and untreated T47D
cells, but expression was not changed with 10nM E2 treatment. In 76N Tert-ESR1 cells
without ERα induced, 10nM ICI treatment resulted in a small but significant increase in
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AREG (p < 0.05). Treatment with 10nM E2 and doxycycline significantly reduced AREG
expression (p < 0.05). In HME-CC-ESR1 cells, treatment with doxycycline and 10nM ICI
increased AREG relative to control treated cells without ERα expression, though this was
not significant when compared to the control doxycycline treated cells. Lastly, in the
doxycycline treated ME16C2-ESR1 cells, treatment with 10nM ICI significantly increased
AREG while treatment with 10nM E2 significantly decreased expression (p < 0.05). It is
clear from these results that the modest E2-induced proliferation observed in 3/4 iERα
HMECs does not correspond with AREG or PGR target gene regulation. In addition, the
76N Tert-ESR1 and ME16C2-ESR1 lines may exhibit negative regulation of AREG when
ERα is expressed after estrogen treatment.

E2-Induced Proliferation in iERα HMECs is Due to Cell Intrinsic Factors
We next performed conditioned growth media assays to determine if the modest
E2-induced proliferation observed in 3/4 iERα HMECs is due to cell intrinsic factors or
secreted growth factor production. Previous studies in normal breast epithelium support a
paracrine signaling model for estrogen-induced proliferation, where estrogen receptor
positive luminal epithelial cells produce growth factors that stimulate the proliferation of
nearby estrogen receptor negative cells. However, in breast cancer cells estrogen-induced
proliferation can occur through autocrine signaling, as treatment with epidermal growth
factor receptor (EGFR) inhibitors does not block proliferation.
In our iERα HMECs, we wanted to determine if autocrine or paracrine signaling
was contributing to estrogen-induced proliferation. For this, we used 76N Tert-ESR1 and
MCF10A-ESR1 cells, as they both exhibited E2-induced growth. Conditioned growth
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media assays were performed as outlined in Figure 4.32. Conditioned growth media was
collected from these two iERα cell lines 2 days and 4 days after treatment with control,
10nM ICI, or 10nM E2 and treatment with 100ng/mL doxycycline. Media was also
collected from T47D cells with the same treatments. The conditioned media filter sterilized
and added to parental HMEC lines lacking ERα (76N Tert and MCF10A) on day 1 and day
3 of proliferation assays. 76N Tert parental cells exhibited no significant change in
proliferation with conditioned media from doxycycline treated 76N Tert-ESR1 cells in our
first experiment (Figure 4.33). In a follow up experiment with T47D conditioned media
as an additional treatment, there was a small but significant increase in proliferation with
E2 treatment in the 76N Tert-ESR1 media treated cells (Figure 4.34), but analysis of the
fold change between day 2 and day 5 Alamar Blue reduction revealed no significant
increase from control treated cells. No significant change was observed with conditioned
media from T47D cells (Figure 4.34). Comparison of the fold change in Alamar Blue
reduction between normal growth media, T47D conditioned media, and 76N Tert-ESR1
conditioned media treated cells revealed a similar fold change between all treatment groups
(Figure 4.34d), suggesting that the 76N Tert parental cells are not responsive to the
conditioned growth media from 76N Tert-ESR1 or T47D cells. In MCF10A parental cells,
no significant change in proliferation was observed in treatment with MCF10A-ESR1
conditioned media (Figure 4.35b), and small but significant increases or decreases were
observed in normal growth media or T47D conditioned media with E2 treatment (Figure
4.35a and Figure 4.35c). Comparison of fold change in Alamar Blue reduction among
treatment groups revealed a small but significant increase in proliferation when treated with
T47D control or 10nM ICI conditioned media (Figure 4.35d). This data suggests that the
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proliferation observed in our 3/4 iERα HMECs is due to intracellular factors and not
secretion of factors into the media.
To confirm the results of our conditioned media experiments from 76N Tert and
MCF10A parental cell lines, we performed the same experiments with T47D breast cancer
cell lines. Our lab and numerous others have shown that T47D cell proliferation is
increased with estrogen treatment. We wanted to determine if conditioned media from
76N Tert-ESR1 or MCF10A-ESR1 cells could enhance the proliferative response of T47D
cells, which would suggest there is a secreted factor present in the media. T47D cells
treated with conditioned media from 76N Tert-ESR1 cells exhibited a significant increase
in proliferation with 10nM E2 media, and this increase was enhanced with media from
10nM E2 treated 76N Tert-ESR1 cells (Figure 4.36a-b).

However, this increased

proliferation is likely due to the high amounts of AREG produced by the 76N Tert-ESR1
cells (Figure 4.31), as proliferation was also enhanced in T47D cells treated with
conditioned media from control and 10nM ICI treated 76N Tert-ESR1 cells. Additionally,
T47D cells treated with conditioned media from 76N Tert-ESR1 cells without doxycycline
treatment showed a significant increase, which suggests the increased proliferation is due
to high basal AREG levels in the 76N Tert line (Figure 4.36c). T47D cells treated with
conditioned media from MCF10A-ESR1 cells exhibited a significant increase in
proliferation with 10nM E2 treatment and was slightly enhanced by treatment with
conditioned media from MCF10A-ESR1 cells treated with 10nM E2 (Figure 4.37).
However, since the increase was also observed in cells treated with media from MCF10AESR1 cells without doxycycline treatment, it is likely not the mechanism driving E2induced proliferation in our MCF10A-ESR1 cells. These results indicate that any increased
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proliferation observed in T47D cells treated with media from 76N Tert-ESR1 cells is likely
due to constitutively high AREG expression in these cells, as the enhanced proliferation
was not seen with MCF10A-ESR1 conditioned media, which are not producing high levels
of AREG (Figure 4.31). This can be confirmed with further experiments using inhibitors
of epidermal growth factor receptor to block proliferation due to AREG. Collectively, this
data suggests that the E2-induced proliferation in 3/4 iERα HMECs is due to cell intrinsic
factors, not secreted factors.

FOXA1 and GATA3 Expression is Not Sufficient for ERα Induced Responses
As recent literature has suggested that the ERα coactivators FOXA1 and GATA3
are essential for carrying out estrogen-induced biological responses, especially in
previously ER negative cell lines with exogenous ERα expression, we checked mRNA
expression of these two cell intrinsic factors in our parental HMEC lines. If this hypothesis
is correct, we would expect the 3 HMEC lines which responded to E2 with proliferation
(76N Tert-ESR1, MCF10A-ESR1, HME-CC-ESR1) to have higher expression of these two
factors or a lack of expression in the unresponsive ME16C2-ESR1 line. The 76N Tert cells
had the highest expression of FOXA1, followed by the MCF10A line, HME-CC line, and
the ME16C2 cells (Figure 4.38a). While the 76N Tert and MCF10A cells had significantly
higher expression of FOXA1 than the ME16C2 cells, expression between the HME-CC and
ME16C2 were not significantly different. Additionally, the amount of FOXA1 expressed
in the ME16C2 cells was similar to that seen in normal breast tissue. GATA3 expression
was highest in the MCF10A cells, followed closely by the 76N Tert cells (Figure 4.38b).
The expression in these two cell lines was comparable to normal breast tissue. The HME-

122

CC and ME16C2 cell lines, in contrast, had significantly lower GATA3 expression.
However, there was also no significant difference between the HME-CC and ME16C2
GATA3 expression levels. This data suggests that, while FOXA1 and GATA3 may be
necessary for ERα induced responses, expression of these factors is not sufficient to impart
E2-induced responses. A summary of responses from each iERα HMEC generated in this
study is shown in Table 4.3.

Discussion
Although Tert and spontaneously immortalized HMECs lose expression of
p16INK4A, p14ARF, and/or p15INK4B, our results suggest that they are a useful model
for studying regulation of estrogen-induced responses in breast epithelial cells. The 4 iERα
HMEC lines developed here are capable of estrogen response element transactivation upon
E2 treatment, express levels of ERα similar to MCF7 cells, and 3 of 4 lines demonstrate
modest E2-induced proliferation. Like many other primary breast epithelial cell models,
these HMECs exhibit primarily basal epithelial keratin expression profiles (Prat et al.,
2013), although some have suggested that the 76N Tert and MCF10A lines have luminal
KRT8/KRT18 expressing subpopulations (Zhao et al., 2010; Qu et al., 2015). Even though
these HMECs are primarily basal epithelial cells, our results illustrate that they can be used
to study factors which enhance or restrict estrogen-induced responses.
Exogenous expression of ESR1 in both breast cancer cell lines (MDA-MB-231) and
HMECs has been shown to bind E2 as an agonist (Pilat et al., 1996; Lazennec and
Katzenellenbogen, 1999) and generate significant levels of transactivation with estrogen
response element reporters (Pilat et al., 1996; Lazennec and Katzenellenbogen, 1999;
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Pugazhendhi and Darbre, 2010; Kong et al., 2011), but this does not always equate to E2induced biological responses. In MDA-MB-231 basal breast cancer cells, exogenous ESR1
expression has consistently been demonstrated to result in decreased proliferation (Jiang
and Jordan, 1992; Zajchowski et al., 1993; Lazennec and Katzenellenbogen, 1999).
However, these cells can still control mRNA expression of some growth factors (TGFα
and TGFβ2) associated with proliferation (Jeng et al., 1994) and increase expression of
some ER target genes (TFF1) with E2 treatment (Lazennec and Katzenellenbogen, 1999).
In HMECs, response to E2 treatment after exogenous ESR1 expression has
produced conflicting reports. Most studies report that MCF10A or other HMECs with
exogenous ESR1 are capable of transactivation in reporter assays (Pilat et al., 1996; Wolf
et al., 2007; Kong et al., 2011) but have no change in proliferation with E2 treatment
(Zajchowski et al., 1993; Pilat et al., 1996; Thomas et al., 1998). However, others report
modest increases in MCF10A proliferation of 1.3-fold (Pugazhendhi and Darbre, 2010) or
1.5 to 2-fold increases in MCF10A clones expressing ESR1 in the absence of EGF
(Abukhdeir et al., 2006). All of our 4 iERα HMEC lines are responsive to E2 treatment in
reporter assays (Figure 4.12, Figure 4.13, Figure 4.14, and Figure 4.15), but only 3 of 4
(76N Tert-ESR1, MCF10A-ESR1, and HME-CC-ESR1) demonstrated a 20-25% increase
in proliferation with 10nM E2 treatment (Figure 4.29 and Figure 4.30), compared to ~60%
in estrogen responsive T47D breast cancer cells (Figure 4.36a and Figure 4.37a). While
our proliferation media does not contain added EGF, it is likely that our serum still contains
residual amounts of EGF and treatment with EGFR inhibitors may increase our
proliferative phenotype in these lines. In studies where no change in proliferation was
observed, MCF10A cells demonstrated no change in expression of ER target genes TFF1
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or PGR mRNA (Pilat et al., 1996) while our MCF10A-ESR1 and other HMEC lines
expressed no detectable PGR (data not shown). Studies that showed proliferation with E2
treatment in MCF10A cells also observed induced expression of TFF1 and PGR
(Abukhdeir et al., 2006). We did not examine expression of TFF1 in our HMECs, but
expression of AREG and PGR did not appear to be regulated by E2 treatment (Figure 4.31).
Recent papers have suggested that ERα mediated responses to E2 treatment can be
induced through exogenous expression of other factors. Most primary HMECs do not
express of ERα, but transduction with ESR1 and BMI1, a Polycomb-group gene which is
capable of suppressing the p53 and Rb pathways and increases stem cell renewal, allows
for growth of HMECs stably expressing ERα (Duss et al., 2007). These ERα/BMI1
expressing HMECs exhibit a 50% increase in proliferation with E2 treatment and increases
in expression of ER target genes GREB1, PGR, and PRLR, while expression of ER target
gene TFF1 remains unchanged. This suggests that many but not all E2-induced responses
can be generated in HMECs with BMI1. Other work suggests that expression of ERα
coregulators FOXA1 and GATA3 are necessary for generating normal E2-induced
responses in ER negative breast cells.

While expression of ESR1 alone is able to

transactivate ERE luciferase reporters, co-expression of FOXA1 and GATA3 is required to
induce proliferative responses (Kong et al., 2011). In MDA-MB-231 cells, a 2-fold
increase in proliferation is observed with E2 treatment and these 3 factors; in BT-549 breast
cancer cells, a 40% increase in proliferation is observed with ESR1, FOXA1, and GATA3
compared to a 30% decrease in proliferation with ESR1 alone and E2 treatment.
Comparison of E2-ER mediated transcriptional profiles of MDA-MB-231 cells with ESR1,
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FOXA1, and GATA3 are closer to MCF7 profiles, but expression of key target genes is still
missing (Kong et al., 2011).
Our conditioned media experiments support the hypothesis that other intrinsic
cellular factors are involved in E2-induced proliferation in our 3 iERα HMECs (Figure
4.33 through Figure 4.37), but our data suggests that expression of FOXA1 and GATA3
are not sufficient to impart E2-induced proliferation in our ME16C2-ESR1 HMEC line
(Figure 4.38). Conditioned media from 2 iERα HMECs which demonstrate E2-induced
proliferation is not able to increase proliferative responses in T47D cells (Figure 4.36 and
Figure 4.37) or increase proliferation in parental HMECs without ERα expression (Figure
4.33, Figure 4.34, and Figure 4.35). Expression of FOXA1 and GATA3 is significantly
higher in the 76N Tert-ESR1 and MCF10A-ESR1 lines, but expression of these two factors
is not significantly different between the ME16C2-ESR1 and HME-CC-ESR1 cells, which
proliferate in response to E2 (Figure 4.29 and Figure 4.30).
It is interesting that Kong et al. suggested that lack of FOXA1 and GATA3 was
responsible for the abnormal phenotypes in MDA-MB-231 breast cancer cells with
exogenous ESR1 because others have demonstrated low basal expression of FOXA1 (Wolf
et al., 2007) in these cells, but co-expression of ESR1 and GATA3 is not sufficient to
generate E2-induced proliferative responses (Kong et al., 2011). This would suggest that
increased expression of FOXA1 is needed, which our results contradict. Our results are
supported by another recent paper that expressed exogenous ESR1 in mouse mammary
epithelial cells, where co-expression of FOXA1 and GATA3 also was not sufficient to
impart responsiveness to E2 treatment (Cornelissen et al., 2019). This group, however,
attributed this result to the differences in number of FOXA1 and GATA3 binding sites
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between mice and humans, suggesting mice rely less on these pioneer factors. Our results
suggest that, in HMECs, FOXA1 and GATA3 expression is not sufficient to induce
complete responsiveness to estrogen. These results in combination suggest the presence
of other coregulators involved in regulation of E2-induced responses, which may influence
sensitivity to estrogen in individuals as well.
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Table 4.1: Antibody information for Western Blot Analysis
Antibodies used in western blots on HMEC cell lysates.

Name of Antibody,
Catalog Number

Manufacturer

Dilution
Used

Species

Sp1, #ab16660

Abcam

1:100

Rabbit,
monoclonal

MC-20, #sc-542

Santa Cruz
(discontinued)

1:500

Rabbit,
monoclonal

F-10, #sc-8002

Santa Cruz

1:200

Mouse,
monoclonal

C1355, #06-935

Millipore
Sigma

1:1000

Rabbit,
polyclonal

β-actin

AC-15, #A1978

Sigma

1:5000

β-actin

#4967

Cell Signaling

1:5000

Target
Estrogen
receptor alpha
(ERα)
Estrogen
receptor alpha
(ERα)
Estrogen
receptor alpha
(ERα)
Estrogen
receptor alpha
(ERα)

Mouse,
monoclonal
Rabbit,
polyclonal

Table 4.2: RT-qPCR primer sequences
Primer sequences used in RT-qPCR of HMECs. Used on BioRad CFX thermocycler.

Gene
Amphiregulin (AREG)
Progesterone receptor (PGR)
Forkhead box protein A1
(FOXA1)
GATA binding protein 3
(GATA3)

Sequence: 5’ to 3’
Fwd – CGG AGA ATG CAA ATA TAT AGA GCA C
Rev – CAC CGA AAT ATT CTT GCT GAC A
Fwd – TTT AAG AGG GCA ATG GAA GG
Rev – CGG ATT TTA TCA ACG ATG CAG
Fwd – GGA ACA GCT ACT ACG CAG AC
Rev – ATG TTG CCG CTC GTA GTC AT
Fwd – CAC AAA ATG AAC GGA CAG AAC A
Rev – GTT GTG GTG GTC TGA CAG TT
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Table 4.3: Summary of HMEC responses
Summary of data from chapter 4 illustrating the responses of each cell line across all assays
performed. Clonality of each iERα HMEC line can be inferred from the initial percent
GFP positive cell population during and after FACS sorting. Fold change in luciferase
assays is relative to 10nM ICI treated cells. ERα protein expression is shown as a
percentage of quantified levels in MCF7 cells (n = 2 for iERα HMECs, n = 1 for MCF7).
AREG expression is shown relative to fresh breast tissue IRC. Significant E2-induced
proliferation is also indicated.

Cell
Line

% GFP
Fold
Initial
positive change in
% GFP
after
luciferase
positive
FACS
assays

76N Tert

5%

90%

5-8

MCF10A

17%

70%

3-5.6

HMECC

19%

90%

3-5

ME16C2

72%

99%

37-60

ERα
Expression
(% of
MCF7
level)
Similar
(107%)
Similar
(99%)
Similar
(130%)
Increased
(720%)
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Relative
Expression E2-induced
of AREG proliferation
and PGR
AREG: 915
PGR: none
AREG: 0.3
PGR: none
AREG: 5-8
PGR: none
AREG: 523
PGR: none

Yes
Yes
Yes
No

pINDUCER14-FLAG-ESR1
(pIND-ESR1)

Figure 4.1: Inducible ESR1 expression in pINDUCER14 backbone
A FLAG tagged ESR1 coding sequence was cloned into the lentiviral pINDUCER14
backbone, to create pIND-ESR1. An internal ribosome entry site (IRES) drives constitutive
GFP expression. The human EF1-α promoter (EEF1A1) drives expression of reverse
tetracycline-transactivator (rtTA), which will bind to the tetracycline response element
(TRE2) only in the presence of doxycycline to induce ESR1 transcription. ESR1 has a
FLAG tag expressed on the N-terminal region. Cloning performed by Puneet Singh,
former AMB master’s student.
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Figure 4.2: GFP expression in 293T cells transfected with pIND-ESR1
293T cells were transfected with the pIND-ESR1 construct and confirmed constitutive GFP
expression in all cells containing the plasmid. (a) Phase contrast image of 293T cells and
(b) fluorescent image of cells with filter for GFP. Images were taken one day after
transfection.
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Figure 4.3: Transient transfection of 76N Tert cells with pIND-ESR1
Transfection of 76N Tert cells with pIND-ESR1. 76N Tert cells were transfected with
pIND-ESR1, an ERE luciferase reporter, and a renilla transfection control. No receptor
control cells (ERE-Ctrl and ERE-E2) were transfected with reporter but no pIND-ESR1.
Cells were treated with control, 10nM ICI, or 10nM E2 for 24 hours. (a) Luciferase, (b)
Renilla, and (c) normalized data shown. Results showed some leaky expression of ESR1
in the cells without doxycycline treatment, as a significant increase in transactivation with
10nM E2 was observed. However, transactivation with doxycycline treatment and 10nM
E2 produced a significantly higher level of transactivation. Error bars indicate SEM. (* p
< 0.05).
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Figure 4.4: FACS of 76N Tert cells after lentiviral infection with pIND-ESR1
After infection with pIND-ESR1, (a) 76N Tert cells (b) expressing GFP indicated
successful incorporation of pIND-ESR1. This subpopulation was selected using FACS
sorting (c) with the parameters shown. Side scatter area (SSC-A) and forward scatter area
(FSC-A) were used to isolate viable cells, SSC width (W) and height (H) were used to
remove doublets, FSC-W and FSC-H confirmed selection of single cells, and PE-Texas
Red was used to detect autofluorescence. Parental 76N Tert cells were used as a negative
control to set background autofluorescence. Approximately 5% of 76N Tert cells were
GFP positive. Images were taken with 10x objective.
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Figure 4.5: Post FACS check of 76N Tert-ESR1
After FACS for GFP expressing 76N Tert cells, an aliquot was checked for purity. Side
scatter area (SSC-A) and forward scatter area (FSC-A) were used to isolate viable cells,
SSC width (W) and height (H) were used to remove doublets, FSC-W and FSC-H
confirmed selection of single cells, and PE-Texas Red was used to detect autofluorescence.
Approximately 90% of the sorted cell population expresses GFP, which are considered the
76N Tert-ESR1 cell line.
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Figure 4.6: FACS of MCF10A cells after lentiviral infection with pIND-ESR1
After infection with pIND-ESR1, (a) MCF10A cells (b) expressing GFP indicated
successful incorporation of pIND-ESR1. This subpopulation was selected using FACS
sorting (c) with the parameters shown. Side scatter area (SSC-A) and forward scatter area
(FSC-A) were used to isolate viable cells, SSC width (W) and height (H) were used to
remove doublets, FSC-W and FSC-H confirmed selection of single cells, and PE-Texas
Red was used to detect autofluorescence. Parental MCF10A cells were used as a negative
control to set background autofluorescence. Approximately 17% of MCF10A cells were
GFP positive. Images were taken with 10x objective.
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Figure 4.7: Post FACS check of MCF10A-ESR1
After FACS for GFP expressing MCF10A cells, an aliquot was checked for purity. Side
scatter area (SSC-A) and forward scatter area (FSC-A) were used to isolate viable cells,
SSC width (W) and height (H) were used to remove doublets, FSC-W and FSC-H
confirmed selection of single cells, and PE-Texas Red was used to detect autofluorescence.
Approximately 70% of the sorted population expresses GFP, which are considered the
MCF10A-ESR1 cell line.
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Figure 4.8: FACS of HME-CC cells after lentiviral infection with pIND-ESR1
After infection with pIND-ESR1, (a) HME-CC cells (b) expressing GFP indicated
successful incorporation of pIND-ESR1. This subpopulation was selected using FACS
sorting (c) with the parameters shown. Side scatter area (SSC-A) and forward scatter area
(FSC-A) were used to isolate viable cells, SSC width (W) and height (H) were used to
remove doublets, and FSC-W and FSC-H confirmed selection of single cells. PE-Texas
Red showed minimal autofluorescence. Parental HME-CC cells were used as a negative
control to set background autofluorescence. Approximately 19% of HME-CC cells were
GFP positive. Images were taken with 20x objective.
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Figure 4.9: Post FACS check of HME-CC-ESR1
After FACS for GFP expressing HME-CC cells, an aliquot was checked for purity. Side
scatter area (SSC-A) and forward scatter area (FSC-A) were used to isolate viable cells,
SSC width (W) and height (H) were used to remove doublets, and FSC-W and FSC-H
confirmed selection of single cells. PE-Texas Red showed minimal autofluorescence.
Approximately 90% of the sorted cell population expresses GFP, which are considered the
HME-CC-ESR1 cell line.
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Figure 4.10: FACS of ME16C2 cells after lentiviral infection with pIND-ESR1
After infection with pIND-ESR1, (a) ME16C2 cells (b) expressing GFP indicated
successful incorporation of pIND-ESR1. This subpopulation was selected using FACS
sorting (c) with the parameters shown. Side scatter area (SSC-A) and forward scatter area
(FSC-A) were used to isolate viable cells, SSC width (W) and height (H) were used to
remove doublets, FSC-W and FSC-H confirmed selection of single cells, and PE-Texas
Red was used to detect autofluorescence. Parental ME16C2 cells were used as a negative
control to set background autofluorescence. Approximately 72% of ME16C2 cells were
GFP positive. Images were taken with 10x objective.
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Figure 4.11: Post FACS check of ME16C2-ESR1
After FACS for GFP expressing ME16C2 cells, an aliquot was checked for purity. Side
scatter area (SSC-A) and forward scatter area (FSC-A) were used to isolate viable cells,
SSC width (W) and height (H) were used to remove doublets, FSC-W and FSC-H
confirmed selection of single cells, and PE-Texas Red was used to detect autofluorescence.
Approximately 99% of the sorted cell population expresses GFP, which are considered the
ME16C2-ESR1 cell line.
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Figure 4.12: Doxycycline dose response in 76N Tert-ESR1
Luciferase reporter assays in the 76N Tert-ESR1 line with 24-hour control, 10nM ICI, or
10nM E2 treatment and either 0ng/mL, 100ng/mL, 150ng/mL, or 200ng/mL doxycycline.
(a) Luciferase, (b) Renilla, and (c) Luciferase normalized to Renilla. Error bars indicate
SEM. Significance is calculated with comparison to control treatment of same doxycycline
dose unless otherwise indicated by lines. (* p < 0.05).
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Figure 4.13: Doxycycline dose response in MCF10A-ESR1
Luciferase reporter assays in the MCF10A-ESR1 line with 24-hour control, 10nM ICI, or
10nM E2 treatment and either 0ng/mL, 100ng/mL, 150ng/mL, or 200ng/mL doxycycline.
(a) Luciferase, (b) Renilla, and (c) Luciferase normalized to Renilla. Error bars indicate
SEM. Significance is calculated with comparison to control treatment of same doxycycline
dose unless otherwise indicated by lines. (* p < 0.05).

142

a

b

c

Figure 4.14: Doxycycline dose response in HME-CC-ESR1
Luciferase reporter assays in the HME-CC-ESR1 line with 24-hour control, 10nM ICI, or
10nM E2 treatment and either 0ng/mL, 100ng/mL, 150ng/mL, or 200ng/mL doxycycline.
(a) Luciferase, (b) Renilla, and (c) Luciferase normalized to Renilla. Error bars indicate
SEM. Significance is calculated with comparison to control treatment of same doxycycline
dose unless otherwise indicated by lines. (* p < 0.05).
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Figure 4.15: Doxycycline dose response in ME16C2-ESR1
Luciferase reporter assays in the ME16C2-ESR1 line with 24-hour control, 10nM ICI, or
10nM E2 treatment and either 0ng/mL, 100ng/mL, 150ng/mL, or 200ng/mL doxycycline.
(a) Luciferase, (b) Renilla, and (c) Luciferase normalized to Renilla. Error bars indicate
SEM. Significance is calculated with comparison to control treatment of same doxycycline
dose unless otherwise indicated by lines. (* p < 0.05).
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Figure 4.16: Luciferase Reporter Assays with 76N Tert-ESR1 and MCF10A-ESR1
ERE-luciferase reporter assays with 76N Tert-ESR1 and MCF10A-ESR1 cell lines with
increasing concentrations of doxycycline. Cells were treated with control, 10nM ICI, or
10nM E2 for 24 hours. Data is normalized to renilla transfection control and set relative
to 76N Tert-ESR1 no dox control. Error bars indicate SEM. Significance is calculated
with comparison to control treatment of same doxycycline dose unless otherwise indicated
by lines. (* p < 0.05).
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Figure 4.17: Luciferase Reporter Assays with HME-CC-ESR1 and ME16C2-ESR1
ERE-luciferase reporter assays with HME-CC-ESR1 and ME16C2-ESR1 cell lines with
increasing concentrations of doxycycline. Cells were treated with control, 10nm ICI, or
10nM E2 for 24 hours. Data is normalized to renilla transfection control and set relative
to 76N Tert-ESR1 no dox control. Experiment was performed at the same time as Figure
4.12. Error bars indicate SEM. Significance is calculated with comparison to control
treatment of same doxycycline dose unless otherwise indicated by lines. (* p < 0.05).
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Figure 4.18: Fold change in ERE-Luc responses in 76N Tert-ESR1
Fold change in ERE-luciferase reporter data from 76N Tert-ESR1 with increasing
concentrations of doxycycline relative to ICI treatment. Cells were treated with control,
10nm ICI, or 10nM E2 for 24 hours. Fold change is shown for (a) luciferase normalized
to renilla and (b) both raw luciferase and ratio (normalized data). Error bars indicate SEM.
(* p < 0.05).
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Figure 4.19: Fold change in ERE-Luc responses in MCF10A-ESR1
Fold change in ERE-luciferase reporter data from MCF10A-ESR1 with increasing
concentrations of doxycycline relative to ICI treatment. Cells were treated with control,
10nm ICI, or 10nM E2 for 24 hours. Fold change is shown for (a) luciferase normalized
to renilla and (b) both raw luciferase and ratio (normalized data). Error bars indicate SEM.
(* p < 0.05).
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Figure 4.20: Fold change in ERE-Luc responses in HME-CC-ESR1
Fold change in ERE-luciferase reporter data from HME-CC-ESR1 with increasing
concentrations of doxycycline relative to ICI treatment. Cells were treated with control,
10nm ICI, or 10nM E2 for 24 hours. Fold change is shown for (a) luciferase normalized
to renilla and (b) both raw luciferase and ratio (normalized data). Error bars indicate SEM.
(* p < 0.05).
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Figure 4.21: Fold change in ERE-Luc responses in ME16C2-ESR1
Fold change in ERE-luciferase reporter data from ME16C2-ESR1 with increasing
concentrations of doxycycline relative to ICI treatment. Cells were treated with control,
10nm ICI, or 10nM E2 for 24 hours. Fold change is shown for (a) luciferase normalized
to renilla and (b) both raw luciferase and ratio (normalized data). Error bars indicate SEM.
(* p < 0.05).
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Figure 4.22: ERα antibody optimization for Western blot analysis
Summary of antibody optimization for Western blot analysis, using 35ug of protein per
sample. Samples: 1- MCF7 (positive control), 2- 76N Tert parental cells (negative control),
3- 76N Tert-ESR1 with 100ng/mL doxycycline, 4- 76n Tert-ESR1 with 200ng/mL
doxycycline. Results with (a) F-10 monoclonal antibody, (b) MC-20 monoclonal antibody,
(c) Sp1 monoclonal antibody, and (d) C1355 polyclonal antibody for ERα.
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Figure 4.23: β actin expression during ERα antibody optimization for Western blot
Summary of antibody optimization for Western blot analysis, using 35ug of protein per
sample. Samples: 1- MCF7 (positive control), 2- 76N Tert parental cells (negative control),
3- 76N Tert-ESR1 with 100ng/mL doxycycline, 4- 76n Tert-ESR1 with 200ng/mL
doxycycline. β-actin protein expression in blots previously probed with (a) F-10
monoclonal antibody, (b) MC-20 monoclonal antibody, (c) Sp1 monoclonal antibody, and
(d) C1355 polyclonal antibody for ERα.
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Figure 4.24: ERα protein expression in iERα HMEC lines compared to MCF7
Western blot analysis showing detection of ERα protein using 1:100 dilution of ERα clone
Sp1 antibody from Abcam. Amount of protein loaded was either 28ug (or 25 ug if
indicated). β-actin is shown as a loading control. ERα protein was detected in (a) 76N
Tert-ESR1, (b) MCF10A-ESR1, (c) HME-CC-ESR1, and (d) ME16C2-ESR1 cells in the
presence of doxycycline. MCF7 cell lysates were used as a positive control, and parental
HMECs were included as a negative control for ERα.
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Figure 4.25: Quantification of ERα protein expression in 76N Tert-ESR1
Quantification of western blot data from for 76N Tert-ESR1 HMEC line for (a) ERα, (b)
β-actin, and (c) ERα normalized to β-actin. 2 replicates were used for each condition,
except for the MCF7 cell positive control. Error bars indicate SEM.
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Figure 4.26: Quantification of ERα protein expression in MCF10A-ESR1
Quantification of western blot data from for MCF10A-ESR1 HMEC line for (a) ERα, (b)
β-actin, and (c) ERα normalized to β-actin. 2 replicates were used for each condition,
except for the MCF7 cell positive control. Error bars indicate SEM.
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Figure 4.27: Quantification of ERα protein expression in HME-CC-ESR1
Quantification of western blot data from for HME-CC-ESR1 HMEC line for (a) ERα, (b)
β-actin, and (c) ERα normalized to β-actin. 2 replicates were used for each condition,
except for the MCF7 cell positive control. Error bars indicate SEM.
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Figure 4.28: Quantification of ERα protein expression in ME16C2-ESR1
Quantification of western blot data from for ME16C2-ESR1 HMEC line for (a) ERα, (b)
β-actin, and (c) ERα normalized to β-actin. 2 replicates were used for each condition,
except for the MCF7 cell positive control. Error bars indicate SEM.
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Figure 4.29: E2-induced proliferation in 76N Tert-ESR1 and MCF10A-ESR1
HMECs
(a-b) 76N Tert-ESR1 and (c-d) MCF10A-ESR1 HMECs were treated with 100 ng/mL
doxycycline and control, 10nM ICI, or 10nM E2 media for 4 days. The amount of
proliferation was measured each day by Alamar blue reduction. Media was refreshed on
day 3. Two experiments were performed in each cell line, shown in separate graphs. Error
bars indicate SEM. Significance calculated using T-test (* p < 0.05).
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Figure 4.30: E2-induced proliferation in HME-CC-ESR1 and ME16C2-ESR1
HMECs
(a) HME-CC-ESR1 and (b) ME16C2-ESR1 HMECs were treated with 100ng/mL
doxycycline and control, 10nM ICI, or 10nM E2 media for 4 days. The amount of
proliferation was measured each day by Alamar blue reduction. Media was refreshed on
day 3. Error bars indicate SEM. Significance calculated using T-test (* p < 0.05).
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Figure 4.31: AREG expression in iERα HMEC lines
After 2-day treatment with doxycycline to induce ESR1 expression, HMECs were treated
with control, 10nM ICI, or 10nM E2 for 24 hours. Gene expression from RT-qPCR is
shown relative to normal breast tissue. Untreated T47D cells are included for reference.
Error bars indicate SEM. (* p < 0.05).

160

Figure 4.32: Overview of conditioned media assay
Schematic overview of conditioned media assay. Briefly, iERα HMECs (76N Tert-ESR1
and MCF10A-ESR1) and T47D cells were treated with control, 10nM ICI, or 10nM E2
media for 48 hours. After 48 hours, the conditioned media was collected, filter sterilized
using a 0.2-micron filter, diluted 1:1 with fresh media, and transferred to HMEC parental
cells (76N Tert or MCF10A) and T47D cells. New media was added to iERα HMECs and
T47D cells to condition for another 48 hours and again added to the parental HMECs and
T47D cells. Alamar Blue growth assays were performed on parental HMECs and T47D
cells, where conditioned growth media was added on day 1 and day 3 of treatment. Cells
were also grown in normal growth media (no conditioned media) as a control.
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Figure 4.33: Conditioned Growth Media Assay in 76N Tert
Alamar Blue proliferation assay was performed on 76N Tert parental cells (without ERα)
using (a) normal growth media or (b) conditioned growth media from doxycycline treated
76N Tert-ESR1 cells, diluted 1:1 with normal growth media. (c) Fold change in Alamar
Blue reduction between day 5 and day 1 cells is shown for normal and conditioned media
experiments. Error bars indicate SEM. (p < 0.05).
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Figure 4.34: Expansion of Conditioned Growth Media Assay in 76N Tert
Alamar Blue proliferation assay was performed on 76N Tert parental cells (without ERα)
using (a) normal growth media (b) conditioned growth media from doxycycline treated
76N Tert-ESR1 cells, or (c) conditioned growth media from T47D cells. (d) Fold change
in Alamar Blue reduction between day 5 and day 2 cells is shown for normal and
conditioned media (CM) experiments. Error bars indicate SEM. (* p < 0.05).
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Figure 4.35: Conditioned Growth Media Assay in MCF10A
Alamar Blue proliferation assay was performed on MCF10A parental cells (without ERα)
using (a) normal growth media (b) conditioned growth media from doxycycline treated
MCF10A-ESR1 cells, or (c) conditioned growth media from T47D cells. (d) Fold change
in Alamar Blue reduction between day 5 and day 2 cells is shown for normal and
conditioned media (CM) experiments. Error bars indicate SEM. (* p < 0.05).
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Figure 4.36: Conditioned Growth Media Assay in T47D with 76N Tert-ESR1 media
Alamar Blue proliferation assay was performed on T47D cells using (a) normal growth
media or (b) conditioned growth media from doxycycline treated 76N Tert-ESR1 cells,
diluted 1:1 with normal growth media. (c) Fold change in Alamar Blue reduction between
day 5 and day 1 is shown for normal and conditioned media (CM, with and without Dox)
experiments. Error bars indicate SEM. (* p < 0.05).
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Figure 4.37: Conditioned Growth Media Assay in T47D with MCF10A-ESR1 media
Alamar Blue proliferation assay was performed on T47D cells using (a) normal growth
media or (b) conditioned growth media from MCF10A-ESR1 cells, diluted 1:1 with normal
growth media. (c) Fold change in Alamar Blue reduction between day 5 and day 1 is shown
for normal and conditioned media (CM, with and without Dox) experiments. Error bars
indicate SEM. (* p < 0.05).
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Figure 4.38: FOXA1 and GATA3 expression in HMEC lines
RT-qPCR expression of (a) FOXA1 and (b) GATA3 in untreated HMECs. Gene expression
is shown relative to normal breast tissue. Error bars indicate SEM. (* p < 0.05).
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CHAPTER 5
SUMMARY AND FUTURE
Chronic lifetime exposure to estrogen through early menarche, late menopause,
hormone replacement therapy, and high serum estrogen levels all increase a woman’s risk
for developing breast cancer. These reproductive risk factors suggest that longer lifetime
exposure to estrogen increases breast cancer risk. Accordingly, estrogen is known to
contribute to tumor growth/initiation and treatment with SERMs lowers incidence of breast
cancer. However, estrogen exposure can also decrease breast cancer risk through early in
life pregnancy, which decreases breast cancer risk by up to 50%. High dose estrogen
treatment is also an effective antitumor therapy for postmenopausal women with breast
cancer and is thought to sensitize tumors to estrogen-induced apoptosis. This data suggests
that high levels of estrogen exposure, depending on context, have antagonistic effects on
breast cancer risk.
Although all women are exposed to estrogen, only 1 in 8 women will develop breast
cancer during their lifetime. Familial breast cancer risk accounts for 27-30% of overall
breast cancer risk, but 60-70% of familial breast cancer risk is due to currently unknown
inheritable factors. Rodent models demonstrate genetic susceptibility to estrogen-induced
mammary tumor development and estrogen-induced responses in the mammary gland
which are not linked to any known breast cancer risk genes, suggesting unique sensitivity
to estrogen exposure. We hypothesized that a subset of women may be more sensitive to
estrogen and that these women may be at increased risk for developing breast cancer.
Responses to estrogen exposure in the breast are mediated through estrogen
receptors alpha and beta (ERα and ERβ). Estrogen acts as a ligand for these receptors to
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activate transcription of target genes in coordination with estrogen receptor coregulators,
which modulate the activity of ERα and ERβ. Estrogen receptor coregulators are expressed
in a tissue specific manner. Through the use of human breast ex-vivo and primary cell
models, we sought to characterize the level of variation in estrogen receptor expression and
estrogen-induced responses to determine if some individuals are more responsive to
estrogen and if this correlates with ER expression or is due to downstream regulation of
the estrogen signaling pathway.
In microarray data from over 100 donor breast tissue samples, we observed
significant variation in ESR1 and ESR2 expression, and expression of these receptors
changes with age. Our data for ESR1 expression agrees with previously published data for
ERα expression, suggesting that ESR1 expression can be used as an endpoint. To examine
if estrogen receptor expression correlates with estrogen-induced biological endpoints, we
utilized a human breast explant model with over 20 donor tissue samples. The breast
explant model allowed us to examine responses within a single donor to control or E2
treatment, which is advantageous to other studies of ERα expression which relied on data
gathered from women at a single time point. We again observed significant variation in
ESR1 and ESR2 expression, with up to 80 or 100-fold variation between individuals. For
estrogen-induced endpoints, we examined transcriptional and functional E2 responses in
our explant samples. Global transcription levels indicated by R-loop formation were
similar between donors, suggesting that E2 induces transcriptional responses regardless of
individual genetic background.

When we looked at specific transcriptional targets,

however, we observed quite variable responses. Expression of ER target genes AREG,
PGR, and TGFβ2 were consistently increased in nulliparous donors, but in parous donor
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expression of these genes with E2 treatment increased in some donors and decreased in
others. Some individual donors also had high basal levels of target gene expression.
For functional endpoints of estrogen treatment, we examined PR, PCNA, and
apoptotic responses among donors. PR expression was significantly decreased in E2
treated explants compared to fresh tissue timepoints, but there was no significance between
control and E2 treated explants. This data agrees with other published results in human
breast tissue but differ from what is known in breast cancer cell lines. E2-induced
proliferation, assayed by PCNA expression, revealed a trending increase with E2 treatment
but overall expression varied widely among individuals. In mice, our lab has shown that
irradiation induced apoptotic responses are enhanced by E2 treatment. However, in our
human breast explants we did not observe any significant increase in apoptotic cells
compared to control treated tissues, though responses again varied by individual.
Correlation analysis with E2 mediated transcriptional and functional responses
revealed no significant correlation of ESR1 or ESR2 with any endpoints. These results
indicate that while there is significant variation in estrogen receptor expression among
individuals and also variation in E2-induced responses, estrogen receptor expression alone
is not dictating sensitivity to E2 treatment. In order to expand upon these results, we began
working with human primary breast epithelial cell models. Conditionally reprogrammed
primary human mammary epithelial cells (ciHMECs) and stably immortalized HMECs
were used as individual donor samples to examine estrogen-induced responses as well as
responses to environmental xenoestrogens BP3 and PP.
Our primary HMECs enriched primarily for basal epithelial cell populations, which
corresponds with what others have noted about the limited growth of luminal epithelial
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cells in 2D culture. Others have also noted that the conditional reprogramming culture
method generates an epithelial population with some stem cell like properties.
Accordingly, in mammosphere forming assays, we found that most ciHMEC lines were
able to form mammospheres in ultra-low attachment conditions, compared to half of
permanently immortalized HMEC lines. One main drawback to HMEC models is that
most HMECs do not express estrogen receptors, so for our HMEC studies we used transient
transfection of the estrogen receptors along with reporter constructs as an endpoint. Dose
response experiments with E2, BP3, and PP treatment revealed that BP3 and PP are
agonists for both ESR1 and ESR2, but transactivation is significantly higher with ESR1.
Characterization revealed variation in ciHMEC responses to E2 (2.5-fold), BP3 (2.3-fold),
and PP (3.6-fold) treatment, but the activity between donors cell lines was more consistent
than what we had observed with our human breast explant model. This data reveals that
xenoestrogens BP3 and PP act as ligands for both ERα and ERβ, but their main activity is
through ERα, and that xenoestrogen exposure has the potential to activate estrogen
receptors in the majority of individuals and therefore could influence the effects of estrogen
signaling on breast cancer development.
Our last model for studying variation in estrogen-induced responses was our
inducible ERα HMEC lines. Using a doxycycline inducible vector, we generated an
inducible ESR1 expression construct and stably infected 4 HMEC lines. Characterization
of these lines using luciferase reporter assays revealed significant transactivation with E2
treatment in all 4 HMECs, but the amount of transactivation and potential leaky construct
expression varied between the 4 HMEC lines. We confirmed ERα protein expression by
western blot, and expression levels of ERα were comparable to MCF7 breast cancer cells.
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For biologically relevant responses, we examined proliferation and target gene expression
in our 4 iERα HMECs. In 3 of 4 iERα HMECs, we observed modest but significant
proliferation induced by E2 treatment resulting in a 20-25% increase in proliferation.
However, target gene expression was no longer regulated by estrogen, as PGR was not
expressed in any lines and AREG expression was consistently high in 3 of 4 HMEC lines.
The data from our 4 iERα HMEC lines complimented our observations from our
human breast explant model, where we observe some variation in biological responses with
E2 treatment. In our 4 iERα HMECs, we observed significant proliferative responses to
E2 in 3 of 4 lines, but clearly E2-induced responses are not consistent with what is known
in breast cancer cell lines despite having similar levels of ERα. We hypothesized that
coregulators of estrogen receptor signaling expressed in these 4 cell lines could be
modulating E2-induced responses, which was supported by the work of other labs showing
that co-expression of FOXA1 and GATA3 with ESR1 is required in ER negative breast
cancer cell lines to restore some E2-induced responses. In order to test this hypothesis, we
first determined if the proliferative responses observed in 3 of 4 iERα HMECs was due to
cell intrinsic factors. Conditioned media assays in 2 iERα HMEC and one breast cancer
cell line revealed that the iERα HMEC proliferation does not appear to be stimulated by
secretion of growth factors, which suggests that intracellular factors are responsible for
modulating these responses. Examination of FOXA1 and GATA3 expression in our HMEC
lines, however, demonstrated that expression levels of these factors is not correlated with
E2-induced proliferative responses. Future work with these cell lines will involve somatic
cell hybrid formation with breast cancer cell lines and our 4 iERα HMECs in order to
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determine if there are intracellular factors in our HMECs that are restricting E2-induced
responses.
Collectively, these results demonstrate significant variation in estrogen receptor
expression and estrogen-induced responses among individuals. This data mirrors results
in rodent models which have demonstrated genetic susceptibility to estrogen-induced
responses and tumor formation, where individual genetic background appears to amplify
or suppress the effects of estrogen exposure. Our human breast explant model data
demonstrated that estrogen receptor expression level is not correlated with E2-induced
responses, suggesting that other factors in the estrogen signaling pathway are mediating
individual sensitivity to estrogen. As estrogen receptor coregulators are known to modulate
estrogen receptor activity and are expressed in a tissue specific manner, we hypothesized
that these coregulators may be responsible for determining individual sensitivity to
estrogen. Our iERα HMECs are a useful model for studying estrogen-induced responses
and illustrate that cell intrinsic factors appear to mediate E2-induced proliferative
responses.

However, unlike other studies which suggest FOXA1 and GATA3 are

necessary and sufficient for E2-induced responses, we found that FOXA1 and GATA3
expression is not sufficient to restore E2-induced biological responses.
In order to determine whether specific coregulators of estrogen receptor signaling
may alter E2-induced biological responses and expression of ER target genes, a single cell
RNA sequencing (scRNA-seq) approach can be used with the models outlined here. Many
recent studies have utilized scRNA-seq to examine the differentiation of basal and luminal
progenitors in the mammary gland.

One group suggests that the differentiation of

progenitor cells into mature basal and luminal epithelial cells occurs along a continuum

173

(Bach et al., 2017), while others seem to agree that epithelial cells form distinct clusters of
basal and luminal epithelial cells which can be further classified by expression profiles (Pal
et al., 2017; Nguyen et al., 2018; Sun et al., 2018; Chen et al., 2019). In human breast
tissue scRNA-seq analysis, 2 luminal cell populations and 1 basal cell population are
identified, with some inter-individual variability noted in certain sub clusters (Nguyen et
al., 2018; Chen et al., 2019). The luminal epithelial subtypes are defined as either
secretory, which do not express estrogen receptors, or hormone-responsive, which express
ESR1 and PGR (Bach et al., 2017; Nguyen et al., 2018). While ESR1 is most highly
expressed in hormone-responsive luminal epithelial cells, some cells from basal and
secretory luminal clusters also express low levels of ESR1 in the human breast (Chen et
al., 2019). For our future work, we would be interested in isolating the hormone-responsive
luminal epithelial cell cluster to examine expression of estrogen receptor coregulators.
As estrogen receptor coregulators control estrogen-induced signaling inside ERα
positive cells, scRNA-seq can be used to isolate hormone-responsive luminal epithelial
cells from digested human breast donor tissue samples using previously identified profiles
in the human breast (Nguyen et al., 2018; Chen et al., 2019). This cluster of cells can be
further examined to select those which express ESR1, and expression of estrogen receptor
coregulators can be compared within this cell population. Once these cells are selected,
expression of ER coregulators can be compared between human breast tissue donors and
compared to E2-induced responsiveness determined in human breast explant or HMEC
experiments. Alternatively, scRNA-seq can be used to analyze coregulator expression in
our 4 iERα HMEC lines to compare ER coregulator expression in E2-proliferative cell
lines (76N Tert-ESR1, MCF10A-ESR1, and HME-CC-ESR1) to our unresponsive cell line

174

(ME16C2-ESR1) and ERα positive breast cancer cell lines T47D or MCF7.

We

hypothesize that these experiments would lead to the identification of ER coregulators
which correlate with increased or decreased E2-responsiveness. These experiments would
determine if ER coregulators are rate-limiting for estrogen receptor signaling.
Overall, we demonstrate that some individuals are more sensitive to estrogen
exposure, this sensitivity is most likely not due to estrogen receptor levels alone, and cell
intrinsic factors such as estrogen receptor coregulators appear to modulate these responses.
Further work to expand upon the role of estrogen receptor coregulators on mediating
estrogen sensitivity is still needed, but these results provide a potential mechanism for the
antagonistic roles of estrogen in mediating breast cancer risk. This data also suggests that
a subpopulation of women is more sensitive to estrogen and thus may be more at risk of
breast cancer development through estrogen exposure.
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